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CHAPTER 1. INTRODUCTION 
1.1 Sialic acids 
Sialic acids are the 9-carbon keto sugar acids found at the terminal, non-reducing 
end of various glycoproteins and glycolipids that are involved in a wide range of 
biological processes.1-5 To date, 43 different sialic acids have been discovered of which 
the most common is N-acetylneuraminic acid (Figure 1), which is found in various 
glycosidic linkages such as equatorial (2→3) and equatorial (2→6) linkages to galactose 
and equatorial (2→8) or equatorial (2→9) linkages in polysialic acids. Therefore, N-
acetylneuraminic acid itself is considered to be the parent sialic acid, whereas the other 
members of the family are treated as its derivatives. 
 
Figure 1: Fischer projections and cyclic structures of legionaminic acid, 
pseudaminic acid and N-acetylneuraminic acid 
 
1.2 Biological roles of sialic acids 
Sialic acids, one of the most diverse classes of sugar, are found on the outermost 
glycan chains of glycoproteins and glycolipids. On the positive side they perform 
important functions and are necessary for normal development,6-7 while on the negative 
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2 
side they are frequently the sites that pathogens recognize and attach to.8-14 Sialic acids 
link to the preceding sugar in a glycan from the 2-position, and can carry different 
substituents at the 4,5,7,8 and 9-positions, which is the primary reason for their 
diversity.9,10 They are present at the outermost position of glycans leading to their 
diversity being utilized by a variety of sialic acid binding proteins of many bacterial and 
viral pathogens.7 Additionally, sialic acids are recognized by intrinsic receptors in 
vertebrate cells such as the selectins and the siglecs.10,14 The pathological significance of 
sialic acid diversity can be understood by the following three examples. 
1) Avian influenza viruses, also called ‘bird flu’, preferentially recognize sialic acids 
that are equatorial (2→3) linked to the glycan chains. Fortunately, humans display 
equatorial (2→6) linked sialic acids on the epithelium of the upper airways and 
consequently are resistant to such viruses. Therefore, the avian influenza virus 
must undergo certain mutations of the sialic acid-binding region of the virus 
hemagglutinin to infect humans. This is the case in the intermediate hosts like 
pigs, where both equatorial (2→3) and equatorial (2→6) linked sialic acids are 
present on the airways.15 Chimpanzees, our closely related great apes, have been 
found to be devoid of equatorial (2→6) linked sialic acids in the airway. This is 
the reason for the resistance of chimpanzees to human influenza A infection.16 
2) The addition of 9-O-acetyl esters to the side chain of sialic acids has two 
contradictory effects. On one hand, this can block the binding of the influenza A 
virus; on the other hand, this modification is required for binding of common cold 
viruses like influenza C and certain coronaviruses, which make up about a third of 
human common cold viruses.8,12 This finding helped to find a detector for the 
 
 
 
 
3 
presence of 9-O-acetylated sialic acids in situ by developing recombinant soluble 
forms of the influenza C hemagglutinin.12,17 
3) Merozoites of Plasmodium falciparum, governed by different proteins, invade 
human red blood cells by binding with the sialic acids. Our closely related great 
apes, chimpanzees are susceptible to Plasmodium reichnowii malarial parasites 
instead of Plasmodium falciparium, largely due to the differential preference of 
the parasite binding proteins for human and nonhuman sialic acids.18 This can be 
explained as an adaptation that humans developed to deal with the P. reichnowii 
infection, only to be infected later by P. falciparum. 
Some examples of the naturally occurring sialosides with various linkages are shown 
here (Figure 2). 
 
Figure 2: Naturally occurring sialoside linkages 
In bacteria, sialic acids are found on glycoconjugates such as capsular 
polysaccharides (K-antigens) and lipopolysaccharides (O-antigens). Sialic acid 
expressing bacteria are the cause of various harmful diseases in humans, such as 
Escherichia coli strain K1, Neisseria meningitides group B,C (meningitis),19 and 
Camphylobacter jejuni (food-borne gastroenteritis).20 Sialic acids on the cell surface of 
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4 
these bacteria provide a protective barrier that enables bacteria to evade detection and 
attack by the host’s immune system.  
Some bacterial pathogens require sialic acids to interact with their host cells. The 
lectins involved, typically called adhesins, are attached to the bacterial surface. 
Helicobacter pylori, expresses two different adhesins which can recognize sialic acid, 
and causes peptic ulcers in humans.21,22 E. coli strain K99 causes lethal dysentery among 
animals;23,24 the adhesins expressed by it show high specificity toward the Neu5Gc-
equatorial(2→3)Gal-axial(1→4)Glc structure on glycolipids.25 Vibrio cholerae causes 
cholera toxin, and is an example of soluble sialic acid-binding lectins.26 Its B subunits 
show specific binding to a sialylated glycolipid (ganglioside GM1), which delivers the A 
subunit to the cytosol. This results in overproduction of adenylate cyclase, producing 
cyclic AMP in gastrointestinal epithelial cells ultimately causing severe diarrhea. Other 
sialic acid bearing toxins are Clostridium tetani, that causes tetanus, and Clostridium 
botulinum, that causes botulism. 
The legionaminic acid and pseudaminic acids are deoxy acetamido analogues of 
N-acetylneuraminic acid found in microorganisms (Figures 1 and 3). These two 
derivatives are quite common and significant given the fact that their glycosides are 
found in lipopolysaccharides and glycoproteins of multiple Gram-negative bacteria 
including Pseudomonas aeruginosa, Legionella pneumophila serogroup 1, 
Camphylobacter jejuni, and Camphylobacter coli.27-29 The equatorial glycosides of 
NeuAc and Leg are considered to be α-glycosides, whereas the equatorial glycosides of 
Pse are considered to be β-glycosides. This is based on the Rosanoff nomenclature 
convention, which links the anomeric configuration to the configuration of the 
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stereogenic center at the bottom position of the Fischer projection (Figure 1).30 Therefore, 
in order to avoid any confusion, in this thesis, all glycosides will be simply referred as 
equatorial or axial glycosides.  
1.3 Legionaminic acid and its biological roles 
Legionaminic acid was originally characterized in 1994 from the 
lipopolysaccharide (LPS) serotype 1 O-chain of Legionella pneumophila, the Gram-
negative bacterium responsible for Legionnaires’ disease, where it is present as a 5-N-
acetimidoyl-7-N-acetyl-legionaminic acid homopolymer with equatorial-2→4-linkages.31 
Legionnaire’s disease, a type of pneumonia, is acquired by breathing mist from water that 
contains the Legionella pneumophila bacteria, typically from hot tubs, showers or air-
conditioning units of large buildings. The pneumonia is chronic and often fatal due to the 
fact that Legionella pneumophila replicates within the alveolar macrophages of the 
human lung tissues.32 Legionaminic acid has since been reported in various bacterial 
glycoconjugates including the repeating unit of heteropolymeric LPS, capsular 
polysaccharides, and O-linked monosaccharide modifications on the flagellae of 
Camphylobacter jejuni.33,34 Though it is structurally homologous to Neu5Ac, the role of 
legionaminic acid in the physiology of bacteria and its impact on host-pathogen 
interaction is largely unknown.35 Studies examining the biology of Leg5,7Ac2 have been 
critically hindered by the low availability of this sugar. The existing synthetic routes for 
Leg5,7Ac2 are highly demanding and low yielding.  
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Figure 3: Naturally occurring bacterial nonulosonate (NulO) sugars. 
Legionaminic acids belong to the growing family of bacterial nonulosonate 
(NulO) sugars, of which currently there are six known members: legionaminic acid, 4-
epi-legionaminic acid, 8-epi-legionaminic acid, pseudaminic acid, acinetaminic acid, and 
fusaminic acid (Figure 3).27, 36-39 All are 9-carbon keto acid sugars and therefore resemble 
sialic acid, but differ in being deoxy at C9. Also, excluding fusaminic acid, all contain 
various N-acyl substituents at C7 instead of a hydroxyl group. It has been observed that 
there is much greater diversity in their C5 and C7 N-acyl substituents than is found in N-
acetylneuraminic acid itself. The legionaminic acid Leg5,7Ac2 is structurally homologous 
to N-acetylneuraminic acid (Neu5Ac, sialic acid) in having the same configuration, with 
the differences at C9, with methyl group instead of –CH2OH, and at C7, with an 
acetamido group instead of a hydroxyl. Therefore, if Neu5Ac is replaced with Leg5,7Ac2 
on the termini of glycoconjugates, biological interactions that depend upon the glycerol 
or exocyclic moiety will be affected. For example, studies on a fluorescently labeled 
lactosyl derivative have shown that susceptibilities to sialidases are greatly reduced by 
the presence of Leg5,7Ac2 instead of Neu5Ac.40  
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Siglecs are defined as sialic acid-binding lectins and are another class of Neu5Ac 
interacting molecules whose biological activity is influenced by the sialic acid analogs. 
GD1a, a di-sialylated ganglioside, acts as a ligand for the glycoprotein (MAG or Siglec-
4) associated with myelin. Synthesis of a form of GD1a containing Leg5,7Ac2 was 
carried out and the product showed no interaction with Siglec-4,41 showcasing the 
importance of the glycerol or exocyclic moiety on the biological properties of NulOs. 
Modification of glycans on therapeutic glycoproteins can also change their biological 
activities. Previously, the best approach was to develop resistance for the sialidase 
cleavage, but the recent finding of natural antibodies in human sera has shown the 
exchange with Leg5,7Ac2 is beneficial and enhances serum half-life. For example, it was 
found that exchanging NeuAc with Leg5,7Ac2 counteracts the serum protection afforded 
to Neisseria gonorrhoeae by Neu5Ac. N. gonorrhoeae modifies its cell surface lacto-N-
neotetraose lipooligosaccharide (LNnT LOS) molecules with Neu5Ac, utilizing host-
derived CMP-Neu5Ac and its sialyltransferase Lst. This is the primary mechanism by 
which the organism evades complement-mediated killing and survives in the host. 
However, when N. gonorrhoeae is treated with CMP-Leg5,7Ac2, these cells modify their 
surface LNnT LOS with Leg5,7Ac2 and are then prone to complement-mediated killing. 
In the light of this finding, CMP-Leg5,7Ac2 is now being considered and evaluated for its 
therapeutic potential in the treatment of N. gonorrhoeae infections.42  
The structures of legionaminic acid found in different pathogenic bacteria are 
summarized in the Table 1. 
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Table 1:  Structures of legionaminic acids found in different pathogenic bacteria 
 
Legionaminic acid Bacterial source Reference 
 
Vibrio alginolyticus 945-80 
Acinetobacter baumannii O24 
Vibrio parahaemolyticus O2 
Campylobacter jejuni 11168 
Escherichia coli O161 
43,44 
43,45 
46,47 
33 
48 
 
 
Legionella pneumophila 
serogroup 1 
Pseudomonas fluorescens 
ATCC 49271 
Vibrio salmonicida NCMB 
2262 
Campylobacter coli VC167 
Campylobacter jejuni 11168 
31,43 
 
43,49 
 
43,50 
 
34 
33 
 
R’ = C(=O)CH2CH(OH)CH3; R” = Ac 
R’ = Ac; R” = C(=O)CH(NHAc)CH3 
 
R’ = CH(NHCH3)CH3; R” = Ac 
 
R’ = C(=O)CH2CH2CH(CO2H)NHCH3; 
R” = Ac 
 
 
 
 
 
Acinetobacter baumannii O24 
Vibrio parahaemolyticus KX-
V212; Escherichia coli O161 
Campylobacter coli VC167 
Campylobacter jejuni 11168 
Clostridium botulinum 
 
 
 
 
 
43,45 
46,48 
 
34 
33 
51 
 
1.4 Pseudaminic acid and its biological roles 
Pseudaminic acid (Pse5Ac7Ac) was first discovered by Knirel and co-workers in 
the lipopolysaccharides of Pseudomonas aeruginosa O7/O9 and Shigella bodyii type 7 in 
1984.52 The structure was found to be 5,7-diacetamido-3,5,7,9-tetradeoxy-L-glycero-L-
manno-non-2-ulosonic acid, which was a nonulosonic acid but not a direct derivative of 
neuraminic acid. This opened a whole new chapter of the family belonging to 
pseudaminic acid that differed in the N-acyl functionality at C-5 and C-7. In comparison 
with N-acetyl neuraminic acid, Pse contains one more amido group (on C7) and one less 
O
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AcHN
HO NHAc OH
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hydroxyl group (on C9), together with the opposite stereochemistry at C5, C7 and C8. 
The two amido groups have been found to be quite diverse, ranging from acetyl to 3-
hydroxybutyryl and formyl groups, further increasing the structural complexity of Pse. 
Pseudaminic acid containing glycan structures have been isolated from a large number of 
pathogenic bacteria, wherein the bacterial proteins are glycosylated with pseudaminic 
acid via a very common and essential post-translational modification. Such types of post-
translational modification, commonly called protein glycosylation, is quite common in 
eukaryotes and helps increase the functional and structural diversity of proteins. 
However, bacterial protein glycosylation is a recently discovered phenomena, and has 
significantly helped in the study of bacterial pathogenesis and in the development of 
therapeutic and diagnostic tools.53-56 Unique to bacteria, the pseudaminic acids have been 
found to be important components of cell surface glycans (such as lipopolysaccharide O-
antigens, and capsular polysaccharides) and glycoproteins (such as pilins and flagellins) 
which are associated with the bacterial virulence.28,57 In glycoproteins, pseudaminic acid 
uses two amino acids Ser and Thr (in case of Helicobacter pylori and Campylobacter 
jejuni) or other glycans (in case of P. aeruginosa) to link with the peptide backbone. 
Pseudomonas aeruginosa, in particular, is a notorious pathogen which has been linked to 
cystic fibrosis and wide varieties of gastrointestinal diseases. The importances of sialic 
acids in eukaryotes are pretty well characterized and therefore, there is no doubt about 
their importance in bacteria.37,58 Unfortunately, the exact biological role of pseudaminic 
acid in bacterial glycoproteins remains understudied, largely due to the unavailability of 
homogeneous pseudaminic acid and its derivatives. Therefore, an efficient synthesis of 
 
 
 
 
10 
Pse and its derivatives will not only pave the way to study its biological roles, but also 
will be significant in developing therapeutic and diagnostic vaccines. 
Post-translational modification with pseudaminic acid is necessary for functional 
flagella and this glycosylation has been considered important for motility in bacteria. Liu 
et al.59 attempted to verify this phenomenon via glycoengineering analysis. They 
supplemented exogenous azide-labelled pseudaminic acid biosynthetic precursors in a C. 
jejuni strain that lacked the biosynthetic enzymes for pseudaminic acid synthesis. The 
results showed that the motility was restored in this C. jejuni strain. The authors were 
also able to perform different chemical biology analyses of this incorporation using the 
biotin tag. Kaewsapsak et al.60 utilized azide-labeled glycosylated proteins in H. pylori to 
ligate immune stimulants, which helped promote immunological destruction of bacteria 
carrying pseudaminic acid. Menard et al.61 also recently discovered three small molecule 
inhibitors of the enzyme PseB which could penetrate the cell membrane of Gram-
negative bacteria preventing the formation of flagella. 
The structures of pseudaminic acid found in different pathogenic bacteria are 
summarized in the Table 2. 
Table 2: Structures of pseudaminic acids found in different pathogenic bacteria 
 
Pseudaminic acid Bacterial source Ref. 
 
 
 
 
 
Escherichia coli O136 
Proteus vulgaris O39 
Campylobacter jejuni 81-176 
Campylobacter jejuni 11168 
Campylobacter coli VC167 
Pseudoateromonas atlantica T9 
Helicobacter pylori 1061 
Pseudoalteromonas atlantica IAM 14165 
Aeromonas caviae UU51 
Rhizobium sp. NGR234 
Sinorhizobium meliloti Rm1021 
62 
63 
64,65 
33 
66 
52 
65,67 
68 
65 
69 
70,71 
O
OH
NHAc
AcHN OH
OH
CO2H
2
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Cellulophaga fucicola 
Vibrio vulnificus 27562 
Pisciricketttsia salmonis 
72 
73 
74 
 
Pseudomonas aeruginosa O10a 
Shigella boydii type 7 
Pseudomonas aeruginosa O9a, 9b 
Sinorhizobium fredii HH103 
Kribbella spp. VKM 
Actinoplanes utahensis VKM Ac-674 
52 
75,76 
76,77 
78 
79,80 
79,81 
 
Pseudomonas aeruginosa O7a, 7b, 7d and 
O7a, 7d 
Pseudoalteromonas distincta KMM 638 
 
82,83 
 
84 
 
Vibrio cholera O:2 
Campylobacter jejuni 81-176 
Campylobacter coli VC167 
85 
64,65 
66 
 
R’ = Ac; R” = glycate 
R’ = C(=O)CH2CH(OH)CH2;  
R” = C(=O)H 
R’ = R” = C(=O)CH(OH)CH2OH 
R’ = Ac; R” = C(=NH)CH3 
R’ = C(=O)CH(OCH3)CH2OCH3; 
R” = C(=NH)CH3 
R’ = C(=O)CH(OCH3)CH2OCH3; 
R” = Ac 
 
 
 
 
Vibrio vulnificus 27562 
Pseudamonas aeruginosa O7a, 7b, 7c 
 
Campylobacter jejuni 81-176 
Campylobacter jejuni 11168 
Campylobacter jejuni 11168 
 
Campylobacter jejuni 11168 
 
 
 
 
73 
83 
 
64 
33 
33 
 
33 
 
1.5 Structure and linkage diversity in legionaminic and pseudaminic acid 
Legionella pneumophila, a Gram-negative bacterium, is the causative agent of 
Legionnaires’ disease in whose serotype 1 O-chain lipopolysaccharide legionaminic acid 
is found in the form of the equatorially linked homopolymer 26.31 Pseudaminic acid is 
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found linked equatorially in the lipopolysaccharide 27 of Pseudamonas aeruginosa O10 
(Figure 4).77 
 
Figure 4: Structures of polylegionaminic acid and the O-specific lipopolysaccharide 
from P. aeruginosa O10 
 
In 2012, Kandiba et al.86 discovered a 5-N-formyl derivative of legionaminic acid 
from the glycan of a haloarchaeal pleomorphic virus (HRPV-1). The glycan was found to 
be the pentasaccharide 28 containing a terminal 5-N-formyl-legionaminic acid residue 
alongside glucose, glucuronic acid, mannose and sulphated glucuronic acid (Figure 5). 
 
Figure 5: Structure of a glycan from HRPV-1 containing legionaminic acid 
Naturally occurring pseudaminic acids and their derivatives have often been 
found to be linked via the amines either at C-5 or C-7. Such example is the C-7 linked 
pseudaminic acid derivative found in Kribella spp (Figure 6).57 
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Figure 6: Structure of Teichulosonic acid fragment in Kribella sp. containing 
pseudaminic acid 
 
Among the Pse-containing glycans and glycoconjugates, the P. aeruginosa 1244 
pilin glycan trisachharide 30 (Figure 7) is of particular importance.  
 
Figure 7: Structure of the P. aeruginosa 1244 pilin containing pseudaminic acid 
P. aeruginosa is a Gram-negative pathogen known to have resistance to many 
antibacterial agents and hard to be detected by our immune system due to biofilm 
formation.87 It causes cystic fibrosis a potentially mortal infection in patients with weak 
immune systems. The glycosylated pilin contains the P. aeruginosa 1244 strain, which 
has been isolated and used in pilus-mediated adhesion studies.88 The trisaccharide is 
glycosylated to D-fucosamine by the pilin at the C-terminal residue through an equatorial-
glycosidic linkage.89 This is mediated by an oligosaccharyltransferase, the pilO gene 
product, which transfers the trisaccharide from the carrier lipid to the pilin.90 Organized 
O
OHHO
O
OH
O
O
OH
AcHN
NH
O
O
OH
OMe
HO OH
O
O
CO2H
29
O
OH
NHCHO
O
OH
O
OH
HO
NHAc
O
OHHN
O
OH
O
CO2H
HO
30
 
 
 
 
14 
pili from the pilin play an important role in the bacterial pathogenesis. Glycosylated P. 
aeruginosa 1244 was found to colonize the lung tissue 3 times more efficiently than the 
non-glycosylated P. aeruginosa 1244,91 and is a vital tool in immunogenicity. The 
trisaccharide 30 glyconconjugate can be considered as a candidate for a potential vaccine, 
as it protected immunized mice from P. aeruginosa.92 
1.6 Biosynthesis of legionaminic acid and pseudaminic acid 
L. pneumophila has been found to contain a homopolymer of Leg as a distal part 
of its lipopolysaccharide (LPS). Studies have found that a segment of the Legionella 
genome involved in the biosynthesis of LPS contains putative genes similar to three 
genes involved in the biosynthesis of Neu5Ac, GlcNAc-6-phosphate 2-epimerase, 
Neu5Ac synthetase and CMP-Neu5Ac synthetase. Therefore, it was concluded that the 
biosynthesis of legionaminic acid is similar to that of Neu5Ac.10,93  
In 2009, the biosynthetic pathway for Leg5,7Ac2 in Campylobacter jejuni was 
elucidated.94 Unexpectedly this pathway used GDP-GlcNac (Scheme 1) as the key 
building block, unlike related nonulosonic acid pathways, which use UDP-GlcNac.  
The first step in the biosynthesis of legionaminic acid is catalyzed by LegB an 
NAD-dependent 4,6-dehydratase, which eliminates water from C4 and C6 of GDP-N-
acetyl-glucosamine 31 to give the 4-keto intermediate, GDP-2-acetamido-2,6-dideoxy-
alpha-D-xylo-hexos-4-ulose 32. Compound 32 was then converted to GDP-4-amino-4,6-
dideoxy-α-D-GlcNAc with the help of LegC, a PLP-dependent aminotransferase, which 
is further converted to GDP-2,4-diacetamido-2,4,6-trideoxy-α-D-glucopyranose (33) by 
LegH, an N-acetyltransferase. The enzyme LegG, acting as an NDP-sugar hydrolase and 
2-epimerase, catalyzes conversion of the intermediate 33 into a 6-deoxy-mannose 
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derivative (or a D-rhamnose sugar), 2,4-diacetamido-2,4,6-trideoxy-D-mannopyranose 34. 
Aldol condensation with phosphoenolpyruvate with the help of enzyme LegI, a 
legionaminic acid synthase, then converts compound 34 to legionaminic acid 1 (Scheme 
1). The so-synthesized legionaminic acid must be nucleotidylated as the CMP-linked 
derivative for incorporation into glycans.10 Legionaminic acid is CMP-activated by the 
enzyme LegF, a CMP-legionaminic acid synthetase, giving CMP-legionaminic acid  35 
(Scheme 1).  
 
Scheme 1: Biosynthetic pathway of legionaminic acid 
Both pseudaminic acid and legionaminic acid are biosynthesized from a common 
precursor, N-acetyl-glucosamine. The complete biosynthesis of pseudaminic acid was 
elucidated in Campylobacter jejuni and Helicobacter pylori, where pseudaminic acid is 
obtained in five steps from UDP-N-acetylglucosamine (Scheme 2).34,95-97 The initial 
conversion of first step of converting UDP-α-D-GlcNAc 36 to UDP-2-acetamido-2,6-
dideoxy-β-D-arabino-hexos-4-ulose 37 is catalyzed by a dual functionality enzyme, PseB 
which acts as both an NAD(P)-dependant dehydratase and a C-5 epimerase.97-100 The 
second enzyme, PseC, then converts compound 37, a D-sugar into UDP-4-amino-4,6-
dideoxy-β-L-AltNac 38, an L-sugar.96,97,101 The intermediate 38 is then converted to 2,4-
diacetamido-2,4,6-trideoxy-β-L-altropyranose 39 with the help of two enzymes PseH and 
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PseG.102,103 Thereafter, an aldol condensation of compound 39 with phosphoenolpyruvate 
(PEP) takes place in the presence of the enzyme PseI, giving the pseudaminic acid 2 
(Scheme 2).62,97,98  For incorporation into glycans, pseudaminic acid is converted to its 
derivative by the enzyme PseF, a CMP-pseudaminic acid synthetase, which utilizes CTP, 
giving CMP-pseudaminic acid 40 and pyrophosphate (Scheme 2).97,98 
 
Scheme 2: Biosynthetic pathway of pseudaminic acid 
All the aforementioned enzymes have been now thoroughly studied and 
characterized. Unfortunately, it was discovered that the first enzyme in the pathway, 
PseB inhibits CMP-pseudaminic acid pathway at a micromolar level. Therefore, huge 
doses of the natural substrate UDP-GlcNAc 36 are required to push this pathway 
forward.97,98 The structure of the fourth enzyme of the pathway PseG was fully 
characterized by X-ray crystallography in 2009, proving that PseG was a UDP-hydrolase 
belonging to a superfamily of inverting glycosyltransferases.103 Even after this revelation, 
Liu and Tanner102 showed that PseG wasn’t the CMP-pseudaminyltransferase responsible 
for linking CMP-activated pseudaminic acid 40 into glycan structures. 
Exactly how the possible glycosyltransferase(s) are responsible for the 
incorporation of these CMP-linked nonulosonates into glycan structures is not known. 
Recently, the glycosyltransferase responsible for the transfer of CMP-activated 
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pseudaminic acid 40 onto the flagellin of Aeromonas caviae has been discovered.104 
Although direct evidence of the motility-associated factor maf1 gene providing the 
enzyme responsible for adding pseudaminic acid onto the flagellin was not provided, the 
studies showed that maf1 is a pseudaminyl transferase. As the first report identifying a 
probable pseudaminyl transferase, it can be expected that this will help in identifying the 
presence of similar glycosyltransferases in other bacteria. 
1.7 Synthesis of sialic acid glycoconjugates  
The universe of the sialic acids including legionaminic acid and pseudaminic acid, 
their diverse linkages and biology is defined as the sialome.105 Unfortunately, nature 
produces sialosides in micro heterogeneous form and in small concentrations, thus the 
development of efficient chemical or enzymatic methods for their synthesis is in great 
need.106 Enzymatic or chemoenzymatic pathways, though providing a solution for the 
synthesis of sialyl glycoconjugates still suffer from scale-up issues. Therefore, the 
chemical approach is the only solution to access natural sialyl glycoconjugtes in 
sufficient quantity to study, and to gain access to non-natural linkages. The naturally 
occurring sialosides, excluding legionaminic and pseudaminic acid, are all equatorially 
linked.  Obtaining the equatorial anomer in preference to the axial one in glycosylation is 
challenging. There are several reasons for this beginning with the high reactivity of 
typical sialyl donors. The unsubstituted nature of C-3 also aids to the formation of the 
axial glycoside. Additionally, the formation of equatorial glycoside requires the 
avoidance of the anomeric effect and cannot depend on stereodirecting participation from 
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C-3 due to absence of the functional group. All of these reasons contribute to the 
generally generally low yields and poor selectivity observed in the glycosylation 
reactions of sialic acid donors. 
Scheme 3: Mechanism of a general glycosylation or sialylation reaction 
Because of all these complications, the development of methodology for the 
synthesis of equatorial sialyl glycosides has been a major focus in synthetic carbohydrate 
chemistry. A variety of approaches have been applied to overcome this problem, and can 
be broadly classified into three main groups: 1) Sialylation assisted by auxiliary groups; 
2) Conversion of acetamide at C-5 to more electron withdrawing groups; and 3) Use of 
cyclic protecting groups. 
1.7.1 Sialylation assisted by auxiliary groups 
Glycosylation assisted by the neighboring groups is a popular and common 
method applied to the control of stereoselectivity.107 In sialyl donors, incorporation of an 
auxiliary groups at the C-1 or C-3 positions is a common theme and has led to the 
improvement of the glycosylation selectivity. Two groups have studied the C-1 
auxilliaries, those of Gin (Scheme 4)108 and Takahashi109 utilizing 2-thioethyl ester and 
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N,N glycolamide auxiliaries, respectively.  
Scheme 4: Gin’s C-1 auxiliary mediated glycosylation using N, N-glycolyamide 
Gin’s N,N-dimethylglycolamide auxiliary assisted sialylation (Scheme 4) was 
selective for primary alcohols, but lost its selectivity with the less reactive secondary 
alcohol acceptors.108 Takahashi’s thioether auxillary assisted approach was even less 
successful, giving only modest selectivities.109 Installation of the auxiliaries at the C-3 
position requires a complicated process of installing and then removing the auxiliary 
from the methylene group at C3. The C-3 auxiliaries employed include halides, acetyl 
esters, thioethers and phenyl selenides; all of which are at least partially successful in 
providing the desired equatorial selectivity (Scheme 5).110 
 
Scheme 5: The general approach of C-3 auxiliary mediated glycosylation 
1.7.2 Conversion of the acetamide at C-5 to more electron withdrawing groups 
The C5 acetamide of sialic acids can be converted chemically to various 
protecting groups, which results in changes in the reactivity and stereoselectivity of the 
glycosylation reactions.111 This is important because the stereoselectivity of the 
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sialylation is improved tremendously by the introduction of various electron withdrawing 
protecting groups at C-5, such as the NAc2,112,113 azide,114-117 isothiocyanate,118 
trifluoroamide,119-122 N-Troc,123,124 NAcBoc,125,126 cbz,127 N-Fmoc, N-Alloc and 
trichloroacetyl128,129 groups (Scheme 6). These groups at C-5 have all been reported to 
increase the equatorial selectivity in glycosylation,112-129 especially with primary alcohol 
acceptors.  
 
Scheme 6: Sialylation approach by various modifications on N-5 
1.7.3 Use of cyclic protecting groups  
A revolutionary method for the equatorial-selective sialylation introduces a cyclic 
protecting group on the 4O and 5N positions of sialyl donors. Crich et al. synthesized 
trans-fused N-acetyl 5N,4O oxazolidinone protected phenylthio and thioadamantyl 
sialosides, which gave the excellent glycosylation selectivity and yields under the typical 
NIS/TfOH in situ activation conditions.130,131 The extra acetyl group in the Crich method 
had the advantage of affording the native C-5 acetamide in very mild condition after 
glycosylation, in contrast to the simple 5N, 4O-oxazolidinones developed by Takahashi132 
and De Meo,133 which required harsher conditions to cleave the 4,5-O,N-oxazolidinone 
ring (Figure 8).  
PG = NAc2 (58), N3 (59), NHCOCH3 (60), 
         NHTroc (61), NPhth (62), NCS (63)
Sialylation
LG = SMe (55), SPh (56), 
SAda (57)
64
O
AcO
AcHN
AcO OAcAcO
LG
CO2Me
O
AcO
PG
AcO OAcAcO
LG
CO2Me
O
AcO
PG
AcO OAcAcO
CO2Me
OR
 
 
 
 
21 
 
Figure 8: Sialic acid donors with 4O,5N-oxazolidinone ring 
1.8 Synthesis of legionaminic acid and its glycosides 
1.8.1 Tsvetkov’s synthesis of Leg 
Tsvetkov et al.43 synthesized legionaminic acid by condensing 2,4-diacetamido-
2,4,6-trideoxy-D-mannose 74 with oxalacetic acid in the presence of sodium tetraborate 
while maintaining the pH at 10.5.  A mixture of legionaminic acid and it’s C4 epimer was 
obtained with the yields of 7% and 10%, respectively. The precursor 74 was in turn 
obtained from benzyl β-D-fucopyranoside 69 by a sequence of reactions in 38% overall 
yield. The sequence began with Bu2SnO mediated selective benzoylation on 69 which 
gave 70. Compound 70 was converted to the corresponding 2,4-ditriflate, which in turn 
was treated with Bu4NN3 to give diazide 71 with the manno configuration. Saponification 
of the benzoyl group followed by hydrogenation without affecting the benzyl group and 
then N-acetylation gave compound 73. Finally, removal of the benzyl group by 
hydrogenolysis gave the precursor 74 (Scheme 7). 
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Scheme 7: Tsvetkov’s synthesis of legionaminic acid 
1.8.2 Seeberger’s synthesis of Leg and a glycoside 
Seeberger et al.134 performed a de novo synthesis of the Leg donor 77 from D-
threonine in 17 steps and 7% overall yield. Donor 77 was converted to crude thioether 78 
via dehydrative glycosylation. Due to the difficulty associated with purification of 78, 
acetal hydrolysis with aq. TFA was performed to give 79 as the axial anomer in 63% 
yield in two steps. A small amount of the equatorial anomer was obtained in this step but 
couldn’t be purified by silica gel column chromatography and so was not characterized. 
Deacetylation of compound 79 gave compound 80 in 95% yield. Methyl ester hydrolysis 
was followed by global deprotection by reductive cleavage of the thioester and the N-
sulfonamide groups under Birch reduction conditions. Finally N-acetylation of the amine 
thus obtained gave the acetamide 81. The overall yield of 81 starting from D-threonine 
was reported to be 6% (Scheme 8). 
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Scheme 8: Seeberger’s approach to synthesize a leg glycoside 
1.8.3 Whitfield’s chemoenzymatic synthesis of Leg 
Whitfield et al.135 developed a de novo Leg5,7Ac2 biosynthetic pathway by 
combining various metabolic modules from three different bacterial sources 
(Saccharomyces cerevisiae, C. jejuni, and L. pneumophila), taking inspiration from 
earlier chemoenzymatic work by Tanner et al.136 Application of the synthetic route in E. 
coli procured a decent amount of legionaminic acid in the culture broth (120 mg L-1) 
(Scheme 9). Purification of Leg5,7Ac2 from the culture broth was carried out, which was 
then activated in the form of CMP-legionaminic acid for biochemical purposes, and a 
donor in the form of phenyl thioglycoside was synthesized for the chemical glycosylation 
reactions. 
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Scheme 9: Whitfield’s bioinspired synthesis of legionaminic acid 
To activate the biosynthesized Leg5,7Ac2 for chemical glycosylation, it was 
converted into its methyl ester followed by acetylation and reaction with thiophenol to 
generate an α-phenylthioglycoside ready for chemical glycosylation. Whitfield et al. did 
not report any glycosylation reaction, but the method provides a donor for possible future 
chemical glycosylation reactions (Scheme 10). 
 
Scheme 10: Whitfield’s further functionalization of Leg to provide a Leg donor 
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1.8.4 Chen’s chemoenzymatic synthesis of Leg and its glycosides 
Chen et al.137 synthesized a library of equatorial (2,3) and equatorial (2,6) linked 
Leg5,7Ac2-glycosides from chemically synthesized 2,4-diazido-2,4,6-trideoxymannose 
(6deoxyMan2,4diN3) in one-pot multienzyme sialylation method. The six-carbon 
precursor of Leg5,7Ac2, 6-deoxy-Man2,4-di-N3 was synthesized in 9 steps from 
commercially available D-fucose (Scheme 11). 
 
Scheme 11: Chen’s chemoenzymatic approach to legionaminic acid 
The diazido precursor 94 was then further functionalized enzymatically to afford 
a donor, which was then enzymatically glycosylated with three different acceptors, para-
nitrophenyl β-glycoside (Gal-β-pNP), thiotolyl β-galactoside (Gal-β-STol) and lactosyl β-
propyl chloride (Lac-β-ProCl) to give the equatorial (2,3/6) glycosides depending upon 
the type of the enzymes employed. The diazido precursor 94 was reacted 
chemoenzymatically with pyruvate in presence of PmAldolase (obtained from 
Pasteurella multocida) to form the diazido derivative of Leg (95, Leg-5,7-di-N3), which 
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O
HO
OH
OH
1) Py, Ac2O
2) PMPOH, 
    BF3.Et2O
O
AcO
OPMPAcO
1) NaOMe, MeOH
2) Me2SnCl2, BzCl
   DIPEA
94%
O
HO
OPMPHO
1) Tf2O, Py
2) TBAN3, toluene
O
BzO
OPMP
N3
1) NaOMe, MeOH
2) CH3CN/H2O (4:1)
  CAN
81%
O
HO
N3
AcSH, Py
O
HO
NHAc
CO2-
O
PmAldolase
OH
OH
84%
93%
73%
71%
90 91 92
93 94
34
1
HO AcO BzO
N3 N3
AcHN O
HO
AcHN
HO NHAc OH
CO2-
 
 
 
 
26 
meningitidis CMP-sialic acid synthetase (NmCSS) to form CMP-Leg-5,7-di-N3 96 in 
situ. This was finally converted by a sialyltransferase (PmST1_M144D or PsP2, 6ST) to 
equatorial (2,3/6) linked Leg-5,7-di-N3-containing glycosides 97. When PmST1_M144D 
was used as the sialytransferase, equatorial (2,3) linked Leg-5,7-di-N3-containing 
glycosides were formed in the yields of 71-98%, while the use of Psp2,6ST as 
sialyltransferase gave equatorial (2,6) linked Leg-5,7-di-N3-containing glycosides with 
the same acceptors in the yields of 73-97%. Among the different strategies used to 
convert the azido groups of the glycosides to the requisite acetamido groups, thioacetic 
acid-mediated one-pot conversion in saturated aqueous sodium bicarbonate proved to be 
the most efficient giving the final Leg-5,7-Ac2 containing glycosides 98 in 69-88% yields 
(Scheme 12). The protocol required the use of three different enzymes to obtain the 
legionaminic acid glycosides. 
 
 
Scheme 12: Chemoenzymatic synthesis of Leg-5,7-di-N3 followed by glycosylations 
and deprotections. 
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1.9 Synthesis of pseudaminic acid and its glycosides 
1.9.1 Tsvetkov’s synthesis of Pse 
Tsvetkov et al.138 in 2001 synthesized different classes of 5,7-diamino-3,5,7,9-
tetradeoxynon-2-ulosonic acids with benzyl β-L-rhamnopyranoside 99 as the precursor of 
choice. In the final step, the intermediate 2,4-diacetamido-2,4,6-trideoxy-L-allose 113 
was reacted with oxalacetic acid in basic conditions to produce pseudaminic acid- 
diacetate (Pse5Ac7Ac) 2. The final step was plagued by the formation of a mixture of 
isomers with the target Pse5Ac7Ac being only a minor product isolated in 3% yield only 
(Scheme 13). Nevertheless, this method provided the first total synthesis of Pse5Ac7Ac, 
and enabled confirmation of the definitive structures and configuration of the bacterial 
nonulosonates paving the way for further work in the field.  
 
Scheme 13: Tsvetkov’s approach to synthesize Pse5Ac7Ac 
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1.9.2 Ito’s synthesis of Pse and its glycoside 
Ito et al.139 synthesized pseudaminic acid starting from N-acetylglucosamine 82, 
which was subjected to deoxygenation and deoxyamination with inversion of 
configuration to give 6-deoxy-AltdiNAc 39, the key precursor for the biosynthesis of 
pseudaminic acid. This precursor was subjected to In-mediated allylation with a 
bromomethacrylate ester followed by ozonolysis and hydrolysis to give the pseudaminic 
acid 115. In order to do a chemical glycosylation reaction, this pseudaminic acid was 
converted to the dibenzyl phospite donor 116. Glycosylation with the primary acceptor 
117 in acetonitrile afforded the disaccharide 118, albeit in only 28% yield, with the 
undesired axial anomer as the major anomer in the ratio of 10:1 (Scheme 4).  
 
Scheme 14: Ito’s synthesis of a pseudaminic acid and its glycoside 
1.9.3 Kiefel’s synthesis of Pse 
Kiefel et al. in 2016 reported the synthesis of Pse5Ac7Ac starting from the most 
common sialic acid, N-acetylneuraminic acid (Scheme 15).39,140 While the concept of 
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of the 5-acetamide using acetic acid as nucleophile resulted in the formation of the penta-
acetate 120, losing the differential functionalization at the 5-position in presence of 
mulitiple other acetates. Secondly, the yields toward the end of the synthesis were low 
making it difficult to scale up the total synthesis. Thirdly, the protocol doesn’t provide a 
Pse donor with which to carry out any chemical glycosylation reactions. 
 
Scheme 15: Kiefel’s synthesis of Pse5Ac7Ac starting from Neu5Ac 
1.9.4 Li’s synthesis of Pse and its glycosides 
Li et al.141 synthesized the Pse donor 130 in 16 steps and 11% overall yields, and 
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acceptors (Scheme 16). In all of the cases, the glycosylated products gave the axial 
anomers as the major isomers.  
 
Scheme 16: Li’s synthesis of a Pse donor and its glycosylation 
Nonetheless, it is significant that Li and coworkers went on to synthesize 
pseudaminic acid itself (Scheme 17), and also the pilin trisaccharide 30 (Scheme 18). 
 
Scheme 17: Glycosylation and deprotection of the Pse donor 130 giving Pse5Ac7Ac 
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Scheme 18: Glycosylation of the Pse donor 130 giving the trisaccharide 30 
1.9.5 Chou’s chemoenzymatic synthesis of Pse 
Chou et al.142 in 2005 used a chemoenzymatic approach to synthesize Pse5Ac7Ac 
from the 2,4-diacetamido-2,4,6-trideoxy-β-L-altropyranose (6-deoxy-AltdiNAc) 
precursor 39. The 6-deoxy AltdiNAc precursor 39, synthesized chemically in 12 known 
literature steps from L-fucose, was condensed with phosphoenolpyruvate (PEP) in the 
presence of an enzyme obtained from Campylobacter jejuni, pseudaminic acid synthase 
homolog (NeuB3), to give Pse. It was found that the pseudaminic acid synthase required 
a divalent ion for catalysis and that the optimal catalysis conditions are at pH 7.0 
(Scheme 19). 
 
Scheme 19: Chou’s chemoenzymatic synthesis of Pse 
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1.9.6 Schoenhofen’s chemoenzymatic synthesis of Pse 
Schoenhofen et al.97 in 2006 were able to synthesize CMP-Pse from the natural 
precursor, UDP-GlcNAc. The idea behind this chemoenzymatic approach came from 
close inspection of the biosynthesis of pseudaminic acid observed in C. jejuni and H. 
pylori. Combining all six of the biosynthetic enzymes from H. pylori in one-pot, they 
were able to achieve the first in vitro synthesis of CMP-Pse (Scheme 20). 
 
Scheme 20: Schoenhofen’s one-pot enzymatic synthesis of CMP-Pse 
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replacement of the C-O bonds at the 7- and 9-positions by C-N and C-H bonds, the 
synthesis itself is necessarily challenging.  
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1.10.1 Inversion of configuration at C-5 via oxidative deamination 
One of the major hurdles in converting NeuAc to Pse is the inversion of 
configuration at C-5, the equatorial acetamide of NeuAc needing to be converted to the 
axial acetamide. The only known way is to perform oxidative deamination of the 
acetamide to obtain an oxygenated product, and then try invert the configuration. In 2013, 
Kiefel et al.39 achieved the inversion of configuration at C-5 via the oxidative 
deamination approach using acetic acid as nucleophile en route to the synthethis of Pse 
(Scheme 21).140 Nevertheless, this approach of using acetic acid as nucleophile resulted 
in the formation of a penta-acetate requiring subsequent differentiation of ester groups. 
Further, the protocol demanded heating the acetamido containing substrate to 50 ºC, with 
the strong possibility of losing stereocontrol. 
 
Scheme 21: Kiefel’s approach of oxidative deamination en route to Pse synthesis 
The Crich lab has also been working on the modified Schreiner and Zbiral 
oxidative deamination of the sialic acids using different nucleophiles under the milder 
conditions of -10 ºC, one of the nucleophile being acetic acid (Scheme 22).145 
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Scheme 22: Crich’s approach to oxidative deamination 
1.10.2 Inversion of configuration at C-8 and C-7 
Zbiral et al.146 in 1989 reported the synthesis of 4-epi and 8-epi N-
acetylneuraminic acid, utilizing a two-step protocol involving oxidation (RuO4 in CHCl3) 
followed by stereoselective reduction (BH3.NH3 in MeOH) in 80% yield over two steps. 
Following a similar protocol, Kiefel et al. in 2016 inverted the configuration at C-8 using 
oxidation (Dess-Martin periodine in CH2Cl2) followed by stereoselective reduction (1M 
BH3.THF in THF) in 68% yield in 2 steps (Scheme 23).140 Fortunately, the major product 
formed was the desired isomer but the unintended isomer was also formed in 21% yield, 
and is inconvenient to recycle and tedious to isolate.  
Scheme 23: Kiefel’s method of oxidation and reduction to invert configuration of C8  
Similarly, inversion of configuration at C-7 with replacement of the C-O bond 
with a C-N bond is also challenging. The plan would be to convert the hydroxy group to a 
good leaving group (such as –OTs, -OMs or –OTf) and then carry out SN2 substitution 
with an azide group to install the –C-N bond with correct configuration (Scheme 24). 
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Scheme 24: Planned inversion of configuration replacing C-O with C-N at C7 
1.10.3 Deoxygenation at C-9 
The installation of a C-H bond in place of a C-O bond i.e deoxygenation, at C-9 is 
another challenging aspect of this total synthesis. Previously, only one case of the 
deoxygenation at C-9 of a sialic acid had been performed. Kiefel and Payne et al. in 2016 
achieved this in a two step sequence by first installing an iodo group at C9 and then 
performing hydrogenolysis to obtain the desired product (Scheme 25).140 However, this 
approach yielded only 44% of the desired material in 2 steps. 
 
Scheme 25: Kiefel’s approach of C-9 deoxygenation 
1.10.4 Effect of C-5 stereochemistry on the glycosylation selectivity 
To understand how the C-5 stereochemistry on the sialic acid donor might impact 
the selectivity on the glycosylation reaction, a general glycosylation mechanism with a 
common promoter, NIS/TfOH, leading to the final glycosylated product is shown below 
(Scheme 26).147,148 
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Scheme 26: General equilibria in the glycosylation of sialic acid with NIS/TfOH as 
promoter 
 
In general, the equilibrium position and hence the glycosylation selectivity is 
affected by the ability of the substituents and solvents to shift the equilibria by the 
differential stabilization of positive charge at the anomeric center. More importantly, 
electron-withdrawing groups destabilize the positive charge and shift the equilibria to the 
left toward the contact ion pair (CIP), giving greater equatorial selectivity. While the 
axial C-O and C-N at C-5 stabilize the positive charge electrostatically better than the 
equatorial one,149,150 leading the equilibria towards solvent-separated ion pair (SSIP), 
giving more of the axial selectivity. Therefore, sialyl donors with ax C-N bonds are 
expected to be less selective than the equatorial isomers (similar to that of the relative 
reactivity and selectivity of gluco and galactopyranosyl donors),151-154 meaning that the 
equatorial glycosylation selectivity in the pseudaminic acid is expected to be challenging.  
1.11 Goals of this thesis 
Starting from the commercially available N-acetyl neuraminic acid, the donors of 
rare but important classes of sialic acid, legionaminic acid and pseudaminic acid donors 
will be synthesized, and their glycosylation reactions with various acceptors will be 
described. Additionally, the glycosylation selectivity observed will be discussed with the 
help of the conformational analysis of the exocyclic bond to the side chain. Chapter 2 will 
describe about the synthesis of a legionaminic acid donor and the stereoselective 
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synthesis of its equatorial glycosides. Chapter 3 will describe about the synthesis of a 
azido based 5-epi-equatorial NeuAc donor related to the pseudaminic acid glycosides and 
its use in the stereoselective synthesis of 5-epi-equatorial glycosides. Additionally, the 
synthesis of a NeuAc donor and its stereoselective synthesis of NeuAc glycosides will be 
described, and compared with the 5-epi-equatorial NeuAc in terms of glycosylation 
reactivity and selectivity. The observations will also be analyzed through side chain 
conformation of the donors. Finally, in Chapter 4, synthesis of a pseudaminic acid donor 
and the stereoselective synthesis of its equatorial glycosides will be described, followed 
by the analysis of its side chain conformation. All the synthesized glycosides will be 
subjected to straightforward deprotection sequences to give the final fully deprotected 
glycosides. 
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CHAPTER 2. STEREOSELECTIVE SYNTHESIS OF THE EQUATORIAL 
GLYCOSIDES OF LEGIONAMINIC ACID 
 
2.1 Background 
Legionaminic acid was first identified from the lipopolysaccharide (LPS) of a 
Gram-negative bacteria, Legionella pneumophila in 1994 in the form of the equatorial 
(2→4) linked homopolymer 26.31 Such a late discovery of legionaminic acid can be 
attributed to its low abundance in nature and the lack of powerful glycoanalysis tools. 
With the eventual improvements in analytical tools, legionaminic acid has since been 
reported in other bacterial glycoconjugates, such as the repeating unit of heteropolymeric 
LPS, capsular polysaccharides and O-linked monosaccharide modifications on the 
flagellae of numerous Gram-negative pathogens, such as Campylobacter jejuni,34,35,96 
Cronobacter turicensis,155 Enterobacter cloacae,156 and Acinetobacter baumannii.157 
Therefore, legionaminic acid glycosides can be considered as candidates for the 
development of antibacterial vaccines and for use in diagnostic tools.134,158 For such 
studies to be undertaken, greater quantities of legionaminic acid135,136 and its 
glycosides40,41 are required. Recent biosynthetic works accessing legionaminic acid and 
its glycosides are promising but not sufficient, hence practical chemical syntheses are 
mandatory. Synthetic work by Tsvetkov et al.43 and Seeberger et al.134 provide 
insufficient amount or unwanted glycosylation selectivity. Synthesis of such an azido 
based legionaminic acid donor and the study of its glycosylation reactions is the focus of 
the work described in this chapter. 
 
 
 
 
 
 
 
39 
2.2 Results and discussion 
2.2.1 Retrosynthetic analysis of the synthesis of a legionaminic acid donor 
N-acetylneuraminic acid is the starting material for the synthesis of the 
legionaminic acid donor 154, owing to its low cost commercial availability. The 
thioadamantanyl group is the preferred leaving group in the synthesis of the thioglycoside 
159, as it is relatively easy to activate under the glycosylation conditions at – 78 ºC. The 
use of the electron-withdrawing azide group as in the case of 158 as amine protection is a 
logical one, as similar electron-withdrawing groups such as the 4,5-
acetyloxazolidinone,130,131 oxazolidinone,132,133 isothiocyanate118 moieties furnished 
equatorial glycosylation selectivity. The azide group can also be readily installed and 
deprotected, making it one of the best amine protecting groups. The C-5 acetamido group 
can be converted to the azido group in a sequence of reactions consisting of Boc 
installation, Zemplen deacetylation, removal of Boc group and then use of Stick’s reagent 
to the synthesized amine intermediate. This sequence of reactions requires a selective 
protection of 4- and 8-hydroxy groups to be performed in presence of 7-hydroxy group 
such as in 157. The 7-hydroxy group has been found to be the most hindered hydroxy 
group in N-acetylneuraminic acid,160 so this reaction is quite feasible. Finally inversion of 
configuration at C-7 followed by triflation and azido installation in SN2 fashion was 
expected to furnish the desired legionaminic acid donor such as 154 (Scheme 27).  
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Scheme 27: Retrosynthesis of a planned legionaminic acid donor 154 
2.2.2 Synthesis of the 5-N-Boc protected thioadamantanyl sialoside 162 
Synthesis of the Leg donor started from N-acetylneuraminic acid, which was 
converted to the N-Boc adamantanyl thioglycoside 162 in five known straightforward 
literature steps.131,159 The first step was esterification of NeuAc using Amberlyst-15 H+ 
ion-exchange resin to obtain 159, which was then acetylated to give 160.161 
Thioglycosylation of 160 using 1-adamantanethiol in the presence of boron trifluoride 
etherate gave 141,131 which was the common intermediate for use in the synthesis of all 
of the sialic acid donors. Boc installation on the amine group of 141 gave 161,131 which 
was followed by Zemplen deacetylation to give 162 (Scheme 28). All of these steps 
proceeded with excellent yields. 
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Scheme 28: Synthesis of the 5-N-Boc protected thioglycoside 162 
2.2.3 Selective functionalization of the 9-hydroxy group 
Selective functionalization of the primary hydroxyl group at C9 of sialic acid in 
the presence of other secondary hydroxyl groups is not a new topic. Kiefel et al. has 
attempted installing few groups at the C9 position, either by replacing or protecting the 
hydroxy groups of 163 in attempts to synthesize 165 (Scheme 29).39 
 
Scheme 29: Overview of Kiefel’s attempt to selectively functionalize C9-hydroxy 
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Table 3: Conditions attempted by the Kiefel group to form 164 
R =  Conditions Product 
1. I I2, PPh3, imidazole, THF, Reflux, 2 h N.R. 
2. Br CBr4, PPh3, toluene/MeCN, RT, 12 h N.R. 
3. OTs TsCl, pyridine N.R. 
4. H 2-nitrobenzenesulfonylhydrazide, PPh3, DIAD, THF N.R. 
 
Unsuccessful attempts by Kiefel et al. in functionalizing C9 hydroxy group (Table 
3) suggested some activation issues. Particularly, the lack of reaction with tosyl chloride 
was surprising. Finally, a modified Appel reaction to install an iodo group on 126 gave 
166. It was also able to install a TBDMS protecting group selectively in 167 to give 122 
were applied at C9 in attempts to access pseudaminic acid (Scheme 30).39 
 
Scheme 30: Kiefel’s successful functionalization of the C9-OH to give 166 and 122 
In the light of Kiefel’s work, a novel approach to selective sulfonylation of the C9 
primary hydroxyl group of 162 with 2,4,6-triisopropylbenzenesulfonyl chloride (TPSCl) 
in pyridine was attempted and gave sulfonate ester 168 in 71% yield (Scheme 31).162 
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Scheme 31: Selective trisylation of the C9 hydroxy group to give 168 
2.2.4 Synthesis of a 9-iodo dibenzoylated sialoside 
Functionalization of the trisyl (OTPS) group in compound 168 was attempted 
next to access the 9-deoxy derivative of the sialic acid thioglycoside. Heating 168 in 
presence of potassium tert-butoxide as base in dry DMSO163 at 100 ºC didn’t proceed to 
give the expected product 169 via the formation of an enol, probably due to the hindered 
nature of the tertiary proton at C-8. However, when 168 was heated in acetone with 
excess sodium iodide the iodo product 170 was obtained in excellent yield (Scheme 
32).162 
 
Scheme 32: Attempts at the synthesis of 9-deoxy derivative of 168 
2.2.5 Deiodination and synthesis of 5-azido sialoside. 
Selective benzoylation of 170 with benzoyl chloride in pyridine at 0 ºC afforded 
the 4,8-di-O-benzoate 171 in 91% yield, which followed the established pattern of 
reactivity in the N-acetylneuraminic acid series.160 Selective acetylation was the preferred 
choice, but was less selective and resulted in formation of a substantial amount of 
triacetate product. Thereafter, radical reaction conditions with tris(trimethylsilyl)silane164 
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and initiation by azoisobutyronitrile in benzene at 60 ºC gave the dehydroiodinated 
product 172. Partial cleavage of the carbamate by the silyl iodide generated during the 
reaction was seen. Therefore, the crude product was directly carried forward into the next 
step of removal of Boc group to obtain the hydrochloride salt of the amine 173 using 
hydrogen chloride in ether. The crude amine 173 was converted to the corresponding 
azide 174 in 78% overall yield from 171 with the help of Stick’s reagent165,166 and 
triethylamine in the presence of catalytic copper sulfate in aqueous acetonitrile (Scheme 
33). Traditional bases for the azidation reaction, such as sodium carbonate or potassium 
carbonate were not used in place of triethylamine to suppress competing debenzoylation, 
while the more common aqueous methanol was not used in place of aqueous acetonitrile 
due to the poor solubility of 173 in methanol. 
Hydrogenolytic methods to obtain 172, both in batch and flow conditions, were 
also successful for the hydrodeiodination step, but it was not possible to fully suppress 
the concomitant hydrogenolysis of the thioglycoside. 
 
Scheme 33: Deiodination of 170 and synthesis of 5-azido thioglycoside 174 
2.2.6 Selective formation of a 7,8-di-O-benzoate 
One of the alternative methods attempted to access 174 was the reversal of the 
deiodination and regioselective benzoylation steps. For this, hydrogenolysis of 170 over 
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palladium hydroxide on charcoal in methanol was carried out to give a deiodo derivative 
followed by acid mediated deprotection of the Boc group, and then reaction with Stick’s 
reagent in the presence of catalytic copper sulfate and potassium carbonate in aqueous 
methanol to give the triol 175 in 39% overall yield for the three steps from 170 (Scheme 
34). However, treatment of 175 with benzoyl chloride in pyridine at 0 ºC did not afford 
the anticipated 4,8-di-O-benzoate 174; rather it gave 7,8-di-O-benzoate 176 in 46% yield 
(Scheme 34). Typically, in neuraminic acid derivatives, as has been seen in the 
conversion of 170 to 171, functionalization preferentially takes place at 4-OH in the 
presence of 7-OH.160 The selectivity reversal in the case of 176 suggests that the 
conversion of 170 to 171 depends on the presence of a functional group at the 9-position, 
perhaps due to steric buttressing, and is reversed for 176 due to 9-position being 
unfunctionalized. Alternatively, the difference in regioselectivity may be due to the 
differing functionalities on nitrogens. 
 
Scheme 34: Selectivity reversal of 170 to give the 7,8-di-O-benzoate 176 
2.2.7 Inversion of configuration of the 7-hydroxy group 
Alcohol 174 was converted to ketone 177 with Dess-Martin periodinane 
oxidation167 in 85% yield. Attempted replacement of the C7-hydroxy of 174 with an 
amine functionality in a single step reductive amination of 177 to obtain 178 involved 
reacting 177 with benzylamine with either sodium triacetoxyborohydride168 or sodium 
cyanoborohydride.169 However, the expected product 178 was not obtained. Therefore, 
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the more straightforward but longer route of double stereoinversion at C-7 was 
performed. Thus, consistent with the precedent in the N-acetylneuraminic acid 
series,143,170 Luche reduction171 of 177 in methanolic dichloromethane at -78 ºC afforded 
a 85:15 mixture of epimeric alcohols from which 179 was isolated in 82% yield, giving 
the first stereoinverted product in the sequence (Scheme 35). 
Scheme 35: Inversion of configuration at C7 of 174 
2.2.8 Synthesis of a 5,7-diazido Leg donor 
In order to access an amine functionality at C7, a second stereoinversion was 
performed on 179. Thus, triflation of 179 with triflic anhydride in pyridine in 
dichloromethane at 0 ºC afforded 180, which was treated with excess sodium azide in 
DMF at 0 ºC to give the desired legionaminic acid donor 181 in 81% yield (Scheme 36).  
 
Scheme 36: Synthesis of the 5,7-diazido Leg donor 181 from 179 
In summary, a legionaminic acid donor was synthesized in 15 straightforward 
steps and in 17% overall yield from the commercially available N-acetylneuraminic acid, 
as summarized below in Scheme 37. This synthesis is a significant improvement over that 
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described by the Seeberger laboratory from D-threonine134 achieved in 17 steps and 7% 
overall yield. 
 
Scheme 37: Total synthesis of the Leg donor 181 from NeuAc, 3 
2.2.9 Synthesis of a sialic acid acceptor 
With the eventual synthesis of polylegionaminic acid in mind, a sialic acid based 
acceptor carrying a free hydroxyl group at the 4-position was synthesized to perform 
glycosylation reaction with the new legionaminic acid donor 181. The triol 182 having an 
azido group, readily accessed from NeuAc by known methods,159 was converted to 8,9-O 
acetonide 183 in 83% yield. This was followed by selective silylation at the 4-position to 
give mono silyl ether 184 in 91% yield. Acetylation of the remaining hydroxyl group 
gave 185 in 98% yield, and TBAF mediated cleavage of the silyl ether afforded the 
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acceptor 186 in 98% yield, ready for the glycosylation with the legionaminic acid donor 
181. 
 
Scheme 38: Synthesis of the sialic acid acceptor 186 
2.2.10 Glycosylation study with the Leg donor 
Glycosylation reactions of suitable acceptors with the legionaminic acid donor 
181 was performed at -78 ºC in 1:2 acetonitrile/dichloromethane in the presence of acid-
washed 4Å molecular sieves, with the activation being achieved by the combination of N-
iodosuccinimide and trifluoromethanesulfonic acid. All reactions were quenched by 
addition of triethylamine at -78 ºC (Scheme 39). 
All the glycosylation reactions afforded equatorial glycosides in good to excellent 
yield and selectivity. As expected, the best selectivity was observed with the reactive 
primary acceptor benzyl alcohol followed by the primary carbohydrate-based acceptor 
187. The other two secondary carbohydrate-based acceptors 188 and 189 also gave good 
selectivity. The galactose based 3,4-diol 189 gave three glycosylated products, two of 
them being equatorial and axial 2→3 linked products in comparable selectivity, and the 
third being an equatorial 2→4 linked product. Glycosylation of a relatively less reactive 
tertiary alcohol 190, 1-adamantanol, also gave satisfactory selectivity, in fact better than 
with the secondary alcohols. The glycosylation selectivity observed with the sialic acid 
O
HO
N3
HO OH OMe
CO2Me
HO Me2C(OMe)2,
Me2CO, CSA,
83%
O
HO
N3
O OH OMe
CO2Me
O
O
TBSO
N3
O OAc OMe
CO2Me
O
O
HO
N3
O OAc OMe
CO2Me
O
TBSCl,
imidazole,
DMF, 91%
O
TBSO
N3
O OH OMe
CO2Me
O
Ac2O, py
98%
TBAF, THF
98%
182 183 184
185 186
 
 
 
 
49 
acceptor 186 was also comparable with the other secondary acceptors (Table 4). The 
glycosylation experiments showed that the azido based legionaminic acid donor 181 is 
highly beneficial in imparting equatorial selectivity.  
 
Scheme 39: Glycosylation with Leg donor 181 
Table 4: Glycosylation reactions of various acceptors with 181 
Entry Acceptor Product % 
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5 
 
 
88%,b 
4.7:1: 
0.9 
195eq: 
7.0 Hz 
196eq: 
6.3 
6 1-adamantanol, 190 
 
73%, 
4.2:1 
197eq: 
5.7 Hz 
a) Glycosylation gave an 84% yield of an inseparable 4.5:1 eq.:ax. mixture of the 
disaccharides, which was saponified to give the products 194eq. and 194ax; b) In 
order to determine the regioselectivity of the glycosylation with 190, a chemical 
correlation was done as described in section 2.2.14. 
The anomeric configuration of the synthesized glycosides was assigned based on 
the heteronuclear 3JC1,H3ax coupling constant method as discussed below in section 
2.2.14.172-175 A rationale for the loss of some selectivity in the glycosylation of Leg 
donor, as compared to a 5-azido NeuAc donor synthesized in Chapter 3, invokes the 9-
deoxy nature of the side chain, which makes it less disarming, hence affording greater 
oxocarbenium-like character in the transition state. Additionally, the electron-
withdrawing ability of the azido group in the 7-deoxy-7-azido substitution can also play a 
role in the change of selectivity.176 
2.2.11 Deprotection of regioisomeric equatorial-(2→6) galactosyl disaccharide 
The equatorial 2→6 linked dibenzoyl disaccharide 192 obtained as the 
glycosylated product was subjected to a four-step deprotection sequence to afford the 
final fully deprotected disaccharide 200. Compound 192 was converted to the 
corresponding diol with sodium methoxide in methanol to give 198 and then by 
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hydrogenation and peracetylation to give 199. The final global hydrolysis of all esters 
was carried out by hot aqueous barium hydroxide to give N,N-diacetyllegionaminic acid 
glycoside 200 in good overall yield (Scheme 40). Initial removal of the two benzoate 
esters was selected before the hydrogenolysis of the azide groups to avoid possible O→N 
benzoate migration. 
 
Scheme 40: Deprotection of equatorial 2→6 galactosyl disaccharide 192 to give 200 
2.2.12 Deprotection of regioisomeric equatorial (2→3) galactosyl disachharide  
The equatorial (2→3) linked disaccharide 194 from which the benzoate esters, 
already deprotected to facilitate separation of the anomers, was subjected to the three step 
deprotection sequence of hydrogenation and peracetylation to give 201. Global 
deprotection with hot aqueous barium hydroxide then gave N,N-diacetyllegionaminic 
acid 202 in good yield (Scheme 41). 
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Scheme 41: Deprotection of equatorial 2→3 galactosyl disaccharide 194 to give 202 
In order to prove the regiochemistry of 195eq, deprotection of the benzoate esters 
was carried out to give 203, followed by hydrogenolysis and peracetylation. This 
sequence of reactions afforded a second identical sample of 202, proving the 
regiochemistry of 195eq (Scheme 42). 
 
Scheme 42: Proof of regiochemistry of 195eq 
2.2.13 Influence of configuration of C7 on side-chain conformation 
The synthetic route adopted for the preparation of donor 181 gives us a good 
opportunity to evaluate the influence of C7 configuration on the side-chain conformation. 
Based on their 3J6,7 values, compounds 174 and 181 retaining their D-glycero-D-galacto 
configuration of N-acetylneuraminic acid predominantly adopt the gg-
conformation,143,177-182 whereas 179 differing from 174 only in C7 configuration 
predominantly adopts the gt-conformation about the exocyclic bond.43,144,183 Key spectral 
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parameters and the proposed conformations of the C7 epimers 174 and 179, and of donor 
181 are shown in the Table 5. 
Table 5.  Key spectral parameters and side chain conformations of 174, 179 & 181 
Compound Key NOE Contacts 
3J6,7 
(Hz) C6-C7 conformation 
181 H8-H6 1.4 
 
 
174 
 H8-H6, H7-H5 ≤1 
 
179 H8-H5, H6-H9 2.9 
 
 
2.2.14 Assignment of configuration for coupled sialosides 
There are various conventional methods available for configurational assignment of 
aldopyranosides such as the measurement of 3JH1-H2 and 1JC1-H1 NMR coupling constant 
values. However, these methods cannot be applied to the sialic acid glycosides due to the 
absence of an anomeric proton. To resolve this problem in establishing anomeric 
configuration of sialosides, several alternative methods have been described in the 
literature based on 
1. the chemical shift of the H-3eq,184 and H-4185,186 resonances 
2. the Δδ value of the resonance for H9a-9b,187 
3. the δ values of H-7 and H-8,186,187 
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4. the measurement of 3JC-1, H3ax heteronuclear coupling constants143,172-175 
Methods 1-3 described here are based on the interpretation of chemical shift 
differences, which are unreliable and affected by many factors. But method 4, the 
measurement of  3JC-1, H3ax coupling constants, is an acceptable method as it is based on 
the correlation of coupling constants with torsional angle and is more reliable. This 
method differentiates between equatorial and axial glycosides based on the respective 
numerical values of 5-7 Hz and 0-2 Hz of the 3JC-1, H3ax coupling constants. The coupling 
constant value difference for 3JC-1, H3ax of the sialoside anomers has been rationalized by a 
Karplus relationship, provided the pyranose ring is in the expected 2C5 chair 
conformation. In this scenario, the dihedral angles of C1-C2-C3-H3ax of the equatorial 
and axial anomers are 180º and 60º, respectively (Figure 9).173 
 
Figure 9: Dihedral angles of equatorial and axial sialosides 
One example illustrating the practical implementation of the method is shown in 
Figure 10, whereby three different NMR experiments have been exploited to measure the 
3JC-1,H3ax coupling constants. 
The first experiment is the standard broadband proton decoupled 13C NMR 
showing 5 carbonyl signals in the downfield region (166-172 ppm). The second 
experiment is the 13C NMR spectrum with the broadband decoupler turned off showing 
the complete proton coupling profile for the carbonyl carbons. The most important third 
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experiment is the 13C NMR spectrum obtained after the selective irradiation of the methyl 
group protons of the C-1 ester, which reduces the C-1 resonance to a doublet and 
provides the 3JC-1,H3ax coupling constant value (Figure 10). 
 
Proton decoupled carbon spectrum
Proton coupled carbon spectrum
SFORD carbon spectrum 
Figure 10: Example of 3JC-H analysis using the SFORD experiment 
 
2.3 Conclusion 
          In conclusion, a simple diazido protected legionaminic acid thioglycoside donor 
was synthesized in 15 steps and 17% overall yield from the readily available N-
acetylneuraminic acid. The thioglycoside donor imparted moderate to excellent 
glycosylation selectivity, when coupled with a range of primary, secondary and tertiary 
alcohols. Of particular note is the stereoselective coupling to the neuraminic acid based 
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acceptor 188, whose glycosidic linkage with the donor closely resembles that found in the 
(2→4)-polylegionaminic acid from the lipopolysaccharide of the L. pneumophila 
virulence factor. Two of these glycosylated products were then subjected to a 
straightforward deprotection sequence, to finally afford the fully deprotected N,N-
diacetyllegionaminic acid glycosides. This successful synthesis of a legionaminic acid 
donor and its stereoselective glycosylation reactions opened the way for the synthesis of 
the more complex pseudaminic acid donor, described in the next chapters. 
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CHAPTER 3. STEREOSELECTIVE SYNTHESIS OF EQUATORIAL 5-EPI-
SIALOSIDES RELATED TO THE PSEUDAMINIC ACID GLYCOSIDES 
 
3.1 Background 
As a logical first step in a systematic investigation into the synthesis of the Pse 
glycosides, the synthesis of an azido based 5-epi-NeuAc thioglycoside donor was 
planned, so as to use it as a model for the glycosylation selectivity and reactivity. The use 
of the existing methods for the synthesis of NeuAc glycosides, especially for the 
equatorial glycosides, cannot be applied uncritically to the synthesis of the Leg and Pse 
glycosides, owing to the structural and configurational differences between Pse and 
NeuAc. Notably, the differences in configuration at the 5-,7-, and 8-positions and the 
replacement of the C-O bonds at the 7- and 9-positions by C-N and C-H bonds, 
respectively, in Pse potentially could all result in changes in glycosylation reactivity and 
selectivity. In fact, the simple inversion of configuration at the 7-position of NeuAc leads 
to differences in glycosylation reactivity and selectivity of O4,N5-oxazolidinone-type 
sialic acid donors,143 because of the imposed change in side chain conformation from gg- 
to gt-,144 with the natural 66 being more reactive and more equatorially selective than its 
unnatural C-7 epimer unnatural 205 (Figure 11). 
 
Figure 11: O4, N5-oxazolidinone sialic acid 66 and its unnatural C-7 epimer 205 
This has also been shown to be the case in the previous chapter on the synthesis of 
legionaminic acid donor 181, wherein a simple inversion of configuration at C7 in 179 
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led to a conformational change of the side chain from gg- to gt-.162 Additionally, there is 
substantial literature precedent on the influence of the N5 protecting group on the 
glycosylation selectivity of sialic acid donors.111,118,130-133,188 Notably, the replacement of 
an equatorial substituent by the axial substituent typically affects the glycosylation 
reactivity and selectivity.149,150,189-196 Therefore, before venturing into the complex 
synthesis and glycosylation of a Pse donor, the synthesis of the aforementioned 
intermediate donor, namely an azido based 5-epi-NeuAc thioglycoside was envisioned 
(Figure 12), to check the influence of the configuration at C5 on the reactivity and 
selectivity. Accordingly, synthesis of a 5-epi-NeuAc thioglycoside donor and its 
stereoselective glycosylation reaction is the focus of the work described in this chapter. 
 
Figure 12: Planned 5-epi NeuAc thioglycoside donor 206 
3.2 Results and Discussion 
3.2.1 Zbiral oxidative deamination of a NeuAc thioglycoside with levulinic acid as 
nucleophile 
The only successful route for the inversion of configuration at C5 of N-
acetylneuraminic acid employs Zbiral’s oxidative deamination, to access a derivative of 
3-deoxy-D-glycero-D-galacto-2-nonulosonic acid (KDN, Figure 13) with retention of 
configuration.39,140  
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Figure 13: 3-deoxy-D-glycero-D-galacto-2-nonulosonic acid (KDN) 
The original Zbiral deamination sequence synthesized the nitrosyl sialic acid 208 
with nitrosyl acetate generated in situ from gaseous dinitrogen tetroxide and sodium 
acetate. The gaseous dinitrogen tetroxide needed for the reaction was generated by 
decomposition of lead nitrate. The nitrosyl sialic acid 208 was treated with 
trifluoroethanol and sodium isopropanol to generate the 5-diazo sialic acid 209 in situ, 
which was immediately quenched with a mixture of tetrabutylammonium acetate and 
acetic acid to afford the hexaacetylated sialic acid 210. Similarly, treating the in-situ 
generated 5-diazo sialic acid 209 with hydrazoic acid as nucleophile furnished the 5-
azido sialic acid 211 (Scheme 43).197 
 
Scheme 43: Original Zbiral deamination reaction with acetic acid and hydrazoic 
acid as nucleophiles 
O
HO
HO
HO OH OH
CO2H
HO
207
O
AcO
AcHN
AcO OAc OAc
CO2Me
AcO CH3CO2NO O
OAc
AcN
AcO OAc OAc
CO2Me
AcO
NO
O
OAc
AcO OAc OAc
CO2Me
AcO
N2
O
OAc
AcO OAc OAc
CO2Me
AcO
N2
O
AcO
AcO
AcO OAc OAc
CO2Me
AcO
O
AcO
N3
AcO OAc OAc
CO2Me
AcO
Bu4NOAc
AcOH
HN3
toluene
210
211
CF3CH2OH
NaOiPr
160 208 209
209
53%
65%
 
 
 
 
60 
The use of lead nitrate was not considered green, so a more environmentally 
friendly alternative route to access the intermediate nitrosyl sialic acid was imperative. 
To this end, Crich et al. carried out the nitrosation reaction with nitrosonium 
tetrafluoroborate and pyridine to give the nitrosyl sialic acid intermediate 212 in 
quantitative yield. This compound was then deaminated with the trifluoroethanol/sodium 
isopropoxide couple and acetic acid as nucleophile to access the KDN derivatives 142-
145.145 The reaction was compatible with various other nucleophiles as well, such as 
hydrogen fluoride and thioacetic acid (Scheme 44). 
 
Scheme 44: Crich’s alternate route to generate a N-nitrosoamide intermediate in a 
modified Zbiral reaction 
 
Starting from the 5-acetamido sialoside 119, Kiefel et al. also performed a one-
pot reaction with sodium nitrite and a mixture of acetic acid and acetic anhydride to 
synthesize the KDN derivative 120 via the nitrosyl sialic acid intermediate 213 in situ  
(Scheme 45).39,140 
 
Scheme 45: Kiefel’s one-pot protocol to generate N-nitrosamide in situ 
However, a drawback to their methods was the use of acetic acid as nucleophile in 
oxidative deamination reaction, which resulted in the formation of the penta-acetate 120, 
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lacking the differential functionalization at the 5-position. A first goal was therefore to 
replace acetic acid by an alternative nucleophile, so as to afford a KDN derivative with 
differential protection of O5. 
The common intermediate 141 for the synthesis of all of the sialic acid donors in 
this thesis was synthesized from N-acetylneuraminic acid in 3 steps and 70% overall 
yield.131 With compound 141 in hand, the synthesis of a selectively protected 3-deoxy-D-
glycero-D-galacto-2-nonulosonic acid (KDN) derivative suitable for the introduction of 
nitrogen functionality (azido in our case) at the 5-position was explored. Accordingly, 
141 was treated with nitrosonium tetrafluoroborate in the presence of pyridine in 
dichloromethane at -10 ºC to obtain the N-nitroso derivative 212. This compound was 
subsequently treated with levulinic acid to obtain the 5-O-levulinyl KDN derivative 214 
in 49% yield, alongside the 4,5-di-O-levulinyl product 215 in 21% yield (Scheme 46). 
Reaction of levulinate 214 and dilevulinate 215 with hydrazine monohydrate in acetic 
acid and pyridine afforded the KDN-5-ol 216 and 4,5-diol 217, thus confirming the 
regioselectivity of 215 in the ester exchange reaction.198 
 
Scheme 46: Modified Zbiral deamination with levulinic acid as nucleophile 
The exchange of the 4-O-acetate with the nucleophilic carboxylate as a minor 
process follows same pattern the Crich laboratory has previously observed when using 
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isotopically labeled acetic acid as nucleophile, whereby the exchange was observed only 
with the axial thioglycoside 141 and not with the equatorial thioglycoside 220 (Scheme 
47).159 
 
Scheme 47: Zbiral deamination with isotopically labeled acetic acid as nucleophile 
3.2.2 Synthesis of a 5-epi-azido donor 
Compound 216 was triflated to give 223 in 81% yield, and then treated with 
excess lithium azide in DMF at 0 ºC to afford the D-glycero-D-gulo configured 5-epi-
NeuAc thioglycoside donor 206 in 74% yield (Scheme 48). Lithium azide was used in 
place of more common sodium azide, owing to the higher solubility of lithium azide in 
DMF used as solvent. 
 
Scheme 48: Synthesis of the azido based 5-epi-NeuAc donor 206 
3.2.3 Oxidative deamination of epimeric thioglycoside using levulinic acid 
The same deamination chemistry using levulinic acid as nucleophile was used in 
the deamination of the diastereomeric thioglycoside 220 via the intermediate N-nitroso 
amide 221, obtained by treatment of NOBF4 in presence of pyridine. The intermediate 
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221 gave 5-O-levulinate 224 as a single product in 41% yield. This result confirms the 
previous finding159 that the ester exchange between C4 and C5 occurs only in substrates 
having an axial thioglycoside (Scheme 49). 
 
Scheme 49: Synthesis of the 5-O-levulinoyl epimeric thioglycoside 224 
3.2.4 Oxidative deamination of a NeuAc thioglycoside using triflic acid as 
nucleophile 
The triflated product 223 was also directly accessed from 141 using an oxidative 
deamination protocol with triflic acid as nucleophile in 34% yield (Scheme 50).  
 
Scheme 50: Alternative route to access 223 via deamination reaction with triflic acid 
The triflate anion is widely used as a good leaving group,199,200 but its use as 
nucleophile in substitution reactions is rarely considered, even though there are ample 
examples of such the literature as set out in a recent review.201 
Zefirov and Kozmin have previously shown triflate to be a competitive 
nucleophile that can trap a variety of carbocation-like electrophiles (Scheme 51).202,203 
 
Scheme 51: Electrophilic addition on alkenes to form triflate 
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The high nucleophilicity of triflate toward cation-like species is also apparent 
from an intrinsic reactivity index developed on the basis of a computational study,204 
whereby the ranking of reactivity Cl->Br->>AcO->MeSO3->TfO->MeOH, shows the 
triflate ion to have higher nucleophilicity than methanol. 
The most common use of triflate as nucleophile in preparative chemistry is in the 
generation of glycosyl triflates, which are used as glycosyl donors. Applying appropriate 
conditions, glycosyl donors are converted to the corresponding glycosyl triflates in situ. 
NMR methods have been utilized in the Crich laboratory to reveal the formation of 
glycosyl triflates from glycosyl sulfoxides with triflic anhydride at low temperature 
(Scheme 52).205 
 
Scheme 52: Generation of mannosyl triflate from the sulfoxide 
All of these reactions201 establish the triflate anion as an excellent nucleophile 
toward cation-like electrophiles, and corroborate its use in the direct synthesis of 223. 
The ability to isolate 223 is attributed to the two electron-withdrawing C-O bonds vicinal 
to the triflate which retard any subsequent displacement reactions. 
3.2.5 Glycosylation study with the 5-epi-azido donor 206 
Similar to the case of the Leg donor 181, the glycosylation reactions of assorted 
alcohols were performed with the synthesized 5-epi-NeuAc donor 206 by activating with 
N-iodosuccinimide and triflic acid in a 2:1 mixture of dichloromethane and acetonitrile at 
-78 ºC in the presence of 4Å acid-washed molecular sieves (Scheme 53). The acceptors 
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used were benzyl alcohol, methyl 2,3,4-tri-O-benzyl-β-D-galactopyranoside 187, methyl 
2,4,6-tri-O-benzyl-β-D-galactopyranoside 189 and methyl 2,3,6-tri-O-benzyl-β-D-
galactopyranoside 230. The linkages obtained from the galactopyranosyl 6- and 3-
alcohols 187 and 189 are the most common linkages found in the sialic acid glycosides, 
hence the selection of these alcohols as acceptors for the glycosylation study. The choice 
of highly hindered galactopyranosyl 4-alcohol 230 arose from the presence of the Pse-
eq.(2→4)-6-deoxy-N-acetylgalactosamide linkage in the repeating unit of the 
Pseudomonas aeruginosa O10 lipopolysaccharides.77  
 
Scheme 53: Glycosylation with the 5-epi-NeuAc donor 206 
Glycosylation reactions with all the acceptors including the hindered secondary 
alcohol 230 gave the anticipated products in the form of single equatorial anomers, in 
good to excellent yields as reported in Table 6. 
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Table 6.  Glycosylation Reactions with D-Glycero-D-gulo Donor 206. 
Entry Acceptor Product Yield 3JC1,H3 (Hz) 
1 
 
 
79% 6.9 
2 
  
72% 6.6 
3 
  
57% 7.1 
4 
 
 
44% 7.2 
  
3.2.6 Use of 5-azido as protecting group in sialyl donors 
The excellent selectivity observed with the 5-epi NeuAc donor 206 compares well 
with similar equatorial selectivity reported by Oscarson et al. with the KDO-based 
thioglycoside donor 235 having axial 5-acetoxy group,206 of which example is shown 
below in  Scheme 54. 
 
Scheme 54: Oscarson’s stereoselective glycosylation with the KDO based 5-epi 
acetoxy donor 235 
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With the 5-epi azido protected thioglycoside donor itself, there is no literature 
precedent for the glycosylation reaction, indeed there was no previous synthesis of a 5-
epi donor. However, there are ample examples in the literature of the synthesis of the 
equatorial 5-azido protected NeuAc donors, although the glycosylation stereoselectivity 
has been mostly observed with the primary alcohols as acceptors only. The various 5-
azido protected NeuAc donor and an isothiocyanato protected NeuAc donor described in 
the literature are shown below (Figure 14). 
 
Figure 14: Literature 5-azido and 5-isothiocyanato NeuAc donors 
Schmidt et al. synthesized the ethyl thioglycoside 240, but didn’t follow up with 
any glycosylation reactions.114 The following five laboratories did synthesize 5-azido 
protected NeuAc donors and study their glycosylation reactions as summarized below. 
i) Unverzagt et al. reported the synthesis of the the 5-azido methyl thiosialoside 238 
as an equatorial and axial mixture, alongside the 5-acetamido methyl thiosialoside 
245.207 The acceptor used was the complex trisaccharyl galactosyl 3-OH acceptor 
247, with the activation being achieved at -40 ºC in acetonitrile. Unfortunately, 
this reaction gave only 26% of the tetrasaccharide 250, which was worse than the 
coupling between the 5-acetamido donor 245 and the acceptor 247 (54% yield), 
and there was no discussion of their stereoselectivity (Scheme 55). 
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Scheme 55: Unverzagt’s glycosylation reactions with various NeuAc donors 
ii) The equatorial anomers of 238 and the p-tolyl thioglycoside 251 were 
reported by the Wong group.115 Donors 238 and 251 were coupled with 
various primary and secondary alcohols in acetonitrile at -40 ºC. However, 
good equatorial selectivity was observed only with the carbohydrate based 
primary acceptors 252, 253 and 254 (Scheme  56).  
 
Scheme 56: Wong’s glycosylations with 5-azido NeuAc donors 238 and 251 
The Wong group also reported the synthesis of the sialyl phosphite donor 
242, starting from 251. This donor 242 was also selective toward the primary 
acceptor 259 in acetonitrile at -40 ºC. However, there are no reports of its 
coupling with secondary alcohols (Scheme 57). 
 
O
HO
HO
OH
O
OBz
O(CH2)6NHCbz
NHAc
OO
O
BzOOBz
OBzBzO
O
AcO
R
AcO OAc SMe
CO2Me
AcO
R= NHAc, 54% : 248
      H, 21% : 249
      N3, 26% : 250
R = NHAc (245), H (246), 
       N3 (238)
NIS, TfOH, CH3CN, -40 ºC
O
AcO
R
AcO OAcAcO CO2Me
O O
HO
OH
O
BzO
247
O
AcO
N3
AcO OAc CO2Me
SR’
AcO
R’= p-tolyl: 251
   = Me: 238
ROH
NIS, TfOH
3Å MS
MeCN, 
-40 ºC
O
AcO
N3
AcO OAc CO2Me
OR
AcO
O
OBz
N3
BzO OBz OMe
CO2Me
HO
O
OSiPh2tBu
N3
O
O OH
O
OMP
OH
O
O OH
255: R’= p-tolyl: eq. only; 65%
256: R’= Me: eq. only; 63%
257: R’= p-tolyl: 
       eq:ax (10:1); 53%
258: R’= p-tolyl: 
      eq:ax (3:1); 35%
ROH =
255-258
252 253 254
 
 
 
 
69 
 
Scheme 57: Wong’s glycosylation with the sialyl phosphite donor 242 
iii) The synthesis and glycosylation of 239 from the Li group also suffered the same 
fate of being somewhat selective to the primary acceptors, but not when coupled 
with the secondary acceptors (Scheme 58).116 
 
Scheme 58: Li’s glycosylations with the 5-azido NeuAc donor 239 
iv) Lin et al. reported the synthesis of the more highly armed thioglycoside 241, 
which gave excellent to moderate selectivities with the primary acceptors 261, 
267-270. The yield and selectivity, however, were significantly lower with the 
secondary acceptor 271, and no reaction occurred with a sialic acid-based 
secondary acceptor 272 (Scheme 59).117  
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Scheme 59: Lin’s glycosylation with the armed thioglycoside donor 241 
v) Mukaiyama et al. reported the synthesis of the sialyl fluoride donor 243. On 
reaction with the primary acceptors 268, 279 and 280 at -20 ºC in n-valeronitrile, 
it gave excellent yields and selectivities. With the secondary acceptor 281 only a 
low yield and minimal selectivity were observed (Scheme 60).208 
 
Scheme 60: Mukaiyama’s glycosylation with the sialyl fluoride donor 243 
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reexamination of the use of the N5 azide in the formation of NeuAc glycosides. 
Accordingly, synthesis of the D-glycero-D-galacto configured NeuAc donor 288 was 
attempted. 
3.2.7 Synthesis of a 5-azido NeuAc donor 
The common intermediate 141 for the synthesis of all the sialic acid donors was 
converted to the corresponding 5-amino thioglycoside derivative 286 in 6 known steps 
and 65% overall yield.118,131 Reaction of the 5-amino thioglycoside 286 with Stick’s 
reagent165 in the presence of copper sulfate and potassium carbonate gave the 5-azido 
protected NeuAc thioglycoside 287 in 92% yield, which on acetylation gave the desired 
tetraacetylated 5-azido protected NeuAc donor 288 in 85% yield (Scheme 61).  
 
Scheme 61: Synthesis of the 5-azido thioadamantanyl NeuAc donor 288 
Alternatively, 288 was also accessed directly from 141, making use of the 
oxidative deamination protocol with hydrazoic acid as nucleophile in 51% yield (Scheme 
62). 
 
Scheme 62: Alternate route to access donor 288 via deamination reaction 
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3.2.8 Glycosylation study with the 5-azido NeuAc donor 288 
Glycosylation reactions of various primary and secondary alcohols 187, 188, 229 
and 230 with the 5-azido NeuAc donor 288 were performed using the same temperature, 
activation method and mixture of solvents, as previously employed with the 5-epi-NeuAc 
donor 206 (Scheme 63). 
 
Scheme 63: Glycosylation with the 5-azido NeuAc donor 288 
Gratifyingly, the 5-azido NeuAc donor 288 was also exquisitely selective in its 
reactions with all the acceptors, including the hindered secondary acceptor 230, in line 
with the glycosylation outcome of 5-epi-NeuAc donor 206 (Table 7). 
Table 7. Glycosylation Reactions with D-Glycero-D-galacto Donor 288 
Entry Acceptor Product Yield 3JC1,H3 (Hz) 
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4 
  
41% 6.9 
 
3.2.9 Synthesis of the 5-azido equatorial thioglycoside donor 
There was a possibility that the axial anomeric configuration of donors 206 and 
288 was playing a role in the glycosylation selectivity. To check it, the anomer of the 
donor 288, the 5-azido equatorial thioglycoside donor 296 was synthesized, adapting the 
same protocol applied for the preparation of 288.131 Thus the intermediate 292 was 
subjected to the three-step sequence of Zemplen deacetylation, Boc deprotection and 
azide formation to give 295 in 86% overall yield via the intermediates 293 and 294. 
Thereafter, acetylation of 295 readily afforded the desired 5-azido equatorial 
thioglycoside donor 296 in 84% yield (Scheme 64).  
 
Scheme 64: Synthesis of the equatorial thioglycoside donor 296 
Again, using the same protocol applied for its anomer, 296 was alternatively 
accessed from 220 via the N-nitrosoamide 221 by the Zbiral deamination protocol using 
hydrazoic acid as nucleophile (Scheme 65).197 
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Scheme 65: Alternate route to access the donor 296 via deamination reaction 
3.2.10 Stereoselective glycosylation with the equatorial thioglycoside donor 296 
The equatorial thioglycoside donor 296 was then subjected to glycosylation 
reaction with cyclohexanol as acceptor in the usual conditions of 2:1 
dichloromethane/acetonitrile at -78 ºC with activation by N-iodosuccinimide and triflic 
acid. The glycosylation reaction furnished the equatorial glycoside 289 as a single 
diastereomer in 86% yield. Since both anomer of the donors, 206 and 288, gave 
equatorial glycoside 289 with comparable yields and selectivities, it was concluded that 
the equatorial selectivity observed with the donor 288 is not a function of the initial 
anomeric configuration (Scheme 66). 
 
Scheme 66: Stereoselective glycosylation with the equatorial thioglycoside donor 296 
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acetonitrile/dichloromethane mixtures were obtained by the Crich laboratory with the 
isosteric isothiocyanate protected sialyl donor 244 at -78 ºC,118 suggesting that there is 
virtually no difference between the isosteric azide and isothiocyanato groups if the 
reactions are performed at the same low temperature conditions. 
3.2.11 Deprotection of 5-epi-azido glycosides 
Deprotections of two of the 5-epi-azido NeuAc glycosides, viz. 232 and 233 were 
carried out following a 3-step deprotection sequence (Scheme 67).  
 
Scheme 67: Deprotection protocol of the 5-epi azido glycosides 232 and 233 
Initially, hydrogenolysis over palladium-charcoal in aqueous dioxane was 
performed which resulted in the cleavage of the benzyl ethers and the reduction of the 
azido groups to the corresponding amines. Partial O→N migration of the acetyl groups 
was observed at this step,124,209 therefore no attempt was made to purify the products. 
Consequently, global acetylation of the crude products afforded the peracetate containing 
acetamides 297 and 298, respectively in high yields. Both intermediates 297 and 298 
were subjected to global deprotection of all the esters using hot aqueous barium 
hydroxide to give the final deprotected glycosylated products 299 and 300, respectively, 
in high yields (Table 8). 
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Table 8. Deprotection of the 5-epi azido glycosides 232 and 233 
Substrate Hydrogenolysis Product, % yield Sialic Acid Glycoside, % yield 
22 
  
23 
  
 
3.2.12 Deprotection of 5-azido glycosides 
The same reaction sequence of hydrogenolysis over palladium-charcoal in 
aqueous dioxane, peracetylation and global deprotection of esters using hot aqueous 
barium hydroxide for the 5-epi-azido NeuAc glycosides was applied to the isomers at 5-
position, 204 and 290 (Scheme 68).  
 
 
Scheme 68: Deprotection protocol of the 5-azido glycosides 204 and 290 
This deprotection sequence gave the final deprotected products 303 and 304 via 
the respective intermediates 310 and 311 (Table 9). 
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Table 9. Deprotection of the 5-azido glycosides 204 and 290 
Substrate Hydrogenolysis Product, % yield Sialic Acid Glycoside, % yield 
29 
  
30 
  
 
3.2.13 Leaving group-dependent stereoselectivity in substitution at the 5-position of 
NeuAc 
It is noteworthy that the oxidative deamination of 141 and related substances 
proceeds with the retention of configuration, in line with the results observed by Zbiral 
and other groups. Whereas the similar substrate 223 gave the stereoinverted azido 
product 206 when triflate was displaced by azide. The previous experimental analyses 
done by the Crich laboratory suggest that the stereoretentive property of the oxidative 
deamination reaction is because of the participation of the pyranoside ring oxygen to 
displace the molecular nitrogen via the oxabicyclo[3.1.0]hexanium ion 306.159 This 
particular ring oxygen intervention is dependent upon the nature of the leaving group. 
The extreme leaving group ability of molecular nitrogen is facilitating the participation of 
the pyranoside ring oxygen, either directly or after the formation of the intermediate 
carbenium ion 305.196,197 This is then only followed by the intermolecular attack by 
external nucleophiles such as azide or actetate. Whether the reaction equilibrium favors 
the carbenium ion or oxobicyclo[3.1.0]hexanium ion depends upon the nature of the –OH 
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protecting groups. If the hydroxy protecting groups are electron withdrawing groups, 
such as acetates, the equilibrium favors bicyclic oxonium ion, which leads to the 
stereoselective deaminated products. However, if the protecting groups are less electron 
withdrawing, such as benzyl ethers or isopropylidine groups, the reaction equilibrium 
favors carbenium ion, which leads to unselective deaminated products (Scheme 69). 
 
Scheme 69: Equilibrating carbenium and bridged oxonium ions  
This participation of ring oxygen doesn’t occur in the SN2 displacement of triflate 
by azide in the formation of 206, because though it is a good leaving group, is not as 
excellent a leaving group as molecular nitrogen is. Participation by the ring oxygen may 
become possible if the displacement of the sulfonate by external nucleophiles is sterically 
hindered, such as in the cases described by Stevens and Hanessian laboratories in a series 
of pyranose to furanose ring contractions,210-212 one of the example is shown in Scheme 
70. Ring contraction in the oxidative deamination of an N-acetylneuraminic acid 
glycoside has also been reported, albeit only as a minor product.213 
 
Scheme 70: Ring contraction of a rhamnosyl 4-O-sulfonate 
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3.2.14 Influence of the C5 configuration on side-chain conformation and 
glycosylation selectivity 
Sialic acid donors with an axial C-N bond at the 5-position were initially expected 
to give a greater proportion of axial glycosides than their C-5 epimers. The axial C-N 
bond has a gauche relationship to the ring oxygen whereas the equatorial C-N bond has 
antiperiplanar relationship to the ring oxygen. Therefore the axial C-N bond is better able 
to stabilize the developing positive charge at the ring oxygen during glycosylation 
reaction.149,193 Per this argument, donor 206 should have been less equatorially selective 
than the donor 288. The comparable equatorial selectivity observed in their glycosylation 
reactions at -78 ºC in spite of their differing C-5 configurations provoked close inspection 
of the H6-H7 coupling constant values in their 1H NMR spectra, leading to the 
conclusion that donors 206 and 288 adopt different conformations about the exocyclic 
bond to the side chain. Donor 288 has a 3J6,7 coupling constant of 2.2 Hz consistent with 
the predominant gg-conformation of the side chain,151 in line with the previous analyses 
of the derivatives of N-acetylneuraminic acid.143 On the other hand, donor 206 has 3J6,7 
coupling constant of 8.8 Hz, indicating H6 and H7 to be antiperiplanar and the side chain 
to adopt the gt-conformation. The transformation from the predominant gg- to gt-
conformation for the donor 206 must arise from a combination of dipolar and steric 
interactions between C5-N5 bond and the side chain in the gg-conformation (Scheme 
71a). Seminal work from the Bols group has shown that donors with the gt-conformation 
are less reactive,214 and therefore have less chance to form axial glycosides than their gg-
isomers.144 Hence, it seems that for the donor 206, the negative effect of having an axial 
C5-N5 bond is offset by the positive effect of the conformational change from gg to gt 
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about the the exocyclic bond to the side chain, providing the comparable selectivities 
between donors 206 and 288. 
Furthermore, the previous investigation on the influence of configuration at the 7-
position with the NeuAc and the 7-epi-NeuAc donors 66 and 205, respectively has also 
shown that the 7-epi-NeuAc donor 205 exhibit a different side chain conformation, 
namely the gt-conformation, again in order to avoid unfavorable dipolar and steric 
interactions with the C5-N5 bond (Figure 71b).143 The same case of conformational 
change from the predominant gg- to gt-conformer was observed between 174 and its C-7 
epimer 179, intermediates in the synthesis of the legionaminic acid donor 181.162 
Extrapolating these results, it is predicted that the inversion of both the 
configurations at C-5 and C-7, as that of pseudaminic acid, would again result in 
unfavorable dipolar and steric repulsion in the hypothetical 5,7-bis-epi system 310 to the 
highest level, due to which the side chain conformation would change from the 
predominant gt to the most-disarming and the least active tg-conformer (Scheme 71c).  
Scheme 71: Influence of C5 and C7 configuration on the side chain conformation 
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Therefore, compared to the moderately equatorial selective Leg donor 181, the 
planned pseudaminic acid donor 311 would be expected to adopt the tg-conformation 
very predominantly and as a result of which is predicted to afford excellent equatorial 
selectivity in its glycosylation reactions (Figure 15). 
 
Figure 15: Equatorially selective Leg and Pse donors 
3.3 Conclusion 
In conclusion, the D-glycero-D-gulo configured azido based 5-epi-NeuAc donor 
206 and its C-5 epimer D-glycero-D-galacto configured azido based NeuAc donor 292 
were synthesized and subjected to glycosylation reactions at -78 ºC. The exquisite 
equatorial selectivity obtained from both the donors 206 and 288 suggested that the azido 
group at the 5-position assisted in the equatorial glycosylation selectivity provided that 
the reactions are carried at -78 ºC. 
The observed glycosylation selectivity of 5-epi-NeuAc donor was attributed to the 
conformational change about the exocyclic bond to the side chain from the predominant 
gg- to gt-conformation, which offset the presence of the axial azide in the pyranose ring. 
Therefore, it was concluded that if a suitable pseudaminic acid donor with azido 
protecting group could be synthesized, there would be a high possibility of obtaining its 
equatorial glycosides on glycosylation at -78 ºC. Another significant aspect was 
theobservation of the triflate anion as a nucleophile in Zbiral deamination reaction, which 
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affirmed the previous analyses of its excellent nucleophilicity toward carbenium ion like 
electrophiles. 
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CHAPTER 4. SYNTHESIS AND STEREOCONTROLLED EQUATORIALLY 
SELECTIVE GLYCOSYLATION REACTIONS OF A PSEUDAMINIC ACID 
DONOR 
 
4.1 Background 
Pseudaminic acid was first identified by Knirel and co-workers in the 
lipopolysaccharides of Pseudomonas aeruginosa O7/O9 and Shigella bodyii type 7 in 
1984.52 As with legionaminic acid, its late discovery is attributed to its low abundance in 
nature and the earlier lack of powerful glycoanalysis tools. With the recent improvements 
in analytical tools, pseudaminic acid and its derivatives have been reported in other 
bacterial glycoconjugates such as the LPS O-antigens, capsular polysaccharides, pili and 
flagella of numerous other Gram-negative pathogens,28,57 such as Vibrio cholera,85 
Campylobacter jejuni,64,65 Campylobacter coli,66 Vibrio vulnificus73 and 
Pseudoalteromonas distincta.84 In particular, Pseudomonas aeruginosa is a notorious 
pathogen found in the sufferers of cystic fibrosis and various gastrointestinal diseases. 
The naturally occurring pseudaminic acid and its derivatives have been found to contain 
linkages through the nitrogen functionalities at C-5 and C-7. Two such examples are the 
C-7 linked pseudaminic acid derivative 30 found in Kribella spp,57 and the equatorially 
linked lipopolysaccharide 27 of Pseudomonas aeruginosa O10 (Figure 16).77 Therefore, 
pseudaminic acid glycosides can be considered as the candidates for use in diagnostic 
tools and in the development of antibacterial vaccines. For this to happen, practical routes 
to pseudaminic acid donors are needed, as Pse is presently not available in sufficient 
quantities from natural sources. 
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Figure 16: Naturally occurring Pse glycosides 27 and 30 containing 
differential nitrogen functionalities at C-5 and C-7 
 
Tsvetkov et al. reported the synthesis of Pse by chain extension of a hexose sugar, 
but did not study its glycosylation reactions.138 Ito et al. employed a similar approach to 
synthesize the Pse donor 116 starting from the N-acetylglucosamine 82.139 However, a 
glycosylation reaction of a primary acceptor with the donor 116 in acetonitrile at 0 ºC 
resulted in axial selectivity. Kiefel et al. reported the synthesis of Pse from N-
acetylneuraminic acid, but did not convert it to a donor suitable for glycosylation 
reactions.39,140 Of late, Li et al. reported the de novo synthesis of the Pse donor 130 
starting from L-threonine, and found it to show axial selectivity in dichloromethane at -78 
ºC.141 Two of these literature Pse donors, 116 and 130, and the proposed donor 311 
targeted in this inverstigation are shown in Figure 17. 
 
Figure 17: Literature Pse donors and the planned Pse donor 
In addition to the efficient synthetic routes for pseudaminic acid donors, improved 
understanding of the stereoselectivity of glycosylation is needed. Minor changes in 
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shifts in mechanism at the interface between SN1 and SN2 reactivity.215-217 Identifying the 
ideal donor structure and optimum reaction conditions would lead to efficient 
stereoselective synthesis of the sialic acid glycosides. As such, one of the interests of the 
Crich laboratory has been the stereoselective synthesis of the equatorial sialic acid 
glycosides,118,130,131,145,218 and understanding the role the side chain conformation plays in 
anomeric reactivity and selectivity.43,143,144,162,219,220 As reported in chapter 3, it was found 
that the 5-epi-NeuAc donor 206 has 3J6,7 coupling constant of 8.8 Hz, indicating H6 and 
H7 to be antiperiplanar and the side chain to adopt the gt-conformation (Scheme 71a).198  
 
Scheme 71: Influence of C5 and C7 configuration on the side chain conformation 
The transformation from the predominant gg- to gt-conformation on going from 
the natural isomer to the donor 206 arises from a combination of dipolar and steric 
interactions between the C5-N5 bond and the side chain (Scheme 71a). This resulted in 
the glycosylation equatorial selectivity, as the donors with gt-conformation are less 
reactive,214 and therefore have less chance to form axial glycosides than their gg-
O
AcO
OAc
AcO
NO
OAc
SAda
MeO2C
205, 7-epi-NeuAc (gt)
O
OAc
N
O
SAda
MeO2C
AcO
AcO
OAc
66, NeuAc (gg)
O
AcO
AcO
OAc
N3
OAc
SAda
CO2MeH
7
H6
288, NeuAc
gg, J6,7 = 2.2 Hz
O
AcO
AcO
OAc
OAc
SAda
CO2MeH
7
H6
N3
Invert config
at C5
dipolar repulsion
O
AcO
H7N3OAc
SAda
CO2Me
H6AcO
AcO
206, 5-epi-NeuAc
gt, J6,7 = 8.8 Hz
O OAc
N
O
SAda
MeO2C
AcO
AcO
OAcH
H
H
Invert config
at C7
dipolar repulsion
O
AcO
H7
OAc
OAc
SAda
CO2MeAcO
H6
N3
Invert config
at C7
dipolar repulsion
O
AcO
H7N3OAc
SAda
CO2Me
H6AcO
AcO
206, 5-epi
gt, J6,7 = 8.8 Hz
O
H7
AcON3OAc
SAda
CO2Me
H6AcO
AcO
310, 5,7-bis-epi
predicted tg, J6,7 = 10 Hz
c)
b)
a)
 
 
 
 
86 
isomers.144 Furthermore, investigations on the influence of configuration at the 7-position 
with NeuAc donor 66 and 7-epi-NeuAc donor 205143 showed that the 7-epi sialic acids 
205 underwent a conformational change from gg- to gt- again to avoid unfavorable 
dipolar and steric interactions with the C5-N5 bond (Scheme 71b). Extrapolating these 
results, it is predicted that the inversion of both the configurations at C-5 and C-7, as in 
pseudaminic acid, would again result in unfavorable dipolar and steric repulsion in the 
hypothetical 5,7-bis-epi system 310, due to which the side chain conformation would 
change from the predominant gt to the most-disarming and the least active tg-conformer 
(Scheme 71c). 
Therefore, the trio of inversion of the configurations in Pse with respective to 
NeuAc, especially the two at C-5 and C-7 would again result in unfavorable dipolar and 
steric repulsion are expected to cause the Pse donor 311 to adopt the most disarming and 
the least active tg-conformer (Figure 15). Consequently, compared to the moderately 
equatorial selective Leg donor 181, an excellent equatorial selectivity in the glycosylation 
reaction of the Pse donor 311 was expected. Accordingly, the synthesis of the Pse donor 
311 and its stereocontrolled equatorial synthesis are the focus of this chapter. 
 
Figure 15: Equatorially selective Leg and Pse donors  
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4.2 Results and Discussion 
4.2.1 Retrosynthesis 
Utilizing the strategies developed and lessions learnt from the syntheses of the 
Leg donor 181162 and 5-epi NeuAc donor 206,198 the synthesis of the Pse donor 311 
starting from the readily available NeuAc was planned. The approach for the 
deoxygenation at the 9-position and replacement of C-O by a C-N bond at the 7-position 
utilized for the synthesis of the Leg donor 181 (Scheme 37) still remains valid for the 
synthesis of the Pse donor 311. However, in addition to this, the preparation of 311 
requires inversion of configuration at positions 5 and 7. Similar to Kiefel’s work,39,140 the 
synthesis of a 5,7-diol such as 312 was envisioned, which could be suitably activated for 
displacement by azide anion affording the two C-N bonds at the 5- and 7-positions with 
inversion of configuration. Deoxygenation at the 9-position can be achieved by the usual 
means162 of selective trisylation with TPSCl, then replacement of the -OTPS group by the 
iodo group as in 314, and finally dehydroiodination either by radical methods or 
hydrogenolysis giving 313. A key step would be the replacement of the equatorial 
acetamide at the 5-position of 317 by a hydroxyl group with retention of configuration. 
As was the case for the synthesis of 5-epi-NeuAc donor 206,198 the Zbiral oxidative 
deamination145,197 was the intended approach, with levulinic acid as nucleophile to give 
316, which facilitates the selective functionalization of the synthesized ester at the 5-
position. Utilizing the differential reactivity of the 4- and 7-hydroxy groups of 318, the 4-
hydroxy group can be monoacetylated. Subsequent protection of the 7-hydroxy group 
with either silyl or naphthyl ethers protecting groups is expected to give 317. The 
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substrate 318, in turn, can be obtained in sequence of known reactions from N-
acetylneuraminic acid (Scheme 72).131,161 
 
Scheme 72: Retrosynthetic analysis of the proposed Pse donor 311 
4.2.2 Attempted synthesis of a Pse donor 
4.2.2.1 Synthesis of a 7-O-TBDMS thioglycoside 
The approach of protecting the 7-hydroxy group with a silyl protecting group 
(OTBDMS) was employed first. Keeping in mind the usually modest yields of the 
oxidative deamination reactions, the initial plan was to perform this reaction at a late 
stage of the synthesis. 
Thus, NeuAc was converted to the common intermediate, the thioglycoside 141 
on a 20 g scale by three well-known literature steps131,161 with 70% overall yield. 
Thereafter, Zemplen deacetylation to remove the acetates and then installation of an 8,9-
O-acetonide in another known sequence of reactions gave 318 in 93% yield. Then, 
acetate protection of the 4-OH regioselectively in the presence of the 7-OH following the 
established pattern160 gave the monoacetate 319. This was followed by silylation using 
TBSOTf to give the 7-O-TBDMS protected thioglycoside 320 in 89% yield (Scheme 73). 
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It is noteworthy here that the more common approach of silyation using TBSCl and 
imidazole mixture did not give the desired product, possibly owing to the hindered nature 
of the 7-OH group.  
 
Scheme 73: Synthesis of the 7-O-TBDMS thioglycoside 320 
4.2.2.2 Selective functionalization of 9-hydroxy group 
Acid mediated cleavage of the 8,9-O-acetonide in 320 gave the intermediate 8,9-
diol derivative 321 as a crude product, which was then reacted with 2,4,6-triisopropyl 
benzenesulfonyl chloride (TPSCl) in the presence of pyridine to give the monotrisylated 
product 322, functionalized at the primary 9-OH regioselectively in the presence of the 
secondary 8-OH (Scheme 74). 
 
Scheme 74: Synthesis of the 8,9-diol derivative 321 and its selective trisylation 
4.2.2.3 Inversion of configuration of a 8-hydroxy group 
Oxidation of 322 with Dess-Martin periodinane167 gave the ketone 323 in 86% 
yield, which was then subjected to the Luche reduction171 conditions using sodium 
borohydride and cerium trichloride to give the inverted alcohol 324 as the single isomer 
in 88% yield (Scheme 75). A similar reaction sequence for the inversion of configuration 
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of 7-hydroxy group in Leg synthesis gave a 85:15 mixture of isomers.162 The steric 
hindrance arising from the TBDMS group on the vicinal C-7 and also the bulky trisyl 
group at C-9 presumably assisted the reaction to give the single isomer here in the present 
case. 
 
Scheme 75: Inversion of configuration at C-8 of 322 
4.2.2.4 Synthesis of a 9-deoxy sialoside 
The sulfonate ester at the 9-position of 324 was displaced by an iodo group using 
sodium iodide to give 325 in 87% yield, which was then subjected to hydrogenolysis 
using a mixture of ethyl acetate and triethylamine to give the 9-deoxy derivative 326 in 
92% yield (Scheme 76). In the legionaminic acid series, the same hydrogenolysis reaction 
albeit without triethylamine had cleaved the thioglycoside moiety to some extent, forcing 
the adoption of radical reaction route for hydrodeiodination.162 The use of triethylamine 
in this reaction essentially solved this problem. 
 
Scheme 76: Synthesis of the 9-deoxy sialoside 326 
4.2.2.5 Attempted late stage oxidative deamination with levulinic acid 
Compound 326 was reacted with acetic anhydride in the presence of DMAP and 
triethylamine to give 327, which was the substrate intended for the late stage oxidative 
deamination reaction. Reacting 327 with sodium tetrafluoroborate in pyridine gave the 
corresponding N-nitrosoacetamide, which on heating with levulinic acid at 50 ºC gave the 
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levulinyl derivative 328 as the oxidative deamination product in the form of a mixture of 
diastereomers. It is noteworthy that the synthesized N-nitrosoacetamide derivative was 
quite stable to levulinic acid at lower temperatures under standard conditions, 
necessitating the adoption of the thermal condition by warming the reaction mixture to 50 
ºC, similar to that of the Kiefel group’s approach.39 In order to facilitate purification of 
the crude levulinate mixture, 328 was reacted with hydrazine monohydrate in acetic acid 
and pyridine, which led to the deprotection of the levulinate ester furnishing the 5-
hydroxy derivative 329 in 38% overall yield from 326 as approximately 1:1 mixture of 
stereoisomers (Scheme 77).  
 
Scheme 77: Attempted late stage oxidative deamination with levulinic acid 
Comparing the result with the previous analyses,159 the poor selectivity in the 
final deamination reaction is possibly due to the absence of a C-O group at the 9-position, 
reducing the involvement of the ring oxygen at the 5-position in the stereoretentive 
participation and supporting more of the carbenium ion-like intermediate. This poor 
selectivity at such a late stage of the synthesis forced the change of the route, in such a 
way that the deamination reaction would come before the deoxygenation at the 9-
position. 
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4.2.3 Synthesis of a Pse donor 
4.2.3.1 Synthesis of a 7-O-naphthyl thioadamantanyl sialoside 
The 7-O-naphthylmethyl ether 330 was obtained from the intermediate 318 by 
treating with sodium hydride and 2-naphthylmethyl bromide221 at 0 ºC on a multigram 
scale in 82% yield, so giving the substrate for the early oxidative deamination (Scheme 
78). 
 
Scheme 78: Synthesis of the 7-O-naphthyl thioadamantyl sialoside 330 
4.2.3.2 Oxidative deamination with levulinic acid as nucleophile 
The N-nitrosoacetamide derivative 331 was obtained by reacting the substrate 330 
with nitrosyl tetrafluoroborate in pyridine at -10 ºC, and was then treated with a mixture 
of preformed sodium trifluoroethoxide and 18-crown-6 in dichloromethane at -10 ºC. 
This was followed by addition of levulinic acid before quenching with sodium 
bicarbonate at 0 ºC. The desired levulinate 333 was obtained in the form of a single 
equatorial diastereomer, alongside the alkene 332, a typical byproduct159 in the oxidative 
deamination reaction (Scheme 79). The ability to perform this reaction in >5 g batches of 
330 enabled scale-up for the total synthesis of Pse, in spite of the modest yield of the 
reaction. 
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Scheme 79: Oxidative deamination of 330 with levulinic acid as nucleophile 
4.2.3.3 Selective functionalization of the 9-hydroxy group 
Aqueous trifluoroacetic acid mediated removal of the acetonide gave the 
corresponding 8,9-diol intermediate 334. As in the synthesis of the legionaminic acid 
intermediate 168 and also the 7-OTBDMS containing intermediate 322, selective 
functionalization of the primary C-9 hydroxy group was attempted using 2,4,6-
triisopropyl benzenesulfonyl chloride (TPSCl) in the usual way.162 However, presumably 
due to the presence of a bulky substituents on C-7 and C-5, the reaction time increased 
substantially (more than 40 h), with the procurement of only 55% of the product 335 and 
the recovery of 20% of the starting material 334. Therefore, the procedure was slightly 
modified by incorporating dibutyltin oxide and replacing pyridine by triethylamine as 
base in the reaction,222,223 to obtain the desired product 335 in 83% yield (Scheme 80). 
Formation of the dibutyltin acetal derivative 336 in situ presumably assisted this reaction 
to proceed forward in a shorter time and better yield. 
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Scheme 80: Selective trisylation of 9-OH via a dibutyltin acetal derivative 
4.2.3.4 Inversion of configuration of the 8-hydroxy group 
The usual route of oxidation to the ketone and then reduction to obtain the 
hydroxyl group with inversion of configuration, as were done to obtain 179 and 324,162 
couldn’t be performed here due to the incompatibility with the ketone functionality of the 
levulinoyl moiety in the reduction step. Therefore, in order to invert the configuration of 
the C8-hydroxy group, the Lattrell-Dax reaction protocol224-226 was employed. 
Accordingly, the C8-hydroxy group of 335 was triflated using triflic anhydride in 
pyridine to obtain the corresponding triflate derivative 336, which was then reacted with 
tetrabutylammonium nitrite to give the desired C-8 epimer 337 in 72% yield (Scheme 
81). It is noteworthy that the SN2 displacement with nitrite ion occurred preferentially on 
the secondary triflate keeping intact the primary arenesulfonate ester, thus proving that 
the triflate groups are excellent leaving groups in substitution reactions.227 
 
Scheme 81: Inversion of configuration at C8 of 335 
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4.2.3.5 Synthesis of a 9-deoxy sialoside 
Displacement of the trisyl (-OTPS) group from 338 with sodium iodide under 
reflux afforded the corresponding iodo derivative 339 in 81% yield. Thereafter, 
hydrogenolysis over palladium on carbon in the mixture of ethyl acetate and 
triethylamine, the same protocol that was applied to get 326, gave the 9-deoxy 
thioglycoside 340 in 91% yield. Acetylation of 340 with acetic anhydride in the presence 
of DMAP gave the triester 341 in 95% yield (Scheme 82). 
 
Scheme 82: Synthesis of the 9-deoxy sialoside 
4.2.3.6 Deprotection of the 7-naphthyl and 5-levulinoyl groups 
The two hydroxyl protecting groups of 341, the naphthylmethyl ether at C-7 and 
the levulinoyl ester at C-5, were then sequentially deprotected using DDQ and hydrazine 
monohydrate in the usual ways to give 342 and 312, respectively in good yields (Scheme 
83). The access to the diol intermediate 312 was significant, as this was the precursor for 
the synthesis of the 5,7-diazido Pse donor 311. 
 
Scheme 83: Deprotection of the naphthyl and levulinoyl groups to accesss 312 
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4.2.3.7 Synthesis of the 5,7-diazido Pse donor 311 
The synthesized diol 312 was triflated to give a corresponding ditriflate 
intermediate, which was then reacted with sodium azide in DMF to give the desired 5,7-
diazido Pse donor 311 in 70% yield (Scheme 84). To achieve the Pse donor 311 from the 
diol 312, two correct configurations at 5- and 7- positions with C-N bonds were installed 
in a single sequence of reactions. 
 
Scheme 84: Synthesis of the 5,7-diazido Pse donor 311 
Overall, a practical synthesis of the Pse donor 311 was achieved in 20 steps and 
5% overall yield starting from N-acetylneuraminic acid. Except for the usual moderate 
yield of the Zbiral deamination step, all other reactions in the sequence gave good to 
excellent yields. Therefore, the sequence of reactions described here is simple and 
scalable, affording the product on the scale of multiple hundreds of milligrams, and 
offering the opportunity to investigate the glycosylation reaction. The total synthesis of 
the Pse donor 311 from N-acetylneuraminic acid is summarized in Scheme 85.228 
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Scheme 85: Total synthesis of the Pse donor 311 
4.2.3.8 Glycosylation study with the Pse donor 
The synthesized Pse donor 311 was employed in the glycosylation of various 
acceptors under the same conditions of N-iodosuccinimide and triflic acid as the 
activators in 2:1 mixture of acetonitrile and dichloromethane at -78 ºC (Scheme 86). 
These were employed to facilitate comparison with the earlier results obtained with the 
legionaminic acid donor 181 and the 5-epi-NeuAc donor 288. 
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Scheme 86: Glycosylation reactions with the Pse donor 311 
The acceptors used were benzyl alcohol, methyl 2,3,4-tri-O-benzyl-β-D-
galactopyranoside 187, methyl 2,4,6-tri-O-benzyl-β-D-galactopyranoside 188 and methyl 
2,3,6-tri-O-benzyl-β-D-galactopyranoside 230. The galactopyranosyl 3- and 6-alcohols 
187 and 188 were selected for this study as the linkages obtained from them are the most 
common ones in the sialic acid glycosides. The highly hindered galactopyranosyl 4-
alcohol 230 was selected as a model study, as the linkage Pse-eq.(2→4)-6-deoxy-N-
acetylgalactosamide has been found in the repeating unit of the Pseudomonas aeruginosa 
O10 lipopolysaccharides.77 
Glycosylation of benzyl alcohol gave the equatorial glycoside 343 as a single 
isomer in 89% yield. In the similar manner, the glycosylation reactions of galactose 
acceptors, 187 and 188 also afforded the equatorial glycosides 344 and 345, as single 
anomers in 83% and 77% yields, respectively. Of particular note is the glycosylation 
reaction of the highly sterically hindered acceptor 230, which also afforded 346 with 
exquisite equatorial selectivity in 53% yield, without formation of the competing axial 
anomer (Table 10). As usual, the anomeric configuration of 343-346 was determined 
based on the measurement of the 3JC1-H3axial heteronuclear coupling constant values, 
which were in the range of 6.8-7.5 Hz, characteristic of the equatorial glycoside.172-175 
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Table 10: Glycosylation reactions of various acceptors with the Pse donor 311 
Entry Acceptor Product Yield 3JC1,H3 (Hz) 
1 BnOH 
 
89% 7.1 
2 
 
 
83% 6.8 
3 
  
77% 7.5 
4 
 
 
53% 7.3 
 
4.2.3.9 Analysis of side chain conformation and glycosylation selectivity 
The glycosylation selectivities obtained with the Pse donor validate the earlier 
hypothesis, as the selectivites seen here with the same three carbohydrate based acceptors 
under the same conditions are higher than that obtained with the Leg donor (Table 4, 
page 51).162 As expected, analysis of the 3J6,7 value of the synthesized donor showed that 
it has undergone the conformational change from the predominant gg- to the least active, 
tg-conformation (Figure 18). This rationalizes the observed glycosylation selectivities, 
and therefore it can be concluded that the donor side chain conformation is an important 
aspect in the formation of stereoselective glycosidic bonds. 
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Figure 18: Pse donor 311 in its tg-conformation 
As far as the Pse donor glycosylation is concerned, the results presented in Table 
10 are the first examples of equatorial glycosylation selectivity. Ito et al.139 performed the 
glycosylation with the donor 116 under different conditions (acetonitrile at 0 ºC), leaving 
no basis for meaningful comparison. However, the glycosylation reaction with the Pse 
donor 130 done by Li et al.141 under similar conditions of solvent, temperature and 
activating systems as that for the Pse donor 311 gave mostly unselective or axially 
selective glycosylated products. Close inspection of Li’s donor 130 shows the 3J6,7 
coupling constant value to be 10.0 Hz similar to that of the present donor 311 (9.8 Hz), 
indicating that both the donors 130 and 311 are in tg-conformation about the exocyclic 
bonds to the side chain. Therefore, the contrast in selectivity between Li’s donor 130 and 
the synthesized Pse donor 311 must arise due to the difference in the amine protecting 
groups, with the bulkier protecting groups in the Li’s donor 130 causing the steric 
hindrance or hydrogen bonding. Additionally, the bulky isopropyl ester at the anomeric 
center could have been better accommodated in the equatorial position. 
4.2.3.10 Synthesis of the final Pse5Ac7Ac 
The glycosylated product 343 obtained from the stereoselective glycosylation of 
the benzyl alcohol with the Pse donor 311 was treated with excess thioacetic acid in 
pyridine229 to afford the corresponding bisacetamide derivative 347 in 73% yield. This 
was then heated at 60 ºC with aqueous barium hydroxide in 1,4-dioxane before 
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hydrogenolysis over palladium on charcoal also in aqueous 1,4-dioxane afforded the 
Pse5Ac7Ac 2 in 81% yield (Scheme 87). The spectral data of Pse5Ac7Ac were consistent 
with those provided by Tsvetkov, Kiefel and others.43,97,140,141 
 
Scheme 87: Deprotection of 343 to access Pse5Ac7Ac 2 
4.2.3.11 Regioselective reduction of azide in the deprotection of 345 
Most of the natural Pse glycosides found in various pathogenic bacteria, including 
the axially-linked Pseudomonas aeruginosa 1244 pilin glycoside 3088 and Pse-equatorial 
(2→4)-6-deoxy-N-acetylgalactosaminide linkage formed in the repeating unit of 
Pseudomonas aeruginosa O10 lipopolysaccharide 27,77 possess two different amides at 
positions 5 and 7. To access the Pse glycosides with differential amide functionalities, 
two overall routes can be envisaged. This is possible to start by synthesis of a donor with 
differentially protected amines at positions 5 and 7, as in the synthesis of the Li’s donor 
130. Alternatively, the regioselective unmasking of one of the two identically protected 
amines can be attempted after the glycosylation. 
Kiefel et al.39 showed in a different substrate having incorrect configuration at the 
7-position that the side chain azide was more reactive than the axial azide of the pyranose 
ring toward PPh3 mediated Staudinger reaction (Scheme 88). 
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Scheme 88: Kiefel’s regioselective functionalization of the azides in 121 
Encouraged by this work from the Kiefel group, the differential functionalization 
of the azides in the glycoside 345 was attempted. Gratifyingly, owing to the different 
steric environments of the two azides in the glycoside 345, heating with thioacetic acid 
and lutidine in chloroform afforded the corresponding C7-monoamide derivative 349 in 
68% yield, with the C5-azide remaining intact. Thereafter, modified Staudinger reaction 
conditions with 1,3-propanedithiol and triethylamine in wet pyridine230 followed by 
reprotection with a Boc group converted 349 to the corresponding C5-amido carbamate 
350 in 72% yield. Finally, global deprotection of all the acetates and esters with aqueous 
barium hydroxide in dioxane, and of the benzyl groups by hydrogenolysis afforded the 
regioselectively differentiated Pse glycoside 351, containing a C7 acetamide and a C5 
tert-butylcarbamate, with the C5 tert-butylcarbamate in a position to be further 
deprotected and functionalized as required (Scheme 89). 
 
Scheme 89: Regioselective reduction of azide in the deprotection of 351 
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4.2.3.12 Alternate regioselective reduction of azides in the deprotection of 345 
The reversed sequence of first reducing an azide regioselectively into acetamide, 
followed by conversion of the second azide into a tert-butylcarbamate was attempted in 
the glycoside 345. Accordingly, the azide at the 7-position was first reduced to the 
corresponding amine with 1,3-propanedithiol and triethylamine in wet pyridine followed 
by protection with Boc group to give the corresponding C7 tert-butylcarbamate 352, 
leaving C5 azide intact. Then, thioacetic acid mediated reduction of the reaming azide at 
C5 converted it to the corresponding acetamide containing derivative 353. In the end, 
global deprotection of all the esters with hot aqueous barium hydroxide in dioxane 
followed by benzyl deprotection using hydrogenolysis gave the final deprotected product 
354 containg a C7 tert-butylcarbamate and a C5 acetamide, whereby the 7-position can 
be further functionalized by cleaving the Boc group (Scheme 90). 
 
Scheme 90: Alternate regioselective reduction of azide in the deprotection of 351 
4.3 Conclusion 
 In conclusion, the synthesis of a diazido based pseudaminic acid donor was 
achieved in 20 steps and 5% overall yield from the readily available N-acetylneuraminic 
acid. The synthesis is easily scalable to multi-hundred milligram quantities and provided 
sufficient material for the glycosylation studies. The pseudaminic acid donor turned out 
O
N3
N3
OAc
CO2MeAcO
345
AcSH, lutidine
CHCl3, Δ, 71%
1) Ba(OH)2,
  H2O, dioxane
2) H2, Pd/C,
   MeOH, 83%
O
1) HS(CH2)3SH,
  Et3N, py, H2O
2) Boc2O, Et3N
          51%
O
OMe
OBn
OBnBnO
O
NHBoc
N3
OAc
CO2MeAcO
352
O
O
OMe
OBn
OBnBnO
O
NHBoc
AcHN
OAc
CO2MeAcO
353
O
O
OMe
OBn
OBnBnO
O
NHBoc
AcHN
OH
CO2HHO
354
O
O
OMe
OH
OHHO
 
 
 
 
104 
to be an excellent donor, providing the corresponding equatorial glycosides with 
exquisite selectivity when glycosylated to various primary and secondary alcohols. It was 
found that the selectivity was the factor of the side chain conformation of the donor, and 
the tg-conformation enforced on the new donor, owing to its inversion of configuration at 
5- and 7-positions in comparison to N-acetylneuraminic acid. This study elucidated the 
role of the side chain conformation in the reactivity and selectivity of the glycosyl 
donors, which in turn should assist in the mechanism-based development of 
stereoselective glycosylation reactions. Furthermore, keeping in mind the differentially 
substituted amine functionality in the bacterial lipopolysaccharides, the regioselective 
reduction of azide was achieved in the deprotection reactions, leading to differentially 
substituted amine functionalities in the final deprotected pseudaminic acid glycoside. 
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CHAPTER 5. CONCLUSION 
 Legionaminic acid and pseudaminic acid, two rare classes of bacterial sialic acid, 
are 9-deoxy analogues of the most common sialic acid, N-acetylneuraminic acid. These 
two derivatives are significant given the fact that their glycosides are found in 
lipopolysaccharides and glycoproteins of several pathogenic Gram-negative bacteria 
including Pseudomonas aeruginosa,52 Legionella pneumophila serogroup 1,31 
Campylobacter jejuni33,34 and Campylobacter coli.34 Accordingly, the efficient synthesis 
of a legionaminic acid and pseudaminic acid donor and their stereoselective glycosylation 
reactions were the focus of this thesis. 
 A legionaminic acid donor was synthesized in 15 straightforward steps and 17% 
overall yield from the commercially available N-acetylneuraminic acid. The synthesized 
donor, when glycosylated to various primary and secondary alcohols including a sialic 
acid based acceptor, with N-iodosuccinimide and triflic acid as activator at -78 ºC in 1:2 
acetonitrile/dichloromethane, afforded equatorial glycosides in good to excellent yields 
and selectivities. The less than perfect selectivity with this donor was attributed to the 9-
deoxy nature of the side chain, which made it less disarming and afforded greater 
oxocarbenium-like character in the transition state. A four-step deprotection sequence of 
the selected glycosides then afforded the final deprotected disaccharides.162 
 An intermediate donor, namely azido 5-epi-NeuAc, having the same C-5 
configuration as pseudaminic acid was synthesized. Glycosylation reactions of various 
primary and secondary acceptors with the donor in presence of NIS/TfOH as activator 
and 1:2 acetonitrile/dichloromethane at -78 ºC afforded exclusively equatorial glycosides 
in good to excellent yields. The synthesis of a 5-azido NeuAc donor followed by 
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glycosylation reactions of various acceptors with it under the same glycosylation 
conditions also afforded exquisite equatorial selectivity, in contradiction to the selectivity 
of the various literature 5-azido NeuAc donors. This led to the conclusion that the low 
temperature of -78 ºC is crucial for the selectivity. The comparable glycosylation 
selectivity observed in the azido based NeuAc donors with either axial or equatorial 
azides at the 5-position was attributed to the conformational change of the exocyclic bond 
enforced by the change in configuration at C5. The selected glycosides were then 
deprotected in the three-step deprotection sequence to afford the final fully deprotected 
glycosides.198 
 A pseudaminic acid donor was synthesized in 20 steps and 5% overall yield from 
the commercially available N-acetylneuraminic acid. Glycosylation reactions of various 
primary and hindered secondary alcohols with NIS/TfOH as activators and 1:2 
acetonitrile/dichloromethane at -78 ºC afforded exquisite equatorial selectivity in good to 
excellent yields. The excellent selectivity observed was attributed to the inversion of 
configurations at 5- and 7-positions, which cause the side chain to take up the least 
reactive tg-conformation. Thereafter, regioselective reduction of the azides afforded 
differential amine functionalities in the final deprotected glycoside, suitable for the 
further functionalization to access the bacterial lipopolysaccharides. 
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CHAPTER 6. EXPERIMENTAL SECTION 
General experimental: Commercially available starting materials were used without 
further purification. All solvents were dried according to standard methods. TLC was 
performed on pre-coated glass plates employing UV absorption and charring with ceric 
ammonium molybdate (CAM) for visualization. Silica gel 60, 230−400 mesh, 40−63 µm 
were used for column chromatography. 1H and 13C NMR spectra were recorded on 400 
and 600 MHz instruments at 300 K. Chemical shifts were calibrated to residual solvent 
peaks. Stereochemical assignments of all coupled glycosides were made with the 
assistance of 3JC1−H3ax values.143,172-175 Specific rotations were measured using a digital 
polarimeter and are given with units of 10−1 deg·cm2·g−1. High-resolution mass spectra 
were recorded with an electrospray source coupled to a time-of-flight mass analyzer. 
Methyl (1-Adamantanyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-2-thio-D-
glycero-β-D-galacto-non-2-ulopyranosid)onate (141): To a solution of methyl 5-
acetamido-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-β-D-glycero-D-galacto-2-
nonulopyranosonate161 (22 g; 41.44 mmol) in anhydrous CH2Cl2 (250 mL) was added 1-
adamantanethiol (8.1 g; 45.4 mmol) followed by BF3.OEt2 (12.8 mL; 49.7 mmol). The 
resulting solution was stirred at room temperature under argon for 10 h and then diluted 
with CH2Cl2 (350 mL), washed with saturated aqueous NaHCO3, dried over Na2SO4, and 
concentrated under reduced pressure. The residue was subjected to column 
chromatography over silica gel eluting with 10% isopropanol in toluene to give 141 as a 
white solid (21.2 g; 80%), with 1H and 13C NMR consistent with the reported data.131 1H 
NMR (400 MHz, CDCl3) δ 5.72 (d, J = 10.3 Hz, 1H), 5.47 (s, 1H), 5.27 (td, J = 10.9, 3.9 
Hz, 1H), 5.15 (d, J = 8.2 Hz, 1H), 5.01 (d, J = 12.3 Hz, 3H), 4.55 (d, J = 11.5 Hz, 1H), 
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4.25 – 4.16 (m, 1H), 4.07 (q, J = 10.0 Hz, 3H), 3.82 (s, 3H), 2.53 (dd, J = 13.4, 3.7 Hz, 
3H), 2.10 (s, 3H), 2.06 (s, 3H), 2.03 – 1.94 (m, 9H), 1.86 (s, 6H), 1.65 (s, 6H); 13C NMR 
(101 MHz, CDCl3) δ 171.2, 170.7, 170.2, 170.1, 170.0, 169.7, 85.9, 77.2, 73.9, 72.5, 
69.1, 68.8, 63.2, 52.6, 50.3, 49.3, 43.3, 39.7, 35.7, 29.6, 23.0, 20.9, 20.7, 20.5, 20.5. 
Methyl (1-adamantanyl 3,5-dideoxy-5-N-(1,1-dimethylethoxy)carbonyl-9-O-(2,4,6-
triisopropylbenzenesulfonyl)-2-thio-D-glycero-β-D-galacto-non-2-
ulopyranosid)onate (168): Compound 162 (0.95 g, 1.78 mmol), obtained by a literature 
procedure131 from N-acetylneuraminic acid via compound 141 in overall 65% yield as an 
off-white foam, was dissolved in anhydrous pyridine (15 mL) and 2,4,6-
triisopropylbenzenesulfonyl chloride (TPSCl) (3.23 g, 10.68 mmol, 6 eq) was added 
portion-wise. The mixture was stirred at room temperature for 20 h and the reaction was 
monitored by TLC (hexane/ethyl acetate 1:1). After completion, the reaction was 
quenched by addition of methanol (0.43 mL, 10.68 mmol) and the mixture was 
concentrated in vacuo to dryness. The residue was adsorbed on silica gel and purified by 
flash column chromatography (hexane/ethyl acetate 3:2) to give compound 168 (1.01 g, 
71%) as a white foam. [a]25 D -50.0 (c 1.5, CHCl3); 1H NMR (600 MHz, CDCl3) δ 7.17 (s, 
2H), 4.74 (d, J = 8.5 Hz, 1H), 4.50 (dd, J = 10.6, 2.0 Hz, 1H), 4.23-4.19 (m, 2H), 4.13-
4.06 (m, 3H), 4.01 (s, 1H), 3.77 (s, 3H), 3.72 (d, J = 6.5 Hz, 1H), 3.61 (t, J = 8.1 Hz, 1H), 
3.54 (q, J = 9.5 Hz, 1H), 2.93-2.86 (m, 2H), 2.63 (d, J = 4.9 Hz, 1H), 2.58 (dd, J = 13.7, 
4.3 Hz, 1H,), 1.99-1.90 (m, 6H), 1.86 (d, J = 11.7 Hz), 1.81 (t, J = 12.6 Hz, 1H), 1.63 (s, 
6H), 1.40 (s, 9H), 1.25 (dd, J = 6.8, 2.6 Hz); 13C NMR (151 MHz, CDCl3) δ 170.7, 157.6, 
153.9, 150.9, 128.9 , 123.8, 86.0, 81.0, 72.2, 71.6, 69.7, 68.7, 67.9, 54.2, 52.7, 50.2, 43.2, 
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42.9, 36.0, 34.2, 29.8, 29.6, 28.2, 24.7, 24.7, 23.5, 23.5; HRMS (ESI) m/z calcd for: 
C40H63NO11S2Na, [M+Na]+ 820.3740; found: 820.3735. 
Methyl (1-adamantanyl 3,5,9-trideoxy-9-iodo-5-N-(1,1-dimethylethoxy)carbonyl-2-
thio-D-glycero-β-D-galacto-non-2-ulopyranosid)onate (170): Compound 168 (0.49 g, 
0.62 mmol) was dissolved in anhydrous acetone (4 mL) and sodium iodide (0.93 g, 6.20 
mmol, 10 eq) was added to the mixture. The reaction was heated at 40 °C with stirring for 
17 h and the progress was monitored by TLC (hexane/ethyl acetate 2:3). After 
completion, the mixture was directly adsorbed on silica gel and purified by flash column 
chromatography (hexane/ethyl acetate 2:3) to give compound 170 (0.37 g, 94%) as an 
off-white foam. [a]25 D -89.1 (c 3.05, CHCl3); 1H NMR (600 MHz, CDCl3) δ 4.89 (d, J = 
8.6 Hz, 1H, ), 4.17 (d, J = 10.2 Hz, 1H), 4.01 (d, J = 7.3 Hz, 1H), 3.99-3.96 (m, 1H), 3.79 
(s, 3H), 3.76 (dd, J = 10.2, 1.9 Hz, 1H), 3.64-3.59 (m, 2H), 3.58-3.52 (m, 2H), 3.24 (br s, 
1H), 2.56 (dd, J = 13.5, 4.0 Hz, 1H), 2.29 (d, J = 6.0 Hz, 1H), 1.98 (s, 3H), 1.94 (d, J = 
11.9 Hz, 3H), 1.91-1.83 (m, 4H), 1.63 (s, 6H), 1.43 (s, 9H); 13C NMR (151 MHz, CDCl3) 
δ 170.9, 157.4, 86.1, 81.0, 72.1, 72.0, 69.5, 67.7, 54.2, 52.8, 50.2, 43.3, 42.8, 36.0, 29.8, 
28.4, 17.0; HRMS (ESI) m/z calcd for: C25H40INO8SNa, [M+Na]+ 664.1417; found: 
664.1434. 
Methyl (1-adamantanyl 4,8-di-O-benzoyl-3,5,9-trideoxy-9-iodo-5-N-(1,1-
dimethylethoxy)carbonyl-2-thio-D-glycero-β-D-galacto-non-2-ulopyranosid)onate 
(171): Compound 170 (0.60 g, 0.94 mmol) was dissolved in anhydrous pyridine (15 mL). 
The solution was cooled to 0 °C and benzoyl chloride (0.38 mL, 3.27 mmol, 3.5 eq) was 
added dropwise. The mixture was stirred at 0 °C for 1 h and the reaction was monitored 
by TLC (hexane/ethyl acetate 3:2). After completion, the mixture was diluted with ethyl 
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acetate and washed with sat. NaHCO3, 1 N HCl, brine, dried over Na2SO4, filtered, 
concentrated, co-evaporated with toluene and dried. The crude material was purified by 
flash column chromatography (hexane/ethyl acetate 78:22) to give 171 (0.72 g, 91%) as a 
white foam. [a]23 D -25.8 (c 1.8, CHCl3); 1H NMR (600 MHz, CDCl3) δ 8.10 (d, J = 7.3 
Hz, 2H), 8.00 (d, J = 7.4 Hz, 2H), 7.60-7.56 (m, 2H), 7.47 (t, J = 7.8 Hz, 2H), 7.43 (t, J = 
7.7 Hz, 2H), 5.61 (td, J = 11.2, 4.5 Hz, 1H), 4.95 (d, J = 8.7 Hz, 1H), 4.93-4.91 (m, 1H), 
4.36 (br s, 1H,), 4.32 (dd, J = 10.4, 1.0 Hz, 1H), 4.26 (dd, J = 11.0, 2.4 Hz, 1H), 4.10 (d, 
J = 4.2 Hz, 1H), 3.92 (q, J = 9.6 Hz, 1H), 3.85 (dd, J = 11.0, 6.4 Hz, 1H), 3.82 (s, 3H), 
2.74 (dd, J = 13.2, 4.5 Hz, 1H), 2.12 (dd, J = 13.2, 12.2 Hz, 1H), 1.93-1.89 (m, 6H), 1.74 
(d, J = 11.4 Hz, 3H), 1.54 (d, J = 12.3 Hz, 3H), 1.46 (d, J = 12.0 Hz, 3H), 1.29 (s, 9H); 
13C NMR (151 MHz, CDCl3) δ 170.0, 166.6, 165.8, 157.3, 133.4, 133.3, 130.1, 129.9, 
129.8, 129.8, 129.3, 128.4, 128.4, 86.0, 81.1, 74.3, 73.7, 70.2, 68.7 , 52.8, 52.5, 50.6, 
43.3, 40.4, 35.8, 29.7, 28.1,17.2; HRMS (ESI) m/z calcd for: C39H48INO10SNa, [M+Na]+ 
872.1941; found: 872.1907. 
Methyl (1-adamantanyl 5-azido-4,8-di-O-benzoyl-3,5,9-trideoxy-2-thio-D-glycero-β-
D-galacto-non-2-ulopyranosid)onate (174): A stirred solution of compound 171 (0.46 
g, 0.54 mmol) and and tris(trimethylsilyl)silane (0.25 mL, 0.81 mmol, 1.5 eq) in 
deoxygenated benzene (10 mL) was heated to 60 °C and treated dropwise with a 0.1 M 
2,2′-azobis(2-methylpropionitrile) solution in benzene (0.54 mL, 0.1 eq).  The reaction 
was monitored by TLC (hexane/ethyl acetate 3:2). After full consumption of the starting 
material (1 h), the mixture was cooled down and concentrated in vacuo to dryness to give 
a crude preparation of compound 172. The residue was dissolved in anhydrous methanol 
(2.5 mL) and 2 M hydrogen chloride solution in diethyl ether (5 mL) was added. The 
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mixture was stirred at room temperature for 2 h and then concentrated. The crude residue 
was dissolved in acetonitrile and the solution was extracted with hexanes to remove any 
non-polar impurities from the previous step. The acetonitrile layer was separated and 
concentrated to give a crude preparation of compound 173 that was taken up in a mixture 
of acetonitrile and water (4:1, 10 mL) and the mixture was cooled to 0 °C. Then 
triethylamine (0.23 mL, 1.62 mmol, 3 eq), copper (II) sulfate (9 mg, 0.05 mmol, 0.1 eq) 
and imidazole-1-sulfonyl azide hydrochloride165 (0.17 g, 0.81 mmol, 1.5 eq) were added 
to the reaction mixture. The mixture was allowed to warm to room temperature and was 
stirred for 8 h with reaction progress being monitored by TLC (hexane/ethyl acetate 3:2). 
After full consumption of the starting material, the mixture was diluted with ethyl acetate 
and was washed with 1 N HCl. The aqueous phase was then washed with ethyl acetate 
and combined organic layers were dried over Na2SO4, filtered, concentrated and dried. 
The crude material was purified by flash column chromatography (hexane/ethyl acetate 
7:3) to give 174 (0.28 g, 78% over 3 steps) as a white foam. [a]23 D -49.0 (c 1.6, CHCl3); 
1H NMR (600 MHz, CDCl3) δ 8.05-8.01 (m, 4H), 7.59-7.54 (m, 2H), 7.48-7.42 (m, 4H), 
5.65 (ddd, J = 11.7, 10.0, 4.7 Hz, 1H), 4.99 (dq, J = 8.6, 6.1 Hz, 1H), 4.34 (d, J = 10.1 
Hz, 1H), 4.03 (d, J = 8.6 Hz, 1H), 3.91 (t, J = 10.1 Hz, 1H), 3.77 (s, 3H), 2.83 (dd, J = 
13.4, 4.7 Hz, 1H), 2.77 (br s, 1H), 1.91 (dd, J = 13.4, 11.7 Hz, 1H), 1.84 (s, 3H), 1.76 
(dd, J = 11.7, 1.5 Hz, 3H), 1.62 (dd, J = 11.7, 1.2 Hz, 3H), 1.59 (d, J = 6.1 Hz, 3H), 1.50 
(d, J = 12.4 Hz, 3H), 1.36 (d, J = 11.8 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 170.3, 
165.4, 165.2, 133.4, 133.1, 130.2, 129.7, 129.6, 129.3, 128.5, 128.5, 85.6, 72.3, 71.2, 
71.1, 70.5, 60.8, 52.8, 50.3, 43.2, 39.7, 35.7, 29.6, 17.2; HRMS (ESI) m/z calcd for: 
C34H39N3O8SNa, [M+Na]+ 672.2356; found: 672.2335. 
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Methyl (1-adamantanyl 5-azido-4,8-di-O-benzoyl-3,5,9-trideoxy-7-oxo-2-thio-D-
glycero-β-D-galacto-non-2-ulopyranosid)onate (177): Compound 174 (0.11 g, 0.17 
mmol) was dissolved in anhydrous dichloromethane (2 mL) and the solution was cooled 
to 0 °C and Dess-Martin periodinane (108 mg, 0.26 mmol, 1.5 eq) was added. The 
mixture was stirred at room temperature for 4 h and the reaction was monitored by TLC 
(hexane/ethyl acetate 85:15). After completion, the mixture was diluted with diethyl ether 
and 20% aqueous Na2S2O3 solution was added. The organic layer was then washed with 
brine, dried over Na2SO4, filtered, concentrated and dried. The crude material was 
purified by flash column chromatography (hexane/ethyl acetate 9:1) to give 177 (0.094 g, 
85%) as a white foam. [a]25 D -76.2 (c 2.05, CHCl3); 1H NMR (600 MHz, CDCl3) δ 8.09-
8.07 (m, 2H), 8.02-8.00 (m, 2H), 7.58-7.55 (m, 2H), 7.46-7.42 (m, 4H), 5.57 (q, J = 6.8 
Hz, 1H), 5.47 (ddd, J = 11.2, 9.7, 4.8 Hz, 1H), 5.03 (d, J = 9.8 Hz, 1H), 3.84 (t, J = 9.8 
Hz, 1H), 3.79 (s, 3H), 2.80 (dd, J = 13.7, 4.8 Hz, 1H), 2.03 (d, J = 11.7 Hz, 3H), 1.99-
1.94 (m, 4H), 1.91 (d, J = 11.7 Hz, 3H), 1.70 (d, J = 6.8 Hz, 3H), 1.63 (s, 6H); 13C NMR 
(151 MHz, CDCl3) δ 202.6, 169.8, 166.0, 165.2, 133.4, 133.4, 129.9, 129.7, 129.3, 129.1, 
128.5, 128.4, 86.2, 73.7, 73.5, 70.6, 60.9, 52.8, 50.7, 43.3, 39.1, 35.9, 29.8, 16.2; HRMS 
(ESI) m/z calcd for: C34H37N3O8SNa, [M+Na]+ 670.2199; found: 670.2187. 
Methyl (1-adamantanyl 5-azido-4,8-di-O-benzoyl-3,5,9-trideoxy-2-thio-D-glycero-β-
L-altro-non-2-ulopyranosid)onate (179): A solution of compound 177 (0.172 g, 0.265 
mmol) in dichloromethane (2.25 mL) was cooled to -78 °C and a solution of cerium(III) 
chloride heptahydrate (0.30 g, 0.79 mmol, 3 eq) in methanol (4.75 mL) was added. After 
1 h sodium borohydride (0.015 g, 0.398 mmol) was added and the reaction was 
monitored by TLC (hexane/ethyl acetate 7:3). After completion, the mixture was 
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quenched with sat aqueous NH4Cl, warmed to room temperature and concentrated. The 
residue was diluted with ethyl acetate, washed with water and brine dried over Na2SO4, 
filtered, concentrated and dried. The crude material was purified by flash column 
chromatography (hexane/ethyl acetate 3:1) to give 179 (0.14 g, 82%) as a white foam and 
the recovered substrate 174 (0.24 g; 14%). [a]22 D -68.4 (c 3.5, CHCl3); 1H NMR (600 
MHz, CDCl3) δ 8.06 (dd, J = 8.2, 1.1 Hz, 2H), 8.01 (dd, J = 8.2, 1.1 Hz, 2H), 7.58-7.53 
(m, 2H), 7.45-7.42 (m, 4H), 5.57 (ddd, J = 11.2, 9.4, 4.8 Hz, 1H), 5.53 (dt, J = 12.3, 6.3 
Hz, 1H), 4.38 (dd, J = 10.2, 2.9 Hz, 1H), 4.06 (t, J = 10.2, 1H), 4.04 (dd, J = 12.3, 2.9, 
1H), 3.57 (s, 3H), 2.97 (br s, 1H), 2.72 (dd, J = 13.6, 4.8 Hz, 1H), 1.99-1.96 (m, 6H), 
1.94 (dd, J = 13.6, 11.2 Hz, 1H), 1.83 (d, J = 10.3 Hz, 3H), 1.64-1.59 (m, 6H), 1.49 (d, J 
= 6.3 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 170.2, 166.0, 165.2, 133.4, 133.0, 130.4, 
129.7, 129.7, 129.3, 128.5, 128.3, 85.7, 75.2, 71.9, 71.8, 70.9, 60.3, 52.5, 50.4, 43.4, 39.1, 
35.9, 29.8, 17.4; HRMS (ESI) m/z calcd for: C34H39N3O8SNa, [M+Na]+ 672.2356; found: 
672.2347. 
Methyl (1-adamantanyl 5,7-diazido-4,8-di-O-benzoyl-3,5,7,9-tetradeoxy-2-thio-D-
glycero-β-D-galacto-non-2-ulopyranosid)onate (181): Compound 179 (0.14 g, 0.21 
mmol) was dissolved in anhydrous dichloromethane (2 mL), the solution was cooled to 0 
°C and pyridine (170 µL, 2.10 mmol, 10 eq) was added followed by a drop-wise addition 
of triflic anhydride (106 µL, 0.63 mmol, 3 eq). The mixture was stirred at 0 °C for 1 h 
and the reaction was monitored by TLC (hexane/ethyl acetate 7:3). After completion, the 
mixture was diluted with dichloromethane and poured into ice-cold 1 N HCl solution. 
The organic phase was washed with cold water, dried over Na2SO4, filtered and 
concentrated to get a crude preparation of 180. The crude 180 was dissolved in anhydrous 
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dimethylformamide (4 mL) and the solution was cooled to 0 °C followed by addition of 
sodium azide (0.27 g, 4.20 mmol, 20 eq). The mixture was stirred at 0 °C for 16 h and the 
reaction was monitored by TLC (hexane/ethyl acetate 4:1). After completion, the mixture 
was diluted with ethyl acetate and washed with water. The organic phase was washed 
with brine, dried over Na2SO4, filtered, concentrated and dried. The crude material was 
purified by flash column chromatography (hexane/ethyl acetate 93:7) to give 181 (0.12 g, 
81% over the two steps) as a white foam. [a]21 D -50.7 (c 2.9, CHCl3); 1H NMR (600 
MHz, CDCl3) δ 8.06-8.02 (m, 4H), 7.59-7.56 (m, 2H), 7.47-7.43 (m, 4H), 5.65 (ddd, J = 
11.7, 10.0, 4.7 Hz, 1H), 5.38 (quintet, J = 6.2 Hz, 1H), 4.47 (dd, J = 10.1, 1.4 Hz, 1H), 
3.87 (t, J = 10.0 Hz, 1H), 3.85 (dd, J = 6.4, 1.4 Hz, 1H), 3.77 (s, 3H), 2.87 (dd, J = 13.4, 
4.7 Hz, 1H), 1.98 (dd, J = 13.4, 11.7 Hz, 1H), 1.89-1.85 (m, 6H), 1.71 (d, J = 11.3 Hz, 
3H), 1.68 (d, J = 6.2 Hz, 3H), 1.55 (d, J = 12.2 Hz, 3H), 1.44 (d, J = 12.2 Hz, 3H); 13C 
NMR (151 MHz, CDCl3) δ 169.6, 165.3, 165.2, 133.5, 133.3, 129.8, 129.7, 129.7, 129.2, 
128.5, 128.5, 85.8, 71.2, 71.0, 71.0, 64.1, 61.5, 52.7, 50.5, 43.2, 39.8, 35.8, 29.6, 17.2; 
HRMS (ESI) m/z calcd for: C34H38N6O7SNa, [M+Na]+ 697.2420; found: 697.2410. 
Methyl (1-adamantanyl 5-azido-3,5,9-trideoxy-2-thio-D-glycero-β-D-galacto-non-2-
ulopyranosid)onate (175): Compound 170 (0.35 g, 0.55 mmol) was dissolved in 
methanol (15 mL) and Pearlman’s catalyst (1.55 g, 2.20 mmol) was added to the mixture. 
The flask was filled with hydrogen gas (45 psi) and the mixture was stirred at room 
temperature for 48 h until starting material was no longer present. The mixture was 
filtered through a pad of Celite and the filtrate was concentrated. The residue was 
dissolved in anhydrous methanol (7.5 mL) and 2 M hydrogen chloride solution in diethyl 
ether (5 mL) was added. The mixture was stirred at room temperature for 2 h and then 
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concentrated. The residue was dissolved in a mixture of methanol and water (2:1, 6 mL). 
The mixture was cooled to 0 °C and potassium carbonate (0.23 g, 1.65 mmol, 3 eq), 
copper (II) sulfate (9 mg, 0.06 mmol, 0.1 eq) and imidazole-1-sulfonyl azide 
hydrochloride165 (0.19 g, 1.10 mmol, 2 eq) were added.  The mixture was allowed to 
warm to room temperature and was stirred for 16 h with reaction progress being 
monitored by TLC. After consumption of the starting material, the mixture was slightly 
concentrated, acidified with 1 N HCl and diluted with ethyl acetate. The aqueous phase 
was then washed with ethyl acetate and the combined organic layers were dried over 
Na2SO4, filtered, concentrated and dried. The crude material was purified by flash 
column chromatography to give 175 (0.09 g, 39% over the three steps) as a slightly 
yellow oil. [a]22 D -185.5 (c 4.0, MeOH); 1H NMR (600 MHz, CD3OD) δ 4.22 (d, J = 10.4 
Hz, 1H), 4.03 (ddd, J = 11.9, 9.6, 4.7 Hz, 1H), 3.81 (s, 3H), 3.80-3.76 (m, 1H), 3.42 (d, J 
= 8.9 Hz, 1H), 3.34 (t, J = 10.0 Hz, 1H), 2.42 (dd, J = 13.6, 4.8 Hz, 1H), 1.98-1.96 (m, 
6H), 1.92 (d, J = 11.0 Hz, 3H), 1.74 (dd, J = 13.6, 11.9 Hz, 1H), 1.68 (s, 6H), 1.29 (d, J = 
6.2 Hz, 3H); 13C NMR (150 MHz, CD3OD) δ 172.4, 85.9, 74.2, 70.8, 67.9, 65.5, 64.1, 
52.0, 49.5, 43.0, 42.6, 35.7, 29.9, 19.8; HRMS (ESI) m/z calcd for: C20H31N3O6SNa, 
[M+Na]+ 464.1831; found: 464.1836. 
Methyl (1-adamantanyl 5-azido-7,8-di-O-benzoyl-3,5,9-trideoxy-2-thio-D-glycero-β-
D-galacto-non-2-ulopyranosid)onate (176): Compound 175 (0.08 g, 0.18 mmol) was 
dissolved in anhydrous pyridine (3 mL). The solution was cooled to 0 °C and benzoyl 
chloride (52 µL, 0.45 mmol, 2.5 eq) was added dropwise. The mixture was stirred at 0 °C 
for 1 h and the reaction was monitored by TLC. After completion, the mixture was 
diluted with dichloromethane and washed with sat. NaHCO3. The aqueous layer was 
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extracted with dichloromethane and the combined organic layers were washed with 
water, brine, dried and concentrated. The crude material was purified by flash column 
chromatography to give 176 (0.05 g, 46%) as a slightly yellow oil. [a]23 D -27.2 (c 1.0, 
CHCl3); 1H NMR (600 MHz, CDCl3) δ 8.15 (dd, J = 8.2, 1.0 Hz, 2H), 8.02 (dd, J = 8.1, 
0.9 Hz, 2H), 7.61-7.58 (m, 1H), 7.55-7.53 (m, 1H), 7.49-7.46 (m, 2H), 7.44-7.41 (m, 2H), 
5.88 (dd, J = 6.0, 1.6 Hz, 1H), 5.43 (quintet, J = 6.0 Hz, 1H), 4.36 (dd, J = 9.8, 1.6 Hz, 
1H), 4.23 (ddd, J = 11.8, 9.8, 4.7 Hz, 1H), 3.81 (s, 3H), 3.07 (t, J = 9.8 Hz, 1H), 2.52 (dd, 
J = 13.7, 4.7 Hz, 1H), 1.91-1.87 (m, 6H), 1.77-1.72 (m, 4H), 1.58-1.54 (m, 6H), 1.47 (d, 
J = 11.9 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 170.2, 165.7, 165.6, 133.5, 133.1, 
130.1, 130.1, 129.7, 129.4, 128.6, 128.4, 86.0, 72.8, 71.1, 70.9, 68.6, 64.2, 52.6, 50.3, 
43.3, 42.5, 35.8, 29.7, 16.1; HRMS (ESI) m/z calcd for: C34H39N3O8SNa, [M+Na]+ 
672.2356; found: 672.2387. 
Methyl (methyl 5-azido-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranosid)onate 
(22): Methyl (methyl per-O-acetyl-N-acetyl-β-D-glycero-D-galacto-non-2-
ulopyranosid)onate159 (5.05 g, 10 mmol) was dissolved in anhydrous THF (40 mL) and 
di-tert-butyl dicarbonate (23.0 mL, 100 mmol, 10 eq) and 4-(dimethylamino)pyridine 
(0.49 g, 4 mmol, 0.4 eq) were added to the mixture. The reaction mixture was heated to 
60 °C with stirring for 22 h and the progress was monitored by TLC (hexane/ethyl acetate 
3:2). After completion, the mixture was directly adsorbed on silica gel and purified by 
flash column chromatography (hexane/ethyl acetate 65:35) to give the N-acetyl-N-imide 
as an orange oil. The residue was dissolved in anhydrous methanol (65 mL) and a 
catalytic amount of sodium methoxide (0.27 g, 5 mmol, 0.5 eq) was added to the mixture. 
The mixture was stirred at room temperature for 3 h and then 2 M hydrogen chloride 
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solution in diethyl ether (35 mL) was added. The mixture was stirred at room temperature 
for 5 h and then concentrated to give the free amine. The residue was dissolved in a 
mixture of acetonitrile and water (4:1, 150 mL), cooled to 0 °C and triethylamine (4.18 
mL, 30 mmol, 3 eq), copper(II) sulfate (0.16 g, 1 mmol, 0.1 eq) and imidazole-1-sulfonyl 
azide hydrochloride165 (3.14 g, 15 mmol, 1.5 eq) were added. The mixture was allowed to 
warm to room temperature and was stirred for 15 h with reaction progress being 
monitored by TLC (chloroform/methanol 85:15). After full consumption of the starting 
material, the mixture was diluted with ethyl acetate and was washed with 1 N HCl. The 
aqueous phase was then washed with ethyl acetate and the combined organic layers were 
dried over Na2SO4, filtered, concentrated and dried. The crude material was purified by 
flash column chromatography (chloroform/methanol 9:1) to give 182 (0.98 g, 30% over 
the four steps) as a colorless oil. [a]22 D -61.1 (c 4.85, MeOH); 1H NMR (600 MHz, 
CD3OD) δ 3.97 (ddd, J = 11.3, 9.9, 5.0 Hz, 1H), 3.82 (dd, J = 11.3, 2.3 Hz, 1H), 3.80 (s, 
3H), 3.76-3.73 (m, 1H), 3.73-3.70 (m, 2H), 3.66 (dd, J = 11.3, 5.0 Hz, 1H), 3.44 (t, J = 
9.9 Hz, 1H), 3.22 (s, 3H), 2.28 (dd, J = 12.9, 5.0 Hz, 1H), 1.61 (dd, J = 12.9, 11.3 Hz, 
1H); 13C NMR (151 MHz, CD3OD) δ 169.8, 99.0, 70.5, 70.2, 69.0, 68.0, 63.8, 63.2, 52.0, 
50.3, 39.9; HRMS (ESI) m/z calcd for: C11H19N3O8Na, [M+Na]+ 344.1070; found: 
344.1067. 
Methyl (methyl 5-azido-3,5-dideoxy-8,9-O-isopropylidene-D-glycero-D-galacto-non-
2-ulopyranosid)onate (183): Compound 182 (0.88 g, 2.75 mmol) was dissolved in 
anhydrous acetone (30 mL) and 2,2-dimethoxypropane (0.56 mL, 4.54 mmol, 1.65 eq) 
was added to the mixture followed by camphorsulfonic acid (22 mg, 0.1 mmol, 0.04 eq). 
The reaction was stirred at room temperature for 6 h and the progress was monitored by 
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TLC (toluene/i-PrOH 9:1). Upon completion, the reaction was quenched by addition of 
triethylamine (0.2 mL). After 15 min the reaction mixture was concentrated and the 
residue was dissolved in ethyl acetate and washed with water and brine. The organic 
layer was dried over Na2SO4, concentrated and purified by flash column chromatography 
(toluene/i-PrOH 95:5) to give 183 (0.82 g, 83%) as a white foam. [a]22 D -59.0 (c 4.2, 
CHCl3); 1H NMR (600 MHz, CDCl3) δ 4.14 (dt, J = 8.4, 5.4 Hz, 1H), 4.12-4.06 (m, 2H), 
4.02 (dd, J = 8.4, 4.9 Hz, 1H), 3.96 (d, J = 3.5 Hz, 1H), 3.81 (s, 3H), 3.71-3.68 (m, 1H), 
3.62 (d, J = 10.4 Hz, 2H, H-6, 7-OH), 3.48 (t, J = 10.0 Hz, 1H), 3.19 (s, 3H), 2.35 (dd, J 
= 12.9, 5.1 Hz, 1H), 1.63 (dd, J = 12.9, 11.6 Hz, 1H), 1.37 (s, 3H), 1.26 (s, 3H); 13C 
NMR (151 MHz, CDCl3) δ 169.7, 109.3, 99.1, 74.5, 70.7, 70.7, 68.3, 67.7, 62.8, 53.1, 
51.2, 39.9, 26.9, 25.3; HRMS (ESI) m/z calcd for: C14H23N3O8Na, [M+Na]+ 384.1383; 
found: 384.1389. 
Methyl (methyl 5-azido-4-O-(tert-butyldimethylsilyl)-3,5-dideoxy-8,9-O-
isopropylidene-D-glycero-D-galacto-non-2-ulopyranosid)onate (184): Compound 183 
(0.87 g, 2.4 mmol) and imidazole (0.36 mg, 5.28 mmol, 2.2 eq) were dissolved with 
stirring in anhydrous DMF (5 mL), the mixture was cooled to 0 °C and tert-
butyldimethylsilyl chloride (0.40 mg, 2.64 mmol, 1.1 eq) was added. The mixture was 
allowed to warm to room temperature and the reaction progress was monitored by TLC 
(hexane/ethyl acetate 3:2). After 20 h DMF was removed in vacuo and the residue was 
dissolved in water and extracted with Et2O. The combined organic layers were dried over 
Na2SO4, concentrated and purified by flash column chromatography (hexane/ethyl 
acetate 7:3) to give 184 (1.04 g, 91%) as a white solid. [a]22 D -57.8 (c 2.25, CHCl3); 1H 
NMR (600 MHz, CDCl3) δ 4.13-4.09 (m, 2H), 4.06-4.01 (m, 2H), 3.79-3.75 (m, 4H), 
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3.59 (d, J = 10.2 Hz, 1H), 3.47 (t, J = 10.2 Hz, 1H), 3.20 (s, 3H), 2.48 (d, J = 10.3 Hz, 
1H), 2.23 (dd, J = 13.1, 5.1 Hz, 1H), 1.65 (dd, J = 13.1, 11.1 Hz, 1H), 1.39 (s, 3H), 1.28 
(s, 3H), 0.88 (s, 9H), 0.15 (s, 3H), 0.09 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 168.5, 
109.2, 99.1, 74.9, 70.7, 70.5, 69.3, 67.5, 63.6, 52.7, 51.0, 40.7, 26.9, 25.6, 25.4, 17.8, -
4.6, -5.1; HRMS (ESI) m/z calcd for: C20H37N3O8SiNa, [M+Na]+ 498.2248; found: 
498.2254. 
Methyl (methyl 7-O-acetyl-5-azido-4-O-(tert-butyldimethylsilyl)-3,5-dideoxy-8,9-O-
isopropylidene-D-glycero-D-galacto-non-2-ulopyranosid)onate (185): Compound 184 
(1.04 g, 2.18 mmol) was dissolved in anhydrous DCM (10 mL), the mixture was cooled 
to 0 °C and pyridine (3.53 mL, 44 mmol, 20 eq), acetic anhydride (2.06 mL, 22 mmol, 10 
eq) and a catalytic amount of DMAP were added with stirring. The reaction mixture was 
allowed to warm to room temperature and the progress was monitored by TLC 
(hexane/ethyl acetate 4:1). After 7 h the mixture was concentrated in vacuo and the 
residue was purified by flash column chromatography (hexane/ethyl acetate 85:15) to 
give 185 (1.11 g, 98%) as a colorless oil. [a]20 D -22.1 (c 2.25, CHCl3); 1H NMR (600 
MHz, CDCl3) δ 5.39 (dd, J = 7.3, 1.5 Hz, 1H), 4.32 (dt, J = 7.3, 6.1 Hz, 1H), 4.04-4.01 
(m, 1H), 4.01-3.98 (m, 1H), 3.87 (dd, J = 8.7, 6.1 Hz, 1H), 3.79 (s, 3H), 3.62 (dd, J = 
10.6, 1.5 Hz, 1H), 3.21 (s, 3H), 3.01 (dd, J = 10.6, 9.1 Hz, 1H), 2.24 (dd, J = 13.2, 5.1 
Hz, 1H), 2.17 (s, 3H), 1.66 (dd, J = 13.1, 11.1 Hz, 1H), 1.37 (s, 3H), 1.29 (s, 3H), 0.88 (s, 
9H), 0.14 (s, 3H), 0.09 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 170.0, 168.0, 109.2, 99.0, 
73.7, 70.8, 70.1, 69.5, 66.6, 64.2, 52.6, 51.1, 40.5, 26.7, 25.6, 25.5, 20.9, 17.8, -4.7, -5.1; 
HRMS (ESI) m/z calcd for: C22H39N3O9SiNa, [M+Na]+ 540.2353; found: 540.2354. 
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Methyl (methyl 7-O-acetyl-5-azido-3,5-dideoxy-8,9-O-isopropylidene-D-glycero-D-
galacto-non-2-ulopyranosid)onate (186): Compound 185 (1.11 g, 2.14 mmol) was 
dissolved in anhydrous THF (25 mL) and 1.0 M tetrabutylammonium fluoride solution in 
THF (4.28 mL, 2 eq) was added. When TLC (hexane/ethyl acetate 1:1) showed complete 
conversion, the volatiles were removed in vacuo and the residue was purified by flash 
column chromatography (hexane/ethyl acetate 3:2) to give 186 (0.85 g, 98%) as a 
colorless oil. [a]21 D -27.5 (c 1.65, CHCl3); 1H NMR (600 MHz, CDCl3) δ 5.37 (dd, J = 
7.2, 1.6 Hz, 1H), 4.33 (dt, J = 7.2, 6.1 Hz, 1H), 4.08 (ddd, J = 11.3, 9.4, 5.1 Hz, 1H), 4.03 
(dd, J = 8.7, 6.1 Hz, 1H), 3.88 (dd, J = 8.7, 6.1 Hz, 1H), 3.79 (s, 3H), 3.66 (dd, J = 10.5, 
1.6 Hz, 1H), 3.22 (s, 3H), 3.07 (dd, J = 10.5, 9.4 Hz, 1H), 2.55 (br s, 1H), 2.38 (dd, J = 
13.1, 5.1 Hz, 1H), 2.16 (s, 3H), 1.70 (dd, J = 13.1, 11.3 Hz, 1H), 1.37 (s, 3H), 1.29 (s, 
3H); 13C NMR (151 MHz, CDCl3) δ 170.1, 167.9, 109.2, 98.8, 73.7, 70.6, 70.0, 68.8, 
66.6, 63.4, 52.7, 51.2, 39.6, 26.6, 25.5, 20.8; HRMS (ESI) m/z calcd for: C16H25N3O9Na, 
[M+Na]+ 426.1488; found: 426.1494. 
Acid-washed Molecular Sieves: Molecular sieves (4 Å, 30 g) were soaked in 2 N HCl 
(200 mL) for 12 h, then filtered and washed with de-ionized water (300 mL). The 
resulting solid was dried at 254 °C under vacuum for 24 h to give acid-washed molecular 
sieves (23 g), which were used directly for glycosylation. 
General protocol for glycosylation (GP) for donor 181: A mixture of donor 181 (101 
mg, 0.15 mmol), acceptor (0.18 mmol, 1.2 eq) and activated 4Å acid-washed molecular 
sieves (300 mg) in anhydrous dichloromethane/acetonitrile (2:1) (3 mL) was stirred for 2 
h at room temperature. Then the mixture was cooled to -78 °C and was treated with N-
iodosuccinimide (41 mg, 0.18 mmol, 1.2 eq) and trifluoromethanesulfonic acid (2 µL, 
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0.023 mmol, 0.15 eq). The reaction mixture was stirred at -78 °C until completion and 
then quenched with triethylamine (25 µL). The mixture was diluted with 
dichloromethane, filtered through Celite, washed with 20% aqueous Na2S2O3, dried over 
Na2SO4 and concentrated under reduced pressure. The residue was adsorbed on silica gel 
and was purified by flash column chromatography to give the desired glycosylation 
products. 
Methyl [1-benzyl (5,7-diazido-4,8-di-O-benzoyl-3,5,7,9-tetradeoxy-D-glycero-α-D-
galacto-non-2-ulopyranosid)onate] (30): Glycosylation of benzyl alcohol (8.28 µL, 
0.18 mmol, 1.2 eq) with 181 (100 mg, 0.15 mmol) was performed according to general 
procedure GP at -78 °C for 6 h to afford after flash column chromatography 
(hexane/ethyl acetate 80:20) compound 191 as the only product as colorless oil (87 mg, 
96 %). [a]19 D -21.6 (c 1.0, CHCl3); 1H NMR (600 MHz, CDCl3) δ 8.05 (t, J = 7.8 Hz, 
7H), 7.67-7.55 (m, 4H), 7.45 (t, J = 7.5 Hz, 4H), 5.63 (m, 1H), 5.17 (m, 1H), 4.82 (d, J = 
11.4 Hz, 1H), 4.45 (d, J = 11.4 Hz, 1H), 4.05 (d, J = 10.3 Hz, 1H), 3.97 (t, J = 10.0 Hz, 
1H), 3.71 (d, J = 8.5 Hz, 1H), 3.41 (s, 3H), 2.96 (dd, J = 13.0, 4.8 Hz, 1H), 2.02 (t, J = 
12.4 Hz, 1H), 1.61 (d, J = 6.3 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 167.9 (3JC1,H3ax = 
7.2 Hz), 165.2, 165.1, 136.8, 133.6, 133.2, 133.1, 129.7, 129.1, 128.4, 128.3, 128.0, 
127.8, 98.7, 72.9, 71.4, 68.6, 66.9, 63.4, 61.02, 52.57, 37.71, 18.5; HRMS (ESI) m/z 
calcd for: C31H30N6O8Na, [M+Na]+ 614.2125; found: 614.2132. 
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Methyl [methyl (5,7-diazido-4,8-di-O-benzoyl-3,5,7,9-tetradeoxy-D-glycero-α-D-
galacto-non-2-ulopyranosid)onate]-(2→6)-2,3,4-tri-O-benzyl-β-D-galactopyranoside 
(192eq), and, Methyl [methyl (5,7-diazido-4,8-di-O-benzoyl-3,5,7,9-tetradeoxy-D-
glycero-β-D-galacto-non-2-ulopyranosid)onate]-(2→6)-2,3,4-tri-O-benzyl-β-D-
galactopyranoside (192ax): Glycosylation of acceptor 187 (42 mg, 0.09 mmol, 1.2 eq) 
with donor 181 (51 mg, 0.075 mmol) was performed according to general procedure GP 
at -78 °C for 6 h to afford after flash column chromatography (cyclohexane/ethyl acetate 
85:15) 192eq (major isomer) and 192ax (minor isomer) as slightly yellow oils (63 mg, 
87% overall, eq:ax 6.7:1, separated after column chromatography). 192eq: [a]21 D -3.4 (c 
2.5, CHCl3); 1H NMR (600 MHz, CDCl3) δ 8.07-8.03 (m, 4H), 7.62-7.57 (m, 2H), 7.49-
7.45 (m, 4H), 7.37-7.32 (m, 7H), 7.31-7.29 (m, 3H), 7.28-7.25 (m, 4H), 7.23-7.20 (m, 
1H), 5.52 (dq, J = 8.2, 6.3 Hz, 1H), 5.15 (ddd, J = 12.0, 9.9, 4.9 Hz, 1H), 4.93 (d, J = 
11.4 Hz, 1H), 4.88 (d, J = 11.0 Hz, 1H), 4.74 (m, 2H), 4.70 (d, J = 11.8 Hz, 1H), 4.61 (d, 
J = 11.4 Hz, 1H), 4.29 (d, J = 7.7 Hz, 1H), 3.95 (dd, J = 9.9, 1.5 Hz, 1H), 3.90 (t, J = 9.9 
Hz, 1H), 3.87-3.84 (m, 2H), 3.79 (dd, J = 9.7, 7.7 Hz, 1H), 3.72 (dd, J = 8.2, 1.5 Hz, 1H), 
3.59 (dd, J = 9.2, 8.0 Hz, 1H), 3.55 (s, 3H), 3.53-3.51 (m, 2H), 3.34 (s, 3H), 2.89 (dd, J = 
12.9, 4.9 Hz, 1H), 1.91 (dd, J = 12.9, 12.0 Hz, 1H), 1.59 (d, J = 6.3 Hz, 3H); 13C NMR 
(151 MHz, CDCl3) δ 167.5 (3JC1,H3ax = 6.4 Hz), 165.2, 165.0, 138.8, 138.7, 138.5, 133.6, 
133.2, 130.0, 129.8, 129.7, 129.1, 128.6, 128.5, 128.3, 128.2, 128.1, 128.1, 127.9, 127.5, 
127.4, 127.3, 104.9, 99.0, 82.1, 79.5, 75.1, 74.3, 73.2, 72.9, 72.9, 72.8, 71.5, 68.8, 63.4, 
63.0, 60.9, 57.1, 52.7, 37.3, 17.9; HRMS (ESI) m/z calcd for: C52H54N6O13Na, [M+Na]+ 
993.3647; found: 993.3619. 192ax: [a]19 D -9.6 (c 0.4, CHCl3); 1H NMR (600 MHz, 
CDCl3) δ 8.05 (d, J = 7.5 Hz, 2H), 7.99 (d, J = 7.5 Hz, 2H), 7.59 (t, J = 7.3 Hz, 1H), 7.53 
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(t, J = 7.4 Hz, 1H), 7.47 (t, J = 7.6 Hz, 2H), 7.39-7.26 (m, 16H), 7.18 (t, J = 7.0 Hz, 1H), 
5.45 (ddd, J = 11.3, 10.1, 4.9 Hz, 1H), 5.35 (quintet, J = 6.2 Hz, 1H), 4.98 (d, J = 11.5 
Hz, 1H), 4.87 (d, J = 11.0 Hz, 1H), 4.76-4.70 (m, 3H), 4.56 (d, J = 11.5 Hz, 1H), 4.17 (d, 
J = 7.6 Hz, 1H), 3.93 (t, J = 10.1 Hz, 1H), 3.77-3.74 (m, 2H), 3.73-3.68 (m, 5H), 3.59 
(dd, J = 9.4, 6.5 Hz, 1H), 3.52 (s, 3H), 3.44-3.38 (m, 3H), 2.76 (dd, J = 13.0, 4.9 Hz, 1H), 
1.89 (dd, J = 13.0, 11.3 Hz, 1H), 1.54 (d, J = 6.2 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 
167.1 (3JC1,H3ax = 0.0 Hz), 165.3, 165.3, 138.8, 138.7, 138.5, 133.5, 133.3, 129.7, 129.7, 
129.6, 129.2, 128.6, 128.3, 128.2, 128.1, 128.1, 127.8, 127.5, 127.4, 127.3, 104.6, 98.9, 
82.2, 79.3, 75.0, 74.6, 74.1, 73.0, 72.5, 71.2, 71.1, 70.8, 63.4, 63.2, 60.9, 56.9, 52.9, 36.9, 
17.2; HRMS (ESI) m/z calcd for: C52H54N6O13Na, [M+Na]+ 993.3647; found: 993.3662. 
Methyl [methyl (5,7-diazido-4,8-di-O-benzoyl-3,5,7,9-tetradeoxy-D-glycero-α-D-
galacto-non-2-ulopyranosid)onate]-(2→4)-methyl 7-O-acetyl-5-azido-3,5-dideoxy-
8,9-O-isopropylidene-D-glycero-D-galacto-non-2-ulopyranoside (193eq), and, 
Methyl [methyl (5,7-diazido-4,8-di-O-benzoyl-3,5,7,9-tetradeoxy-D-glycero-β-D-
galacto-non-2-ulopyranosid)onate]-(2→4)-methyl 7-O-acetyl-5-azido-3,5-dideoxy-
8,9-O-isopropylidene-D-glycero-D-galacto-non-2-ulopyranoside (193ax): 
Glycosylation of acceptor 186 (53.7 mg, 0.13 mmol, 1.2 eq) with 181 (75 mg, 0.11 
mmol) was performed according to general procedure GP at -78 °C for 6 h to afford after 
flash column chromatography over silica gel (hexane/ethyl acetate 4:1) 193eq (major 
isomer) and 193ax (minor isomer) as colorless oils (82.8 mg, 82% overall, eq:ax 3.8:1, 
separated after column chromatography). 193eq: [a]21 D 36.4 (c 1.0, CHCl3);1H NMR 
(600 MHz, CDCl3) δ 8.04 (dd, J = 12.8, 4.8 Hz, 4H), 7.58 (m, 2H), 7.46 (t, J = 7.7 Hz, 
4H), 5.55 (dq, J = 12.8, 6.3 Hz, 1H), 5.46 (dd, J = 6.7, 1.4 Hz, 1H), 5.15 (ddd, J = 11.8, 
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10.0, 4.7 Hz, 1H), 4.49 (ddd, J = 11.2, 9.5, 5.0 Hz, 1H), 4.32 (q, J = 6.2 Hz, 1H), 4.04 
(dd, J = 8.8, 6.1 Hz, 1H), 3.96 (t, J = 9.7 Hz, 1H), 3.90 (dd, J = 8.8, 6.1 Hz, 1H), 3.77 (d, 
J = 1.9 Hz, 1H), 3.76 (s, 3H), 3.70 (d, J = 6.6 Hz, 1H), 3.69 (dd, J = 10.6, 1.5 Hz, 1H), 
3.42 (s, 3H), 3.27 (s, 3H), 3.11 (t, J = 9.8 Hz, 1H), 2.91 (dd, J = 12.6, 4.7 Hz, 1H), 2.16 
(s, 3H), 2.11 (dd, J = 12.3, 5.1 Hz, 1H), 1.95 (t, J = 12.3 Hz, 1H), 1.64 (dd, J = 12.4, 4.2 
Hz, 1H), 1.59 (d, J = 6.3 Hz, 1H), 1.39 (s, 3H), 1.31 (s, 3H); 13C NMR (151 MHz, 
CDCl3) δ 170.0, 167.7, 167.6, 165.2, 164.9, 133.6, 133.1, 130.3, 129.8, 129.6, 129.0, 
128.6, 128.4, 109.1, 98.6, 98.2, 74.1, 71.5, 71.4, 70.5, 70.3, 69.8, 66.4, 61.2, 60.8, 52.9, 
52.5, 51.1, 38.0, 36.6, 26.6, 25.5, 20.8, 17.8; HRMS (ESI) m/z calcd for: C40H47N9O16Na, 
[M+Na]+ 932.3038; found: 932.3030. 193ax: [a]21 D 18.6 (c 1.0, CHCl3);1H NMR (400 
MHz, CDCl3) δ 8.07 (m, 4H), 7.59 (t, J = 7.3 Hz, 2H), 7.41 (m, 4H), 5.51 (m, 2H), 5.38 
(dd, J = 7.3, 1.4 Hz, 1H), 4.33 (dd, J = 12.8, 6.2 Hz, 1H), 4.17 (m, 1H), 4.05 (dd, J = 8.7, 
6.0 Hz, 1H), 3.90 (m, 3H), 3.86 (s, 3H), 3.80 (s, 3H), 3.61 (dd, J = 10.6, 1.5 Hz, 1H), 
3.30 (d, J = 6.3 Hz, 1H), 3.20 ( t, J = 9.8 Hz, 1H), 3.13 (s, 3H), 2.94 (dd, J = 13.3, 4.8 Hz, 
1H), 2.56 (dd, J = 12.5, 5.0 Hz, 1H), 2.23 (s, 3H), 1.94 (t, J = 12.6 Hz, 1H), 1.78 (dd, J = 
12.4, 4.1 Hz, 1H), 1.68 (d, J = 6.4 Hz, 1H), 1.39 (s, 3H), 1.31 (s, 3H); 13C NMR (101 
MHz, CDCl3) δ 170.1, 167.0, 166.3 (3JC1,H3ax = 0.0 Hz), 165.5, 165.2, 133.6, 133.3, 
129.9, 129.8, 129.6, 129.1, 128.5, 128.4, 109.2, 100.0, 98.1, 76.7, 73.8, 73.6, 73.5, 72.2, 
70.6, 66.7, 61.1 , 60.9, 52.9, 52.7, 51.1, 38.8, 37.6, 26.7, 25.5, 20.1, 15.9; HRMS (ESI) 
m/z calcd for: C40H47N9O16Na, [M+Na]+ 932.3038; found: 932.3021. 
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Methyl [methyl (5,7-diazido-3,4,5,7,8,9-hexadeoxy-D-glycero-α-D-galacto-non-2-
ulopyranosid)onate]-(2→3)-2,4,6-tri-O-benzyl-β-D-galactopyranoside (194eq), and, 
Methyl [methyl (5,7-diazido-4,8-di-O-benzoyl-3,5,7,9-tetradeoxy-D-glycero-β-D-
galacto-non-2-ulopyranosid)onate]-(2→3)-2,6-di-O-benzyl-β-D-galactopyranoside 
(194ax): Glycosylation of acceptor 188 (83.6 mg, 0.18 mmol, 1.2 eq) and donor 181 (100 
mg, 0.15 mmol) and was performed according to general procedure GP at -78 °C for 6 h 
to afford after flash column chromatography (hexane/ethyl acetate 4:1) an inseparable 
mixture of isomers (120.7 mg; Yield: 84 %). A solution of this mixture of isomers (120 
mg; 0.12 mmol) in methanol (10 mL) was was treated with NaOMe (6.67 mg; 0.12 
mmol). The resulting mixture was stirred at room temperature until completion. The 
reaction mixture was neutralized with Amberlyst-15 H+ ion exchange resin, filtered and 
evaporated. The residue was subjected to column chromatography on silica gel 
(hexane/ethyl acetate 97:3) to obtain compound 194eq (major isomer) and compound 
194ax (minor isomer) as colorless oils (80.3 mg; 88%, 75% overall for 2 steps, eq:ax 
4.5:1, separated after column chromatography). 194eq: [a]21 D 18.2 (c 1.0, CHCl3);1H 
NMR (600 MHz, CDCl3) δ 7.56-7.17 (m, 15H), 4.86 (d, J = 11.2 Hz, 1H), 4.79 (d, J = 
11.6 Hz, 1H), 4.64 (d, J = 11.2 Hz, 1H), 4.49 (dd, J = 11.7, 5.4 Hz, 2H), 4.37 ( d, J = 11.8 
Hz, 1H), 4.26 ( d, J = 7.7 Hz, 1H), 4.05 (m, 1H), 3.95 ( dd, J = 9.9, 3.0 Hz, 1H), 3.77 (s, 
3H), 3.61 (m, 7H), 3.53 (s, 3H, Gal-OMe), 3.45 (t, J = 9.8 Hz, 1H), 3.04 (dd, J = 9.0, 2.3 
Hz, 1H), 2.49 (dd, J = 13.7, 4.6 Hz, 1H), 2.05 ( dd, J = 13.3, 10.9 Hz, 1H), 1.35 (d, J = 
6.2 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 168.9 (3JC1,H3ax = 7.2 Hz), 138.5, 138.2, 
128.3, 128.2, 128.1, 127.9, 127.6, 127.5, 127.4, 127.3, 105.0, 100.4, 77.4, 76.7, 75.9, 
74.9, 74.7, 73.3, 72.9, 69.9, 68.9, 65.8, 65.3, 63.4, 63.3, 57.0, 53.6, 37.6, 20.3; HRMS 
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(ESI) m/z calcd for: C38H46N6O11Na, [M+Na]+ 762.3225; found: 762.3234. 194ax: [a]21 D 
11.6 (c 1.0, CHCl3); 1H NMR (600 MHz, CDCl3) δ 7.32 (m, 15H), 4.77 (d, J = 11.9 Hz, 
1H), 4.72 (d, J = 11.2 Hz, 1H), 4.62 (d, J = 11.2 Hz, 1H), 4.59 (d, J = 11.9 Hz, 1H), 4.43 
(d, J = 11.2 Hz, 1H), 4.38 (d, J = 11.2 Hz, 1H), 4.22 (d, J = 7.6 Hz, 1H), 4.17 (d, J = 2.2 
Hz, 1H), 4.08 (d, J = 7.6 Hz, 1H), 4.17 (d, J = 2.2 Hz, 1H), 4.08 (d, J = 10.4 Hz, 1H), 
4.05 (d, J = 2.5 Hz, 1H), 4.03 (d, J = 2.1 Hz, 1H), 3.67 (m, 3H), 3.53 (m, 2H), 3.49 (s, 
3H), 3.38 (t, J = 10.0 Hz, 1H), 3.35 (s, 3H), 3.01 (d, J = 9.1 Hz, 1H), 2.60 (dd, J = 13.8, 
4.8 Hz, 1H), 1.78 (dd, J = 13.7, 11.7 Hz, 1H), 1.13 (d, J = 6.1 Hz, 3H); 13C NMR (151 
MHz, CDCl3) δ 166.8 (3JC1,H3ax = 0.0 Hz), 138.8, 138.5, 137.2, 128.8, 128.6, 128.2, 
127.5, 127.2, 105.5, 99.2, 76.8, 76.2, 75.2, 74.6, 73.7, 72.9, 71.4, 68.6, 68.1, 64.6, 63.8, 
57.0, 52.3, 39.9, 21.8; HRMS (ESI) m/z calcd for: C38H46N6O11Na, [M+Na]+ 762.3225; 
found: 762.3116. 
Methyl [methyl (5,7-diazido-4,8-di-O-benzoyl-3,5,7,9-tetradeoxy-D-glycero-α-D-
galacto-non-2-ulopyranosid)onate]-(2→3)-2,6-di-O-benzyl-β-D-galactopyranoside 
(195eq), and, Methyl [methyl (5,7-diazido-4,8-di-O-benzoyl-3,5,7,9-tetradeoxy-D-
glycero-β-D-galacto-non-2-ulopyranosid)onate]-(2→3)-2,6-di-O-benzyl-β-D-
galactopyranoside (195ax): Glycosylation of acceptor 189 (67 mg, 0.18 mmol, 1.2 eq) 
with 181 (101 mg, 0.15 mmol) was performed according to general procedure GP at -78 
°C for 6 h to afford after flash column chromatography (cyclohexane/ethyl acetate 4:1) 
195eq (major isomer) and a mixture separable by HPLC (gradient elution hexane/ethyl 
acetate from 95:5 to 7:3) of 195ax (minor isomer) and 196 (eq-glycoside (2→4)) as 
slightly yellow oils (116 mg, 88 %, eq:ax:(eq(4-OH)) 4.7:1:(0.9), separated after column 
chromatography and HPLC). 195eq: [a]22 D 15.3 (c 4.45, CHCl3); 1H NMR (600 MHz, 
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CDCl3) δ 8.02-7.99 (m, 4H), 7.62-7.60 (m, 1H), 7.58-7.55 (m, 1H), 7.48-7.43 (m, 4H), 
7.37-7.32 (m, 4H), 7.27-7.24 (m, 3H), 7.06-7.03 (m, 2H), 6.97-6.95 (m, 1H), 5.42 (dq, J 
= 8.6, 6.3 Hz, 1H), 5.27 (ddd, J = 11.8, 9.0, 5.0 Hz, 1H), 4.80 (d, J = 10.6 Hz, 1H), 4.64 
(d, J = 11.9 Hz, 1H), 4.61 (d, J = 11.9 Hz, 1H), 4.51 (d, J = 10.6 Hz, 1H), 4.33 (d, J = 7.8 
Hz, 1H), 4.05 (dd, J = 9.6, 3.3 Hz, 1H), 3.89 (s, 1H), 3.86-3.82 (m, 3H), 3.79 (dd, J = 
10.2, 6.3 Hz, 1H), 3.72 (dd, J = 8.6, 1.6 Hz, 1H), 3.68 (t, J = 5.7 Hz, 1H, Gal-H-5), 3.58 
(s, 3H), 3.53 (dd, J = 9.6, 7.8 Hz, 1H), 3.35 (s, 3H), 2.74 (dd, J = 13.3, 5.0 Hz, 1H), 2.61 
(s, 1H), 2.05 (dd, J = 13.3, 11.8 Hz, 1H), 1.49 (d, J = 6.3 Hz, 3H); 13C NMR (151 MHz, 
CDCl3) δ 167.8 (3JC1,H3ax = 7.0 Hz), 165.0, 164.8, 138.3, 138.1, 133.5, 133.3, 129.9, 
129.8, 129.7, 129.1, 128.5, 128.5, 128.4, 128.2, 128.1, 127.6, 127.6, 127.5, 104.7, 99.2, 
77.5, 75.3, 75.3, 73.6, 72.9, 72.7, 71.6, 69.6, 69.3, 68.4, 63.8, 60.7, 56.9, 53.0, 36.1, 18.1; 
HRMS (ESI) m/z calcd for: C45H48N6O13Na, [M+Na]+ 903.3177; found: 903.3167. 
195ax: [a]22 D 10.9 (c 0.65, CHCl3); 1H NMR (600 MHz, CDCl3) δ 8.05-8.04 (m, 4H), 
7.60-7.55 (m, 2H), 7.47-7.43 (m, 4H), 7.38 (d, J = 7.5 Hz,), 7.30-7.27 (m, 6H), 7.25-7.20 
(m, 2H), 5.62 (ddd, J = 11.4, 10.0, 4.5 Hz, 1H), 5.54-5.50 (m, 1H), 4.75 (d, J = 11.0 Hz, 
1H), 4.66 (d, J = 11.0 Hz, 1H), 4.58-4.53 (m, 2H), 4.36 (dd, J = 10.0, 1.2 Hz, 1H), 4.24 
(d, J = 7.6 Hz, 1H), 3.97-3.95 (m, 1H), 3.91-3.88 (m, 2H), 3.73 (dd, J = 9.5, 3.1 Hz, 1H), 
3.70 (dd, J = 10.2, 5.4 Hz, 1H), 3.62 (dd, J = 10.2, 5.4 Hz, 1H), 3.57 (s, 3H), 3.52-3.50 
(m, 4H), 3.45 (t, J = 5.4 Hz, 1H), 2.95 (dd, J = 13.2, 4.5 Hz, 1H), 2.80 (d, J = 5.1 Hz, 
1H), 1.97 (dd, J = 13.2, 11.4 Hz, 1H), 1.54 (d, J = 6.3 Hz, 3H); 13C NMR (151 MHz, 
CDCl3) δ 166.9 (3JC1,H3ax = 0.0 Hz), 165.4, 165.3, 138.6, 137.9, 133.5, 133.2, 129.9, 
129.8, 129.7, 129.3, 128.5, 128.5, 128.3, 128.2, 128.1, 127.7, 127.6, 127.4, 104.7, 99.7, 
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78.5, 77.3, 75.1, 73.6, 72.8, 72.0, 71.6, 71.1, 69.4, 68.6, 64.0, 61.1, 57.0, 52.8, 36.8, 16.6; 
HRMS (ESI) m/z calcd for: C45H48N6O13Na, [M+Na]+ 903.3177; found: 903.3151. 
Methyl [methyl (5,7-diazido-4,8-di-O-benzoyl-3,5,7,9-tetradeoxy-D-glycero-α-D-
galacto-non-2-ulopyranosid)onate]-(2→4)-2,6-di-O-benzyl-β-D-galactopyranoside 
(196): This compound was isolated as a minor byproduct from the glycosylation of 189 
with 181 as described above. [a]21 D 22.2 (c 0.7, CHCl3); 1H NMR (600 MHz, CDCl3) δ 
8.05 (d, J = 7.7 Hz, 2H), 8.00 (d, J = 7.7 Hz, 2H), 7.62-7.56 (m, 2H), 7.49-7.44 (m, 4H), 
7.40 (d, J = 7.5 Hz, 2H), 7.33-7.30 (m, 6H), 7.27-7.23 (m, 2H), 5.45-5.41 (m), 5.14 (ddd, 
J = 11.9, 10.0, 4.7 Hz, 1H), 4.86 (d, J = 11.3 Hz, 1H), 4.77 (d, J = 11.3 Hz, 1H), 4.57 (d, 
J = 12.2 Hz, 1H), 4.52 (d, J = 12.2 Hz, 1H), 4.33 (d, J = 2.5 Hz, 1H), 4.25 (d, J = 7.6 Hz, 
1H), 3.99 (d, J = 8.2 Hz, 1H), 3.90 (t, J = 10.0 Hz, 1H), 3.63 (d, J = 10.5 Hz, 1H), 3.61-
3.58 (m, 2H), 3.52 (s, 3H), 3.51-3.45 (m, 2H), 3.40 (dd, J = 9.6, 7.6 Hz, 1H), 3.26 (s, 
3H), 3.21 (d, J = 5.9 Hz, 1H), 3.05 (dd, J = 13.0, 4.7 Hz, 1H), 2.01 (dd, J = 13.0, 11.9 Hz, 
1H), 1.58 (d, J = 6.2 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 166.9 (3JC1,H3ax = 6.3 Hz), 
165.2, 164.9, 138.8, 138.2, 133.6, 133.2, 130.0, 129.8, 129.6, 129.0, 128.6, 128.5, 128.4, 
128.2, 128.1, 127.6, 127.5, 127.4, 104.7, 98.8, 79.8, 74.7, 73.5, 73.4, 73.1, 72.4, 72.2, 
71.4, 69.8, 69.1, 64.4, 60.7, 57.1, 52.8, 37.8, 17.7; HRMS (ESI) m/z calcd for: 
C45H48N6O13Na, [M+Na]+ 903.3177; found: 903.3174. 
Methyl [1-adamantanyl (5,7-diazido-4,8-di-O-benzoyl-3,5,7,9-tetradeoxy-D-glycero-
α-D-galacto-non-2-ulopyranosid)onate] (197eq), and, Methyl [1-adamantanyl (5,7-
diazido-4,8-di-O-benzoyl-3,5,7,9-tetradeoxy-D-glycero-β-D-galacto-non-2-
ulopyranosid)onate] (197ax): Glycosylation of 1-adamantanol 190 (14 mg, 0.090 mmol, 
1.2 eq) with 181 (51 mg, 0.075 mmol) was performed according to general procedure GP 
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at -78 °C for 9 h to afford after flash column chromatography (hexane/acetone 95:5) 
compound 197eq (major isomer) and compound 197ax (minor isomer) as slightly yellow 
oils (36 mg, 73% overall, eq:ax 4.2:1, separated after column chromatography). 197eq: 
[a]19 D -5.4 (c 1.3, CHCl3); 1H NMR (600 MHz, CDCl3) δ 8.04-8.02 (m, 4H), 7.59-7.56 
(m, 2H), 7.47-7.44 (m, 4H), 5.51 (dq, J = 9.7, 6.2 Hz, 1H), 5.00 (ddd, J = 12.3, 10.2, 4.5 
Hz, 1H), 4.29 (dd, J = 10.2, 1.7 Hz, 1H), 3.90 (t, J = 10.2 Hz, 1H), 3.63 (dd, J = 9.6, 1.7 
Hz, 1H), 3.41 (s, 3H), 2.82 (dd, J = 12.7, 4.5 Hz, 1H), 2.10 (br s, 3H), 1.94 (t, J = 12.7 
Hz, 1H), 1.79 (d, J = 2.4 Hz, 6H), 1.60 (d, J = 6.2 Hz, 3H), 1.59 (br s, 6H); 13C NMR 
(151 MHz, CDCl3) δ 170.3 (3JC1,H3ax = 5.7 Hz), 165.2, 165.1, 133.5, 132.9, 130.3, 129.7, 
129.6, 129.2, 128.5, 128.3, 97.9, 79.0, 72.7, 71.1, 68.3, 63.9, 61.2, 52.2, 43.2, 40.8, 36.0, 
31.0, 18.5; HRMS (ESI) m/z calcd for: C34H38N6O8Na, [M+Na]+ 681.2649; found: 
681.2632. 197ax: [a]22 D -10.8 (c 0.4, CHCl3); 1H NMR (600 MHz, CDCl3) δ 8.05-8.03, 
7.59-7.56 (m, 2H), 7.47-7.44 (m, 4H), 5.64 (ddd, J = 11.2, 10.1, 4.7 Hz, 1H), 5.42 (dq, J 
= 7.6, 6.2 Hz, 1H), 4.13 (dd, J = 10.1, 1.1 Hz, 1H), 3.88 (t, J = 10.1 Hz, 1H), 3.74 (s, 3H), 
3.71 (dd, J = 7.6, 1.1 Hz, 1H), 2.78 (dd, J = 12.6, 4.7 Hz, 1H), 1.87 (br s, 3H), 1.72-1.67 
(m, 7H), 1.65 (d, J = 6.2 Hz, 3H), 1.41 (d, J = 12.3 Hz, 3H), 1.29 (d, J = 11.8 Hz, 3H); 
13C NMR (150 MHz, CDCl3) δ 169.5 (3JC1,H3ax = 0.0 Hz), 165.4, 165.2, 133.4, 133.4, 
129.7, 129.7, 129.4, 128.5, 128.5, 96.9, 78.2, 71.1, 71.0, 70.1, 63.7, 61.4, 52.4, 42.6, 40.3, 
35.7, 30.7, 17.6; HRMS (ESI) m/z calcd for: C34H38N6O8Na, [M+Na]+ 681.2649; found: 
681.2624. 
Methyl [methyl (5,7-diazido-3,4,5,7,8,9-hexadeoxy-D-glycero-α-D-galacto-non-2-
ulopyranosid)onate]-(2→6)-2,3,4-tri-O-benzyl-β-D-galactopyranoside (198): To a 
solution of 192eq (130 mg; 0.13 mmol) in methanol (15 mL) was added NaOMe (7.23 
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mg; 0.13 mmol). The resulting mixture was stirred at room temperature until complete 
conversion. The reaction mixture was neutralized with Amberlyst-15 H+ resin and 
filtered. The filtrate was evaporated and subjected to column chromatography over silica 
gel (Hexane/Ethyl acetate 6:4) to give 198 as colorless oil (89 mg; 87%). [a]21 D 20.9 (c 
1.0, CHCl3); 1H NMR: δ 7.28 (m, 15H), 4.97 (d, J = 11.6 Hz, 1H), 4.87 (d, J = 10.9 Hz, 
1H), 4.75 (m, 2H), 4.71 ( d, J = 11.3 Hz, 1H), 4.58 (d, J = 11.6 Hz, 1H), 4.25 (d, J = 7.7 
Hz, 1H), 4.12 (m, 1H), 3.83 (d, J = 2.7 Hz, 1H), 3.80 (m, 1H), 3.77 (t, J = 9.9 Hz, 1H), 
3.61 (s, 3H), 3.59 (dd, J = 10.2, 5.4 Hz, 1H), 3.54 (s, 3H), 3.48 (m, 5H), 3.13 (dd, J = 9.1, 
2.1 Hz, 1H), 2.68 (dd, J = 13.2, 4.7 Hz, 1H), 1.85 (dd, J = 12.8, 10.6 Hz), 1.40 (d, J = 6.2 
Hz, 1H); 13C NMR: δ 168.8, 138.7, 138.4, 128.3, 128.2, 128.1, 128.1, 127.6, 127.6, 
127.5, 127.4, 127.3, 104.9, 98.8, 81.9, 79.5, 75.1, 74.2, 73.2, 73.1, 72.8, 72.6, 69.6, 65.8, 
65.8, 63.8, 62.6, 57.1, 53.4, 39.4 , 20.3; m/z calcd for: C38H46N6O11Na, [M+Na]+ 
762.3225; found: 762.3241. 
Methyl [methyl (5,7-diazido-3,4,5,7,8,9-hexadeoxy-D-glycero-α-D-galacto-non-2-
ulopyranosid)onate]-(2→3)-2,6-di-O-benzyl-β-D-galactopyranoside (203): To a 
solution of 195eq (50 mg; 0.06 mmol) in methanol (10 mL) was added NaOMe (3 mg; 
0.06). The resulting mixture was stirred at room temperature until complete conversion. 
Then the reaction mixture was quenched by Amberlyst-15 H+ resin and filtered. The 
filtrate was evaporated and subjected to column chromatography over silica gel 
(Hexane/Ethyl acetate 6:4) to give 203 as a colorless oil (27.1 mg; 72%). [a]21 D 30.4 (c 
1.0, CHCl3); 1H NMR: δ 7.32 (m, 10H), 4.85 (d, J = 11.2 Hz, 1H), 4.62 (d, J = 11.2 Hz, 
1H), 4.58 (m, 2H), 4.28 (d, J = 7.7 Hz, 1H), 4.06 (dd, J = 8.7, 6.2 Hz, 1H), 3.94 (dd, J = 
9.6, 3.1 Hz, 1H), 3.81 (s, 3H), 3.75 (m, 4H), 3.59 (m, 5H), 3.44 (t, J = 10.1 Hz, H-5). 
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3.08 (dd, J = 8.9, 2.0 Hz, 1H), 2.52 (dd, J = 13.6, 4.6 Hz, 1H), 2.05 (t, J = 11.6 Hz, 1H), 
1.35 (d, J = 6.2 Hz, 3H); 13C NMR: δ 169.0, 138.4, 128.4, 128.2, 127.7, 127.6, 127.5, 
104.8, 99.8, 77.3, 77.0, 76.7, 75.5, 74.9, 73.6, 73.1, 72.5, 69.8, 69.6, 65.4, 63.4, 57.0, 
53.7, 38.0, 20.3; m/z calcd for: C31H40N6O11Na, [M+Na]+ 695.2653; found: 695.2661. 
Methyl [methyl (4,8-di-O-acetyl-5,7-diacetamido-3,5,7,9-tetradeoxy-D-glycero-α-D-
galacto-non-2-ulopyranosid)onate]-(2→6)-2,3,4-tri-O-benzyl-β-D-galactopyranoside 
(199): To a solution of 198 (70 mg; 0.09 mmol) in 1:1 dioxane:water (8 mL) was added 
10% Pd/C (70 mg) followed by glacial acetic acid (0.25 mL). The resulting mixture was 
stirred at room temperature under hydrogen gas (1 atm) for 16 h then filtered and was 
evaporated to dryness. Pyridine (5 mL) and acetic anhydride (5 mL) were added to the 
residue and the resulting mixture was stirred at room temperature for 10 h. The solvents 
were evaporated and the residue was subjected to column chromatography over silica gel 
(dichloromethane/methanol 94:6) to give 199 (45 mg; 68%). [a]21 D 26.2 (c 1.0, CHCl3); 
1H NMR: δ 6.53 (d, J = 10.0 Hz, 1H), 5.71 (d, J = 7.9 Hz, 1H). 5.61 (d, J = 7.8 Hz, 1H), 
5.36 (m, 1H), 5.20 (dd, J = 10.6, 7.9 Hz, 1H), 4.96 (dd, J = 10.6, 6.2 Hz, 1H), 4.94 (dd, J 
= 8.7 Hz, 3.5 Hz, 1H), 4.63 (d, J = 8.0 Hz, 1H), 4.30 (t, J = 9.8 Hz, 1H), 4.10 (dd, J = 9.3, 
6.9 Hz, 1H), 3.84 (s, 3H), 3.60 (dd, J = 12.1, 9.4 Hz, 1H), 3.51 (s, 3H), 3.31 (m, 1H), 
2.63 (dd, J = 12.6, 4.7 Hz, 1H), 2.15 (s, 3H), 2.13 (s, 3H), 2.12 (s, 3H), 2.07 (s, 3H), 1.99 
(s, 3H), 1.98 (s, 3H), 1.92 (s, 3H), 1.67 (t, J = 12.4 Hz, 1H), 1.28 (d, J = 6.2 Hz, 3H); 13C 
NMR: δ 171.9, 171.4, 170.7, 170.5, 170.4, 170.2, 169.6, 166.6, 101.7, 100.7, 72.3, 71.0, 
70.0, 68.5, 67.3, 67.2, 66.8, 64.2, 57.1, 53.0, 52.0, 51.9, 38.7, 29.7, 23.6, 22.9, 21.4, 20.9, 
20.8, 20.7, 17.7; m/z calcd for: C31H46N2O18Na, [M+Na]+ 757.2643; found: 757.2641. 
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Methyl [methyl (4,8-di-O-acetyl-5,7-diacetamido-3,5,7,9-tetradeoxy-D-glycero-α-D-
galacto-non-2-ulopyranosid)onate]-(2→3)-2,4,6-tri-O-benzyl-β-D-galactopyranoside 
(201): Method 1 (From 194eq): To a solution of 194eq (40 mg; 0.05 mmol) in 1:1 
dioxane:water (6 mL) was added 10% Pd/C (70 mg) followed by glacial acetic acid (0.12 
mL). The resulting mixture was stirred at room temperature under hydrogen gas (1 atm) 
for 16 h, then filtered off, and evaporated to dryness. Pyridine (5 mL) and acetic 
anhydride (5 mL) were added to the residue and the resulting mixture was stirred at room 
temperature for 10 h. Then the solvents were evaporated and the residue was subjected to 
column chromatography over silica gel (dichloromethane/methanol 94:6) to give 201 
(28.1 mg; 73%). Method 2 (From 203): To a solution of 203 (20 mg; 0.03 mmol) in 1:1 
dioxane:water (3 mL) was added 10% Pd/C (20 mg) followed by glacial acetic acid (0.06 
mL). The resulting mixture was stirred at room temperature under hydrogen gas (1 atm) 
for 16 h, then filtered off, and evaporated to dryness. Pyridine (3 mL) and acetic 
anhydride (3 mL) were added to the residue and the resulting mixture was stirred at room 
temperature for 10 h. Then the solvents were evaporated and the residue was subjected to 
column chromatography over silica gel (dichloromethane/methanol 94:6) to give 201 
(14.3 mg; 66%). [a]21 D 37.5 (c 1.0, CHCl3); 1H NMR (600 MHz, CDCl3) δ 6.35 (s, 1H), 
5.34 (d, J = 8.9 Hz, 1H), 5.28 (s, 1H), 5.21 (m, 1H), 5.10 (dd, J = 12.3, 6.1 Hz, 1H), 5.03 
(d, J = 2.9 Hz, 1H), 4.64 (d, J = 8.3 Hz, 1H), 4.55 (dd, J = 10.0, 3.2 Hz, 1H), 4.51 (d, J = 
7.6 Hz, 1H), 4.33 (t, J = 10.2 Hz, 1H), 4.08 (d, J = 6.3 Hz, 1H), 3.83 (s, 3H), 3.52 (s, 3H), 
2.64 (dd, J = 12.4, 4.6 Hz, 1H), 2.17 (s, 3H), 2.12 (s, 3H), 2.09 (s, 3H), 2.05 (s, 3H), 2.04 
(s, 3H), 2.00 (s, 3H), 1.90 (s, 3H), 1.56 (t , J = 12.2 Hz, 1H), 1.24 (d, J = 6.2 Hz, 3H); 13C 
NMR (151 MHz, CDCl3) δ 170.8, 170.8, 170.3, 170.3, 170.3, 170.21, 170.19, 167.55, 
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101.48, 96.79, 71.03, 71.03, 70.82, 68.36, 68.36, 67.89, 67.46, 62.05, 56.97, 53.10, 51.37, 
51.05, 37.51, 23.40, 23.02, 21.73, 20.84, 20.82, 20.66, 20.66, 17.79; m/z calcd for: 
C31H46N2O18Na, [M+Na]+ 757.2643; found: 757.2662. 
Methyl [5,7-Diacetamido-3,5,7,9-tetradeoxy-D-glycero-α-D-galacto-non-2-
ulopyranosid)onic acid]-(2→6)-β-D-galactopyranoside (200): To a solution of 199 (30 
mg; 0.04 mmol) in H2O (3.0 mL) was added saturated aq Ba(OH)2 (1.0 mL). The 
resulting solution was stirred at 60 °C for 2 h. Then the reaction mixture was brought to 
room temperature and saturated with CO2. The precipitate was filtered off and the filtrate 
was frozen using a dry ice-acetone bath and lyophilized to obtain the white foam 200 
(18.1 mg, 91 %). [a]21 D 3.3 (c 0.5, H2O); 1H NMR (600 MHz, D2O) δ 4.15 (d, J = 8.0 Hz, 
1H), 3.82 (m, 2H), 3.76 (m, 3H), 3.68 (dd, J = 9.3, 2.9 Hz, 1H), 3.61 (dd, J = 8.1, 4.2 Hz, 
1H), 3.49 (m, 2H), 3.43 (m, 4H) 3.33 (dd, J = 9.9, 8.0 Hz, 1H), 2.58 (dd, J = 12.4, 4.5 Hz, 
1H), 1.83 (s, 3H), 1.78 (s, 3H), 1.52 (t, J = 12.1 Hz, 1H), 1.00 (d, J = 6.3 Hz, 3H); 13C 
NMR (151 MHz, D2O) δ 173.9, 173.6, 173.3, 103.8, 100.4, 73.4, 72.5, 71.6, 70.6, 68.7, 
68.6, 67.1, 63.7, 57.3, 53.9, 52.1, 40.2, 23.2, 21.9, 18.0; m/z calcd for: C20H33N2O13, [M-
H]- 509.1983; found: 509.1962. 
Methyl [5,7-Diacetamido-3,5,7,9-tetradeoxy-D-glycero-α-D-galacto-non-2-
ulopyranosid)onic acid]-(2→3)-β-D-galactopyranoside (202): To a solution of 201 (15 
mg; 0.02 mmol) in H2O (1.5 mL) was added saturated aq Ba(OH)2 (1.0 mL). The 
resulting solution was stirred at 60 °C for 2 h. Then the reaction mixture was brought to 
room temperature and saturated with CO2. The precipitate was filtered off and the filtrate 
was frozen using a dry ice-acetone bath and lyophilized to obtain the white foam 202 (9.2 
mg, 92 %). [a]21 D 1.8 (c 0.5, H2O); 1H NMR (600 MHz, D2O) δ 4.19 (d, J = 7.9 Hz, 1H), 
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3.91 (m, 1H), 3.79 (d, J = 6.4 Hz, 1H), 3.75 (s, 1H), 3.65 (m, 2H), 3.56 (m, 3H), 3.48 (t, J 
= 9.8 Hz, 1H), 3.40 (s, 3H), 3.37 (d, J = 8.0 Hz, 1H), 2.58 (dd, J = 12.8, 4.3 Hz, 1H), 1.81 
(s, 3H), 1.77 (s, 3H), 0.99 (d, J = 6.2 Hz, 3H); 13C NMR (151 MHz, D2O) δ 173.9, 173.8, 
173.7, 103.5, 99.5, 75.8, 74.8, 71.7, 69.0, 68.6, 67.2, 67.0, 60.9, 57.0, 53.8, 51.9, 40.0, 
22.4, 21.9, 18.0; m/z calcd for: C20H33N2O13, [M-H]- 509.1983; found: 509.1996. 
Methyl (1-adamantyl 4,7,8,9-tetra-O-acetyl-5-O-levulinoyl-3-deoxy-2-thio-D-
glycero-β-D-galacto-non-2-ulopyranosid)onate (214), and, Methyl (1-adamantyl 
7,8,9-tri-O-acetyl-4,5-di-O-levulinoyl-3-deoxy-2-thio-D-glycero-β-D-galacto-non-2-
ulopyranosid)onate (215): A solution of sialoside 160131 (1 g ; 1.56 mmol) in dry 
dichloromethane (14 mL) was treated with dry pyridine (1.14 mL; 14.04 mmol) under 
argon and cooled to -10 °C. After stirring for 15 min, crushed nitrosyl tetrafluoroborate 
(0.65 g; 2.62 mmol) was added in one portion. The reaction mixture was stirred for -10 
°C until TLC/MS showed complete conversion, then was diluted with cold 
dichloromethane and washed with cold 1 N HCl, saturated aq. NaHCO3 and brine. The 
organic layer was dried over anhydrous Na2SO4 and concentrated under 10 °C to obtain 
the nitrosated sialoside 212, which was carried forward without any further purification. 
A solution of the crude nitrosated sialoside 212 (1.06 g; 1.59 mmol) in dry 
dichloromethane (16 mL) and 2,2,2-trifluoroethanol (184 µL; 2.38 mmol) under argon at 
-10 °C was stirred for 0.5 h and then treated with freshly prepared sodium isopropoxide 
in isopropanol (0.2 N; 9.49 mL; 1.91 mmol). The resulting mixture was stirred for 2 min, 
then treated with a cold solution of levulinic acid (3.23 mL; 31.77 mmol) in 32 mL of 
dry dichloromethane. After stirring for 5 min, the reaction mixture was warmed to 0 °C 
and quenched with saturated aq. NaHCO3. It was then diluted with dichloromethane, 
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washed with cold brine, dried (Na2SO4) and concentrated under reduced pressure. The 
residue was purified by column chromatography on silica gel eluting with 10% acetone 
in toluene to afford 214 (535 mg; 49%) and 215 (243 mg; 21%). Compound 214: [α]21D -
36.9 (c 1.0, CHCl3); 1H NMR (400 MHz, CDCl3) δ 5.41 (t, J = 2.3 Hz, 1H), 5.36 (ddd, J 
= 11.9, 9.6, 4.9 Hz, 1H), 5.21 (dt, J = 8.7, 1.6 Hz, 1H), 4.96 (dd, J = 12.4, 1.6 Hz, 1H), 
4.87 (t, J = 9.8 Hz, 1H), 4.72 (dd, J = 10.0, 2.6 Hz, 1H), 4.25 (dd, J = 12.4, 8.6 Hz, 1H), 
3.82 (s, 3H), 2.82 - 2.69 (m, 1H), 2.65 - 2.52 (m, 3H), 2.49 - 2.37 (m, 1H), 2.15 (s, 3H), 
2.09 (s, 3H), 2.05 (s, 3H), 2.02 (s, 3H), 2.02-1.96 (m, 9H), 1.92 - 1.84 (m, 4H), 1.71 - 
1.62 (m, 8H); 13C NMR (101 MHz, CDCl3) δ 205.9, 171.7, 170.7, 170.4, 170.2, 170.1, 
169.8, 86.0, 73.2, 71.2, 69.0, 68.6, 68.2, 63.2, 63.2, 52.8, 50.5, 43.8, 43.4, 39.6, 37.7, 
36.1, 35.9, 29.9, 29.8, 29.6, 27.9, 21.0, 20.8, 20.6; ESI-HRMS (C33H46NaO14S): 
[M+Na]+ m/z: 721.2506; found: 721.2486. Compound 215: [α]21D -28.1 (c 0.51, CHCl3); 
1H NMR (400 MHz, CDCl3) δ 5.40 (t, J = 2.2, 1H), 5.36 (ddd, J = 11.9, 9.7, 4.9 Hz, 1H), 
5.20 (dt, J = 8.8, 1.6 Hz, 1H), 4.96 (dd, J = 12.3, 1.5 Hz, 1H), 4.87 (t, J = 9.8 Hz, 1H), 
4.71 (dd, J = 10.0, 2.6 Hz, 1H), 4.25 (dd, J = 12.4, 8.7 Hz, 1H), 3.81 (s, 3H), 2.15 (s, 
3H), 2.14 (s, 3H), 2.09 (s, 3H), 2.05 (s, 3H), 2.02 – 1.96 (m, 9H), 1.92 – 1.80 (m, 4H), 
1.65 (br s, 8H); 13C NMR (101 MHz, CDCl3) δ 206.6, 206.2, 171.7, 170.8, 170.4, 170.2, 
169.8, 86.0, 73.2, 71.2, 69.0, 68.9, 68.1, 63.2, 52.8, 50.5, 43.4, 39.5, 37.7, 35.9, 29.8, 
29.7, 27.9, 27.8, 21.0, 20.6; ESI-HRMS (C36H50NaO15S): [M+Na]+ m/z: 777.2768; 
found: 777.2766. 
Methyl (1-adamantyl 4,7,8,9-tetra-O-acetyl-3-deoxy-2-thio-D-glycero-β-D-galacto-
non-2-ylopyranosid)onate (216): To a solution of 214 (0.56 gm; 0.80 mmol) in 30 mL 
of dry dichloromethane at room temperature under argon was added 1.9 mL of dry 
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pyridine. This was followed by addition of hydrazine monohydrate (0.11 mL; 3.18 
mmol) and glacial acetic acid (1.42 mL). The resulting mixture was stirred at room 
temperature for 1 h. Then the reaction mixture was quenched with 10 mL of acetone and 
further stirred for 15 min. The reaction mixture was then diluted with dichloromethane 
and washed with water and brine. The organic layer was dried (Na2SO4) and 
concentrated under reduced pressure. The residue was purified by column 
chromatography on silica gel eluting with 45% EtOAc in hexane to afford 216 (0.36 g; 
77%). [α]21D -54.8 (c 0.81, CHCl3): 1H NMR (400 MHz, CDCl3) δ 5.53  (dd, J = 3.7, 2.6 
Hz, 1H), 5.36 - 5.22 (m, 2H), 4.84 (dd, J = 12.5, 1.6 Hz, 1H), 4.43(dd, J = 9.6, 2.5 Hz, 
1H), 4.33 (dd, J = 12.5, 7.1 Hz, 1H), 3.80 (s, 3H), 3.22 (t, J = 9.5 Hz, 1H), 3.10 (br s, 
1H), 2.60 (dd, J = 13.6, 4.8 Hz, 1H), 2.18 (s, 3H), 2.07 (s, 3H), 2.05 (s, 3H), 2.01 (s, 
3H), 1.98 (d, J = 11.2 Hz, 6H), 1.88 - 1.81 (m, 4H), 1.79 (dd, J = 13.4, 11.9 Hz, 1H), 
1.65 (s, 6H); 13C NMR (101 MHz, CDCl3) δ 171.5, 170.7, 170.5, 170.3, 170.1, 85.8, 
73.0, 72.1, 71.0, 70.7, 69.2, 62.7, 52.7, 50.3, 43.4, 39.4, 35.9, 29.8, 21.1, 21.0, 20.8, 
20.7; ESI-HRMS (C28H40NaO12S): [M+Na]+ m/z 623.2138; found 623.2137; ESI-
HRMS (C28H40NaO12S): [M+Na]+ m/z: 623.2138; found: 623.2137. 
Methyl (1-adamantyl 7,8,9-tri-O-acetyl-3-deoxy-2-thio-D-glycero-β-D-galacto-non-
2-ulopyranosid)onate (217): To a solution of 215 (150 mg; 0.21 mmol) in 20 mL of dry 
dichloromethane at room temperature under argon was added 0.7 mL of dry pyridine. 
This was followed by addition of hydrazine monohydrate (28 µL; 0.81 mmol) and 
glacial acetic acid (0.5 mL). The resulting mixture was stirred at room temperature for 1 
h. Then the reaction mixture was quenched with 10 mL of acetone and further stirred for 
15 min. The reaction mixture was then diluted with dichloromethane and washed with 
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water and brine. The organic layer was dried (Na2SO4) and concentrated under reduced 
pressure. The residue was purified by column chromatography on silica gel eluting with 
EtOAc in hexane to afford the pale yellow oil 217 (87 mg; 78%). [α]21D -55 (c 0.82, 
CHCl3); 1H NMR (400 MHz, CDCl3) δ 5.42 (dd, J = 3.7, 2.2 Hz, 1H), 5.30 (ddd, J = 6.6, 
3.8, 1.5 Hz, 1H), 4.88 (dd, J = 12.6, 1.4 Hz, 1H), 4.36 (dd, J = 12.4, 6.9 Hz, 1H), 4.33 
(dd, J = 9.5, 2.2 Hz, 1H), 4.11 (ddd, J = 12.0, 8.9, 4.7 Hz, 1H), 3.80 (s, 3H), 3.39 (br s, 
1H), 2.96 (t, J = 9.3 Hz, 1H), 2.78 (br s, 1H), 2.54 (dd, J = 13.8, 4.7 Hz, 1H), 2.19 (s, 
3H), 2.07 (s, 3H), 2.01 (s, 3H), 1.96 (d, J = 12.5 Hz, 7H), 1.81 (d, J = 10.7 Hz, 4H), 1.75 
(dd, J = 13.7, 12.1 Hz, 2H), 1.64 (s, 7H); 13C NMR (101 MHz, CDCl3) δ 172.4, 170.5, 
170.3, 170.3, 86.1, 72.7, 72.1, 71.9, 71.5, 67.8, 62.7, 52.7, 50.1, 43.4, 41.3, 35.9, 29.7, 
21.1, 20.9, 20.7; ESI-HRMS (C26H38NaO11S): [M+Na]+ m/z: 581.2033; found: 
581.2020. 
Methyl (1-adamantyl 4,7,8,9-tetra-O-acetyl-5-O-triflyl-3-deoxy-2-thio-D-glycero-β-
D-galacto-non-2-ulopyranosid)onate (223) : Method 1: A solution of sialoside 160 
(50 mg; 0.08 mmol) in dry dichloromethane (1 mL) was treated with dry pyridine (63 
µL; 0.78 mmol) under argon and cooled to -10 °C. After stirring for 15 min, crushed 
nitrosyl tetrafluoroborate (36 mg; 2.62 mmol) was added in one portion. The reaction 
was stirred for -10 °C until TLC/MS showed complete conversion, then was diluted with 
cold dichloromethane and washed with cold 1 N HCl, saturated aq. NaHCO3 and brine. 
The organic layer was dried over anhydrous Na2SO4 and concentrated under 10 °C to 
obtain the nitrosated sialoside 212 which was carried forward without any further 
purification. 18-crown-6 (47 mg; 0.18 mmol) and sodium 2,2,2-trifluoroethoxide (2 mg; 
0.164 mmol) were dissolved in anhydrous dichloromethane (0.4 mL) under argon, 
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cooled to -10 °C and added to the crude nitrosyl sialoside 212 (55 mg; 0.082 mmol) in 
anhydrous dichloromethane (0.8 mL) at -10 °C under argon. After 2 min, triflic acid 
(0.37 ml; 4.1 mmol) was added to the reaction mixture. The mixture was stirred for 5 
minutes and quenched with methanol (2 mL). The volatiles were evaporated and the 
crude compound was purified by column chromatography on silica gel (eluent: 25% 
EtOAc in hexane) to afford 223 (19 mg, 34%). Method 2: To a solution of 216 (100 mg: 
0.156 mmol) in 5 mL of dry dichloromethane was added dry pyridine (50 µL; 0.62 
mmol) and the temperature was lowered to -78 °C. At -78 °C, Tf2O (52 µL; 0.312 mmol) 
was added and the mixture was stirred for 15 min. Then the mixture was brought to 0 °C 
and further stirred for 2 h, before it was diluted with dichloromethane, washed with 1 N 
HCl and water. Then the organic layer was dried (Na2SO4) and concentrated to give a 
yellowish solid, which was then subjected to column chromatography (25% EtOAc in 
hexane) to give 223 (98 mg; 81%). [α]21D -72.1 (c 1.0, CHCl3) 1H NMR (400 MHz, 
CDCl3) δ 5.45 (ddd, J = 11.7, 9.1, 5.1  Hz, 1H), 5.36 (dt, J = 8.8, 4.4 Hz, 1H), 5.32 - 5.25 
(m, 1H), 5.01 (t, J = 9.4 Hz, 1H), 4.76 (dd, J = 9.6, 2.3 Hz, 1H), 4.68 (dd, J = 12.3, 2.1 
Hz, 1H), 4.24 (dd, J = 12.4, 7.1 Hz, 1H), 3.85-3.76 (m, 2H), 2.72 (dd, J = 13.7, 5.1 Hz, 
1H), 2.14 (s, 3H), 2.10 (s, 3H), 2.06 (s, 3H), 2.01 (s, 3H), 1.91 - 1.82 (m, 4H), 1.66 (s, 
6H), 1.43(m, 5H); 13C NMR (101 MHz, CDCl3) δ 170.8, 170.5, 169.4, 169.3, 169.2, 
85.3, 79.9, 71.7, 70.0, 69.0, 68.2, 62.8, 52.9, 50.9, 43.5, 43.3, 39.4, 35.9, 29.8, 29.7, 
20.6, 20.5; ESI-HRMS (C29H39F3NaO14S2): [M+Na]+ m/z: 755.1601; found: 755.1592 
Methyl (1-adamantyl 4,7,8,9-tetra-O-acetyl-5-azido-3,5-dideoxy-2-thio-D-glycero-β-
D-gulo-non-2-ulopyranosid)onate (206): To a solution of 223 (201 mg, 0.28 mmol) in 
15 mL of dry DMF was added LiN3 (202 mg; 4.13 mmol). The resulting mixture was 
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stirred at 0 °C for 24 h, then was diluted with ethyl acetate, and washed with NaHCO3, 
water and brine. The organic layer was dried (Na2SO4) and concentrated under reduced 
pressure. The residue was purified by column chromatography on silica gel eluting with 
30% EtOAc in hexane system to afford 206 (127 mg; 74%). [α]21D -106 (c 1.0, CHCl3) 
1H NMR (400 MHz, CDCl3) δ 5.64 (dd, J = 8.8, 3.3 Hz, 1H), 5.38 (ddd, J = 11.4, 5.4, 
3.3 Hz, 1H), 5.27 (dt, J = 6.5, 3.8 Hz, 1H), 4.51 (dd, J = 8.9, 1.0 Hz, 1H), 4.43 (dd, J = 
12.1, 4.2 Hz, 1H), 4.19 (dd, J = 12.1, 6.7 Hz, 1H), 4.10 (d, J = 1.5 Hz, 1H), 3.78 (s, 3H), 
2.35-2.21 (m, 2H), 2.11 (s, 3H), 2.10 (s, 3H), 2.08 (s, 3H), 1.97 (d, J = 11.4 Hz, 8H), 
1.82 (d, J = 11.1Hz, 3H), 1.65 (s, 6H); 13C NMR (101 MHz, CDCl3) δ 170.6, 169.9, 
169.9, 169.8, 169.3, 86.0, 70.7, 69.4, 69.0, 61.6, 58.5, 52.7, 50.4, 43.3, 36.0, 34.2, 29.8, 
20.8, 20.7, 20.6, 20.6 ESI-HRMS (C28H39N3NaO11S): [M+Na]+ m/z: 648.2203; found: 
648.2199.  
Methyl (1-adamantyl 4,7,8,9-tetra-O-acetyl-5-O-levulinic-3-deoxy-2-thio-D-glycero-
α-D-galacto-non-2-ulopyranosid)onate (224): The nitrosyl sialoside 221 (157 mg, 0.23 
mmol) was deaminated using the general procedure with 2,2,2-trifluoroethanol (27 µL, 
0.35 mmol), 0.2 N sodium isopropoxide in isopropanol (1.4 mL, 0.28 mmol) and 
levulinic acid (477 µL, 4.68 mmol) to afford 224 after flash chromatography over silica 
gel eluting with 10% acetone in toluene as a colorless oil (67 mg, 41%). [α]21D +24.5 (c 
= 0.96, CHCl3); 1H NMR (400 MHz, CDCl3) δ 5.28 (s, 2H), 4.87 - 4.78 (m, 2H), 4.30 (d, 
J = 12.3 Hz, 1H), 4.13 (t, J = 10.6 Hz, 2H), 3.81 (s, 3H), 2.87-2.77 (m, 1H), 2.76 - 2.70 
(m, 1H), 2.60 (dd, J = 9.3, 4.0 Hz, 1H), 2.57 - 2.52 (m, 1H), 2.50 - 2.42 (m, 1H), 2.19 (s, 
3H), 2.15 (s, 3H), 2.07 (s, 3H), 2.02 (s, 3H), 2.01 (s, 3H), 1.96 (d, J = 12.0 Hz, 4H), 1.86 
(d, J = 11.7 Hz, 3H), 1.66 (s, 6H); 13C NMR (101 MHz, CDCl3) δ 206.1, 171.7, 170.7, 
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170.4, 169.9, 169.6, 84.5, 72.8, 69.3, 68.5, 67.8, 66.4, 61.5, 52.8, 51.1, 43.5, 39.6, 37.7, 
36.0, 29.9, 29.7, 27.9, 21.1, 20.8, 20.7; ESI-HRMS (C33H46NaO14S): [M+Na]+ m/z: 
721.2506; found: 721.2491. 
Methyl (1-adamantyl 5-azido-3,5-dideoxy-2-thio-D-glycero-β-D-galacto-non-2-
ulopyranosid)onate (287): To a solution of 286118,131 (810 mg; 1.73 mmol) in 1:1 
MeOH/H2O (18 mL) was added imidazole-1-sulfonyl azide hydrochloride165 (0.72 g; 
3.46 mmol), K2CO3 (717 mg; 5.19 mmol) and CuSO4.5H2O (43 mg; 0.17 mmol). The 
reaction mixture was stirred at room temperature for 3 h. Thereafter, the solvent was 
evaporated and the residue was purified by flash chromatography on silica gel eluting 
with 8% MeOH in CHCl3 to afford the white sticky solid 287 (724 mg; 92%). [α]21D -
48.1 (c 1.0, CHCl3) 1H NMR (400 MHz, CD3OD) δ 4.84 (s, 3H), 4.22 (d, J = 10.4 Hz, 
1H), 4.06 (ddt, J = 11.8, 9.8, 5.9 Hz, 1H), 3.90-3.75 (s, 4H), 3.75 - 3.63 (s, 3H), 3.35 (dd, 
J = 23.4, 13.5 Hz, 1H), 2.33 (dd, J = 13.6, 4.7 Hz, 1H), 2.08 - 1.88 (br s, 8H), 1.81 -  
1.60 (m, 7H), 1.22(m, 1H); 13C NMR (101MHz, CD3OD); δ 172.4, 85.9, 78.6, 70.9, 
70.00, 69.8, 67.9, 63.9, 63.8, 59.8, 52.1, 49.5, 43.0, 35.7, 29.9, 19.9, 13.1; ESI-HRMS 
(C20H31N3NaO7S): [M+Na]+ m/z: 480.1796; found: 480.1789. 
Methyl (1-adamantyl 4,7,8,9-tetra-O-acetyl-5-azido-3,5-dideoxy-2-thio-D-glycero-β-
D-galacto-non-2-ulopyranosid)onate (288) : Method 1: To a solution of 287 (724 mg; 
1.58 mmol) in 15 mL of dry pyridine was added acetic anhydride (1.2 mL; 12.66 mmol). 
The resulting mixture was stirred under argon at room temperature for 4 h, was diluted 
with ethyl acetate and washed successively with saturated aq. NaHCO3 solution, 1 N 
HCl and again with saturated aq. NaHCO3 solution. The organic layer was then dried 
(Na2SO4) and concentrated under reduced pressure. The residue was purified by column 
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chromatography on silica gel eluting with 30% EtOAc in hexane to afford 288 (0.84 g; 
85%). Method 2: A solution of sialoside 160 (300 mg; 0.468 mmol) in dry 
dichloromethane (4.6 ml) was treated with dry pyridine (0.38 mL; 4.68 mmol) under 
argon and cooled to -10 °C. After stirring for 15 min, crushed nitrosyl tetrafluoroborate 
(218 mg; 1.872 mmol) was added in one portion. The reaction was stirred for -10 °C 
until TLC/MS showed complete conversion, then was diluted with cold dichloromethane 
(25 mL) and washed with cold 1 N HCl, saturated aq. NaHCO3 and brine. The organic 
layer was dried over anhydrous Na2SO4 and concentrated under 10 °C to obtain the 
nitrosated sialoside 212 which was carried forward without any further purification. A 
solution of the crude nitrosated sialoside 212 (320 mg; 0.48 mmol) in dry 
dichloromethane (4.8 mL) and 2,2,2-trifluoroethanol (55 µL; 0.72 mmol) under argon at 
-10 °C was stirred for 30 min and treated with freshly prepared sodium isopropoxide in 
isopropanol (0.2 N; 9.49 mL; 1.91 mmol). After stirring for 3 mins, the reaction mixture 
was treated with 1.7 N Hydrazoic acid in chloroform231 (5.61 mL; 9.54 mmol). The 
reaction mixture was further stirred at -10 °C for 10 min, warmed to 0 °C and quenched 
with saturated aq. NaHCO3. It was then diluted with dichloromethane, washed with cold 
brine, dried (Na2SO4) and concentrated under reduced pressure. The residue was purified 
by column chromatography on silica gel eluting with 30% EtOAc in hexane to afford 
288 (148 mg; 51%). [α]21D -106 (c 1.0, CHCl3) 1H NMR (400 MHz, CDCl3): δ 5.59 (dd, 
J = 3.6, 2.2 Hz, 1H), 5.32 (ddd, J = 11.7, 9.8, 4.8 Hz, 1H), 5.25-5.17 (m, 1H), 4.82 (dd, J 
= 12.5, 1.6 Hz, 1H), 4.29 (ddd, J = 15.8, 10.6, 4.7 Hz, 2H), 3.79 (s, 3H), 3.19 (t, J = 10.0 
Hz, 1H), 2.67 (dd, J = 13.5, 4.8 Hz, 1H), 2.18 (s, 3H), 2.08 (s, 3H), 2.07 (s, 3H), 2.03 (s, 
1H), 2.02 (s, 3H), 1.98 (s, 3H), 1.95 (s, 3H), 1.85 - 1.72 (m, 4H), 1.62 (s, 6H), 1.25 (t, J 
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= 7.1 Hz, 2H); 13C NMR (101 MHz, CDCl3): δ 170.5, 170.4, 169.8, 169.7, 169.4, 85.7, 
72.3, 71.0, 70.5, 70.1, 62.6, 60.4, 52.8, 50.6, 43.3, 39.3, 35.9, 29.7, 21.1, 20.9, 20.7; ESI-
HRMS (C28H39N3NaO11S): [M+Na]+ m/z: 648.2203; found: 648.2187 
General Coupling Protocol with Donors 206 or 288: A mixture of donor 206 or 288 
(0.15 mmol), acceptor (0.18 mmol) and activated 4Å acid-washed powdered molecular 
sieves (300 mg; 2 g/mmol of donor) in CH2Cl2/CH3CN (2:1, 2 mL) was stirred for 2 h at 
room temperature, then was cooled to -78 °C and was treated with NIS (42 mg; 0.18 
mmol) and TfOH (2 µL; 0.02 mmol). The reaction mixture was stirred at -78 °C for 5 h 
and then quenched with triethylamine (7 µL). The mixture was diluted with CH2Cl2, 
filtered through Celite, washed with 20% aqueous Na2S2O3, dried over Na2SO4 and 
concentrated under reduced pressure. The residue was purified by column 
chromatography on silica gel eluting with mixture of EtOAc and hexane to afford the 
desired coupled products. 
Methyl (cyclohexyl 4,7,8,9-tetra-O-acetyl-3,5-dideoxy-5-azido-D-glycero-α-D-gulo-
non-2-ulopyranosid)onate (231): Compound 231 was prepared according to the general 
glycosylation procedure using donor 206 (25 mg; 0.04 mmol) and compound 229 as 
acceptor (5 µL; 0.05 mmol) in CH2Cl2/CH3CN (1.0 mL; 2:1) at -78 °C. After 
chromatographic purification (gradient elution of EtOAc/Hexanes 2% to 30%) 231 (17.6 
mg; 79%) was obtained as white foam. [α]21D -11.6 (c 1.0, CHCl3); 1H NMR (600 MHz, 
CDCl3): δ 5.53 - 5.40 (dd, J = 6.0, 4.4 Hz, 1H), 5.26 (td, J = 5.8, 3.0 Hz, 1H), 4.92 - 4.85 
(m, 1H), 4.36 (dd, J = 12.4, 2.9 Hz, 1H), 4.21 (dd, J = 12.4, 5.5 Hz, 1H), 3.96 (dd, J = 
4.3, 0.9 Hz, 1H), 3.91 (d, J = 2.5 Hz, 1H), 3.75 (t, J = 3.5 Hz, 1H), 3.70-3.61 (m, 1H), 
2.38 (dd, J = 12.8, 4.5 Hz, 1H), 2.20 (dd, J = 12.1, 6.5, 1H), 2.11 (s, 3H), 2.10 (s, 3H), 
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2.05 (s, 3H), 1.87 (t, J = 7.3 Hz, 2H), 1.74 - 1.64 (m, 2H), 1.60 (d, J = 11.8 Hz, 2H), 1.47 
(dd, J = 8.8, 4.0 Hz, 2H), 1.41 - 1.02 (m, 6H);  13C NMR (151 MHz, CDCl3): δ 170.6, 
170.1, 170.0, 169.9, 169.0 (3JC-H = 6.9), 99.0, 74.2, 70.3, 70.1, 70.0, 69.1, 61.6, 58.9, 
52.6, 34.5, 33.2, 32.8, 25.4, 24.4, 24.3, 21.0, 20.8, 20.7, 20.6; ESI-HRMS 
(C24H35N3NaO12): [M+Na]+ m/z: 580.2118; found: 580.2109. 
Methyl [methyl (4,7,8,9-tetra-O-acetyl-3,5-dideoxy-5-azido-D-glycero-α-D-gulo-
non-2-ulopyranosid)onate]-(2→6)-2,3,4-tri-O-benzyl-β-D-galactopyranoside (232): 
Compound 232 was prepared according to the general glycosylation procedure using 
donor 206 (45 mg; 0.07 mmol) and acceptor 187 (40.07 mg; 0.08 mmol) in 
CH2Cl2/CH3CN (2.0 mL; 2:1) at -78 °C. After chromatographic purification (gradient 
elution of EtOAc / Hexanes 2% to 30%) compound 232 (47.5 mg; 72%) was obtained as 
a white foam. [α]21D -18.4 (c 1.0, CHCl3); 1H NMR (600 MHz, CDCl3) δ 7.37 - 7.30 (m, 
15H), 5.43 (dd, J = 6.3, 4.6 Hz, 1H), 5.26 (dd, J = 5.6, 3.0 Hz, 1H), 4.99 - 4.90 (m, 2H), 
4.86 (d, J = 11.0 Hz, 1H), 4.78 - 4.67 (m, 3H), 4.63 (t, J = 7.8 Hz, 1H), 4.34 (d, J = 3.0 
Hz, 1H), 4.32 (d, J = 3.0 Hz, 1H), 4.28 (d, J = 7.7 Hz, 1H), 4.20 - 4.14 (m, 1H), 3.95 (dd, 
J = 7.1 Hz, 3.7 Hz, 2H), 3.89 (d, J = 2.7 Hz, 1H), 3.80 (dt, J = 7.1, 3.7 Hz, 1H), 3.79 - 
3.74 (m, 2H), 3.64 - 3.59 (m, 3H), 3.53 (d, J = 4.9 Hz, 3H), 2.38 (dd, J = 12.8, 4.6 Hz, 
1H), 2.21 (t, J = 12.8 Hz, 1H), 2.16 (t, J = 4.5 Hz, 1H), 2.11 (s, 3H), 2.10 (s, 3H), 2.08 
(s, 3H), 2.04 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 170.6, 170.0, 169.9, 169.8, 168.0 
(3JC-H = 6.6), 138.9, 138.8, 138.5, 128.3, 128.2, 128.1, 128.0, 127.6, 127.4, 127.4, 127.2, 
105.0, 98.8, 82.5, 79.6, 75.1, 74.3, 73.2, 72.9, 72.6, 70.5, 70.3, 69.9, 68.9, 62.3, 61.5, 
58.8, 57.0, 52.8, 32.2, 29.7, 20.9, 20.8, 20.7, 20.6; ESI-HRMS (C46H55N3NaO17): 
[M+Na]+ m/z: 944.3429; found: 944.3409. 
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Methyl [methyl (4,7,8,9-tetra-O-acetyl-3,5-dideoxy-5-azido-D-glycero-α-D-gulo-
non-2-ulopyranosid)onate]-(2→3)-2,4,6-tri-O-benzyl-β-D-galactopyranoside (233): 
Compound 233 was prepared according to the general glycosylation procedure using 
donor 206 (40 mg; 0.06 mmol) and acceptor 188 (35.63 mg; 0.07 mmol) in 
CH2Cl2/CH3CN (1.8 mL; 2:1) at -78 °C. After chromatographic purification (gradient 
elution of EtOAc / Hexanes 2% to 30%) compound 233 (33.6 mg; 57%) was obtained as 
a white foam. [α]21D -11.6 (c 1.0, CHCl3); 1H NMR (600 MHz, CDCl3) δ 7.43 - 7.15 (m, 
15H), 5.39 (dd, J = 6.9, 3.4 Hz, 1H), 5.29 - 5.22 (m, 1H), 5.07 - 5.01 (m, 1H), 4.95 (d, J 
= 11.6 Hz, 1H), 4.83 (d, J = 11.1 Hz, 1H), 4.65 (d, J = 11.1 Hz, 1H), 4.53 (d, J = 11.7 
Hz, 1H), 4.47 (d, J = 11.7 Hz, 1H), 4.41 (d, J = 11.6 Hz, 1H), 4.36 - 4.30 (m, 2H), 4.04 
(dd, J = 12.4, 5.1 Hz, 1H), 3.98 (dd, J = 10.0, 2.9 Hz, 1H), 3.92 (s, 1H), 3.87 (d, J = 1.9 
Hz, 1H), 3.83 -3.80 (m, 1H), 3.78 (d, J = 2.8 Hz, 1H), 3.69 (s, 3H), 3.63 (m, 2H), 3.55 (s, 
3H), 2.46 (t, J = 13.0 Hz, 1H), 2.21 (dd, J = 13.5, 4.9 Hz, 1H), 2.16 (d, J = 5.9 Hz, 1H), 
2.08 (s, 3H), 2.04 (s, 3H), 2.02 (s, 3H), 1.88 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 
170.5, 169.9, 169.8, 169.6, 168.2 (3JC-H = 7.1), 139.3, 138.5, 138.1, 128.3, 128.1, 128.0, 
127.9, 127.7, 127.6, 127.4, 127.1, 104.9, 100.0, 77.5, 76.2, 75.1, 74.7, 73.5, 73.4, 70.2, 
69.9, 69.7, 69.0, 68.9, 61.3, 59.3, 57.0, 52.8, 29.6, 20.9, 20.7, 20.6; ESI-HRMS 
(C46H55N3NaO17): [M+Na]+ m/z: 944.3429; found: 944.3412. 
Methyl [methyl (4,7,8,9-tetra-O-acetyl-3,5-dideoxy-5-azido-D-glycero-α-D-gulo-non-
2-ulopyranosid)onate]-(2→4)-2,3,6-tri-O-benzyl-β-D-galactopyranoside (234): 
Compound 234 was prepared according to the general glycosylation procedure using 
donor 206 (30 mg; 0.04 mmol) and acceptor 230 (30 mg; 0.05 mmol) in CH2Cl2/CH3CN 
(1.2 mL; 2:1) at -78 °C. After chromatographic purification (gradient elution of 
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EtOAc/Hexanes 2% to 30%) compound 234 (19 mg, 44%) was obtained as a colorless 
oil. [α]21D -10.2 (c 1.0, CHCl3); 1H NMR (600 MHz, CDCl3) δ 7.53 - 7.06 (m, 15H), 5.54 
(t, J = 5.6 Hz, 1H), 5.40 - 5.30 (m, 2H), 5.10 (s, 1H), 4.77 (d, J = 10.9 Hz, 1H), 5.40 - 
5.30 (m, 2H), 4.73 - 4.66 (m, 1H), 4.60 (d, J = 11.0 Hz, 1H), 4.55 (d, J = 12.2 Hz, 1H), 
4.42 - 4.36 (m, 1H), 4.31 - 4.25 (m, 1H), 4.22 (d, J = 7.3 Hz, 1H), 4.12 (s, 1H), 4.06 (dd, 
J = 12.3, 6.4 Hz, 1H), 3.98 (s, 3H), 3.92 - 3.80 (m, 2H), 3.68 (s, 3H), 3.58 (dd, J = 18.0, 
10.9 Hz, 1H), 3.50 (s, 2H), 2.42-2.30 (m, 1H), 2.10 (s, 3H), 2.09 (s, 3H), 2.05 (s, 3H), 
1.99 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 170.6, 170.1, 169.8, 169.8, 167.7 (3JC-H = 
7.2), 138.6, 137.8, 137.6, 128.4, 128.2, 128.1, 128.0, 127.6, 127.5, 104.9, 98.7, 78.3, 
75.1, 73.5, 73.4, 72.6, 71.1, 69.4, 69.3, 68.9, 68.1, 67.3, 61.6, 60.0, 58.9, 57.1, 52.1, 21.0, 
20.9, 20.7, 20.6; ESI-HRMS (C46H55N3NaO17): [M+Na]+ m/z: 944.3429; found: 
944.3408. 
Methyl (cyclohexyl 4,7,8,9-tetra-O-acetyl-3,5-dideoxy-5-azido-D-glycero-α-D-
galacto-non-2-ulopyranosid)onate (289): Method 1: Compound 289 was prepared 
according to the general glycosylation procedure using donor 288 (40 mg; 0.06 mmol) 
and acceptor 229 (8 µL; 0.07 mmol) in CH2Cl2/CH3CN (1.8 mL; 2:1) at -78 °C. After 
chromatographic purification (gradient elution of EtOAc / Hexanes 2% to 30%) 
compound 289 (28.4 mg; 81%) was obtained as a white foam. Method 2: Compound 
289 was also prepared according to the general glycosylation procedure using donor 296 
(75 mg; 0.12 mmol) and acceptor 229 (15 µL; 0.15 mmol) in CH2Cl2/CH3CN (3.0 mL; 
2:1) at -78 °C. After chromatographic purification (gradient elution of EtOAc/Hexanes 
2% to 30%) 289 (57.2 mg; 86%) was obtained as a white foam. [α]21D -9.2; (c 1.0, 
CHCl3); 1H NMR (600 MHz, CDCl3) δ 5.49 (d, J = 12.6 Hz, 1H), 4.21 (dd, J = 12.5, 4.4 
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Hz, 1H), 3.78 (t, J = 5.1 Hz, 3H), 3.69 - 3.60 (m, 1H), 3.19 (t, J = 10.2 Hz, 1H), 2.71 
(dd, J = 12.7, 4.6 Hz, 1H), 2.17 (s, 3H), 2.14 (s, 3H), 2.09 (s, 3H), 2.06 (s, 3H), 1.88 (s, 
1H), 1.71 (dd, J = 13.1 Hz, 8.7 Hz, 2H), 1.66 (d, J = 14.3 Hz, 2H), 1.55 (d, J = 10.1 Hz, 
2H), 1.48 (d, J = 12.3 Hz, 2H), 1.33 (dd, J = 10.3, 6.3 Hz, 2H), 1.26 - 1.18 (m, 2H), 1.11 
(d, J = 9.2 Hz, 1H); 13C NMR (151 MHz, CDCl3) δ 170.7, 169.8, 169.7, 168.4 (3JC-H = 
6.2), 98.4, 74.3, 71.4, 71.1, 68.1, 67.9, 61.9, 60.1, 52.5, 38.0, 34.7, 33.0, 25.4, 24.2, 24.1, 
21.0, 20.9, 20.8, 20.7; ESI-HRMS (C24H35N3NaO12): [M+Na]+ m/z: 580.2118; found: 
580.2109. 
Methyl [methyl (4,7,8,9-tetra-O-acetyl-3,5-dideoxy-5-azido-D-glycero-α-D-galacto-
non-2-ylopyranosid)onate]-(2→6)-2,3,4-tri-O-benzyl-β-D-galactopyranoside (204): 
Compound 204 was prepared according to the general glycosylation procedure using 
donor 288 (45 mg; 0.07 mmol) and acceptor 187 (40.1 mg; 0.09 mmol) in CH2Cl2 / 
CH3CN (2.0 mL; 2:1) at -78 °C. After chromatographic purification (gradient elution of 
EtOAc/Hexanes 2% to 30%) compound 204 (48.8 mg; 74%) was obtained as a white 
foam. [α]21D -15.7 (c 1.0, CHCl3); 1H NMR (600 MHz, CDCl3) δ 7.43 - 7.14 (m, 15H), 
5.48 (d, J = 9.1 Hz, 1H), 5.34 (dd, J = 9.0, 3.2 Hz, 1H), 4.96 - 4.92 (m, 1H), 4.87 (d, J = 
10.9 Hz, 1H), 4.81(dd, J = 12.0, 4.9 Hz, 1H), 4.76 - 4.68 (m, 2H), 4.65 (t, J = 9.9 Hz, 
1H), 4.30 (d, J = 2.1 Hz, 1H), 4.27 (dd, J = 5.1, 2.6 Hz, 1H), 4.18 (d, J = 4.3 Hz, 1H), 
4.16 (d, J = 4.4 Hz, 1H), 3.88 (dd, J = 8.8, 5.7 Hz, 1H), 3.84 (d, J = 3.2 Hz, 1H), 3.80 - 
3.75 (m, 2H), 3.61 (s, 3H), 3.55 (s, 3H), 3.50 (m, 2H), 3.28-3.18 (m, 1H), 2.70 (dd, J = 
12.9 Hz, 4.8 Hz, 1H), 2.23 (d, J = 4.4 Hz, 1H), 2.14 (s, 3H), 2.12 (s, 3H), 2.10 (s, 3H), 
2.04 (s, 3H), 1.75 (t, J = 12.4 Hz, 1H); 13C NMR (151 MHz, CDCl3) δ 170.7, 169.7, 
169.7, 169.6, 167.4 (3JC-H = 6.4), 138.8, 138.7, 138.5, 128.3, 128.2, 128.1, 128.0, 127.6, 
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127.5, 127.4, 127.2, 104.9, 99.0, 82.0, 79.5, 75.1, 74.2, 73.3, 72.9, 72.6, 71.6, 71.1, 68.0, 
67.8, 52.9, 61.8, 59.9, 57.0, 52.8, 37.3, 21.0, 20.9, 20.8, 20.7; ESI-HRMS 
(C46H55N3NaO17): [M+Na]+ m/z: 944.3429; found: 944.3401. 
Methyl [methyl (4,7,8,9-tetra-O-acetyl-3,5-dideoxy-5-azido-D-glycero-α-D-galacto-
non-2-ulopyranosid)onate]-(2→3)-2,4,6-tri-O-benzyl-β-D-galactopyranoside (290): 
Compound 290 was prepared according to the general glycosylation procedure using 
donor 288 (35 mg; 0.05 mmol) and acceptor 188 (31.2 mg; 0.06 mmol) in 
CH2Cl2/CH3CN (1.5 mL; 2:1) at -78 °C. After chromatographic purification (gradient 
elution of EtOAc / Hexanes 2% to 30%) compound 290 (33.9 mg; 66%) was obtained as 
a white foam. [α]21D -17.8 (c 1.0, CHCl3); 1H NMR (600 MHz, CDCl3) δ 7.50 - 6.99 (m, 
15H), 5.45 (dd, J = 9.2, 1.1Hz, 1H), 5.40 (ddd, J = 9.3, 3.9, 2.2 Hz, 1H), 4.90 - 4.84 (m, 
2H), 4.80 (d, J = 11.2 Hz, 1H), 4.66 (d, J = 11.3 Hz, 1H), 4.51 (d, J = 11.8 Hz, 1H), 4.44 
(d, J = 11.5 Hz, 1H), 4.38 (d, J = 11.6 Hz, 1H), 4.30 (dd, J = 4.9, 2.7 Hz, 1H), 4.28 (d, J 
= 2.1 Hz, 1H), 4.02 (d, J = 4.0 Hz, 1H), 4.00 (d, J = 4.0 Hz, 1H), 3.96 (d, J = 2.9 Hz, 
1H), 3.94 (d, J = 3.0 Hz, 1H), 3.70 (s, 3H), 3.64 - 3.59 (m, 4H), 3.54 (s, 3H), 3.51 (d, J = 
3.9 Hz, 1H), 3.15 (t, J = 10.2 Hz, 1H), 2.61 (dd, J = 13.3, 4.8 Hz, 1H), 2.11 (s, 3H), 2.03 
(s, 3H), 2.01 (s, 3H), 1.92 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 170.5, 169.5, 169.4, 
167.6 (3JC-H = 6.8), 139.1, 138.8, 138.0, 128.3, 128.1, 128.0, 127.8, 127.7, 127.7, 127.4, 
127.1, 104.9, 98.8, 77.5, 76.3, 76.2, 74.9, 74.8, 73.5, 73.1, 71.4, 71.2, 68.5, 68.2, 67.7, 
61.6, 59.8, 57.1, 52.9, 41.7, 35.9, 35.4, 29.4, 28.5, 21.0, 20.8, 20.7, 20.4; ESI-HRMS 
(C46H55N3NaO17): [M+Na]+ m/z: 944.3429; found: 944.3403. 
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Methyl [methyl (4,7,8,9-tetra-O-acetyl-3,5-dideoxy-5-azido-D-glycero-α-D-galacto-
non-2-ulopyranosid)onate]-(2→4)-2,3,6-tri-O-benzyl-β-D-galactopyranoside (291): 
Compound 291 was prepared according to the general glycosylation procedure using 
donor 288 (40 mg; 0.0639 mmol) and acceptor 230 (35.63 mg; 0.0767 mmol) in 
CH2Cl2/CH3CN (1.8 mL; 2:1) at -78 °C. After chromatographic purification on silica gel 
(gradient elution of EtOAc/Hexanes 2% to 30%) compound 291 (23.2 mg; 41%) was 
obtained as a colorless oil. [α]21D -21.4 (c 1.0, CHCl3); 1H NMR (400 MHz, CDCl3) δ 
7.45 - 7.14 (m, 15H), 5.57 (s, 2H), 5.50 - 5.35 (m, 1H), 4.86 - 4.72 (m, 3H), 4.59 (d, J = 
10.9 Hz, 1H), 4.47 (dd, J = 18.1, 12.2 Hz, 3H), 4.34 - 4.24 (m, 1H), 4.19 (d, J = 7.7Hz, 
1H), 4.13 - 4.02 (m, 2H), 3.89 - 3.81 (m, 1H), 3.81 - 3.72 (m, 1H), 3.62 - 3.54 (m, 1H), 
3.49 (s, 3H), 3.44 (s, 3H), 3.31 (dd, J = 16.2, 10.9Hz, 2H), 2.65 (dd, J = 12.9, 4.9 Hz, 
1H), 2.23 (s, 3H), 2.12 (s, 3H), 2.01 (s, 3H), 1.96 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 
170.6, 170.4, 170.1, 169.4, 167.7 (3JC-H = 6.9), 138.1, 137.3, 128.6, 128.6, 128.4, 128.2, 
128.0, 127.9, 127.4, 127.4, 105.2, 98.4, 82.0, 78.5, 75.1, 73.4, 73.3, 72.5, 70.7, 69.6, 
69.1, 68.3, 66.8, 62.0, 60.9, 57.1, 51.9, 38.7, 21.2, 20.9; ESI-HRMS (C46H55N3NaO17): 
[M+Na]+ m/z: 944.3429; found: 944.3407. 
Methyl (1-adamantyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-5-N-(1,1-
dimethylethoxy)carbonyl-2-thio-D-glycero-α-D-galacto-non-2-ulopyranosid)onate 
(292): To a solution of 220 (1.5 g; 2.35 mmol) in anhydrous THF (10 mL) were added 
di-tert-butyl dicarbonate (5.11 g, 23.52 mmol) and DMAP (114 mg; 0.95 mmol) at room 
temperature. The mixture was stirred for 10 h at 60 °C under argon before it was cooled 
to room temperature and concentrated under reduced pressure. The residue was applied 
to silica gel and eluted with 35% EtOAc in hexanes to give 292 (1.3 g; 76%). [α]21D 
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+42.3 (c 1.0, CHCl3); 1H NMR (600 MHz, CDCl3) δ 5.32 - 5.22 (m, 2H), 5.19 - 5.10 (m, 
1H), 4.86 (t, J = 10.5 Hz, 1H), 4.69 (d, J = 10.3 Hz, 1H), 4.32 (m, 1H), 4.04 (dd, J = 
12.6, 3.7 Hz, 1H), 3.77 (s, 3H), 2.76 (m, 1H), 2.35 (s, 3H), 2.17 (s, 3H), 2.05 (s, 3H), 
1.99 (m, 6H), 1.93 (s, 3H), 1.88 (s, 3H), 1.65 (m, 6H), 1.54 (s, 9H), 1.49 (m, 3H); 13C 
NMR (151 MHz, CDCl3) δ 173.9, 170.6, 170.1, 170.1, 169.9, 169.6, 151.8, 84.7, 84.3, 
73.0, 69.0, 67.2, 66.5, 61.4, 52.6, 52.4, 51.2, 43.5, 41.2, 36.0, 27.9, 27.8, 26.7, 21.2, 
20.1, 20.7, 20.6; ESI-HRMS (C35H51NNaO14S): [M+Na]+ m/z: 764.2928; found: 
764.2936. 
Methyl (1-adamantyl 5-azido-3,5-dideoxy-2-thio-D-glycero-α-D-galacto-non-2-
ulopyranosid)onate (295): To a solution of 292 (1.25 g; 1.68 mmol) in dry methanol (7 
mL) was added a catalytic amount of sodium methoxide. The solution was stirred for 1 h 
at room temperature and then quenched with Amberlyst 15 ion-exchange resin. The 
mixture was filtered through Celite and concentrated under reduced pressure to give a 
crude preparation of 293 (0.9 g), which was dissolved in 8 mL of dry THF and was 
treated with 2 N HCl in diethyl ether (6 mL) at 0 °C. The resulting mixture was brought 
to room temperature and stirred for 5 h, and then the mixture was concentrated under 
reduced pressure to give crude a crude preparation of 294 (0.75 g, 1.6 mmol), which was 
dissolved in 1:1 MeOH:H2O (16 mL) followed by addition of imidazole-1-sulfonyl azide 
hydrochloride (0.66 g; 3.2 mmol), K2CO3 (0.66 g; 4.8 mmol) and CuSO4.5H2O (40 mg; 
0.16 mmol). The reaction mixture was stirred at room temperature for 3 h. Thereafter, 
the solvent was evaporated and the residue was purified by flash chromatography on 
silica gel eluting with 8% MeOH in CHCl3 to afford the white sticky solid 295 (0.66 g; 
86% for 3 steps). [α]21D +20.6 (c 1.0, MeOH); 1H NMR (400 MHz, CD3OD) δ 3.84 (s, 
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3H), 3.65 (m, 3H), 3.56 - 3.40 (m, 3H), 3.31 (m, 1H), 2.64 (dd, J = 8.3, 4.2 Hz, 1H), 2.08 
(m, 9H), 1.72 (m, 6H); 13C NMR (101 MHz, CD3OD) δ 171.9, 84.6, 75.1, 71.8, 69.5, 
68.9, 63.3, 62.8, 59.1, 52.2, 50.1, 43.4, 42.1, 41.7, 39.5, 35.7, 31.5, 29.9; ESI-HRMS 
(C20H31N3NaO7S): [M+Na]+ m/z: 480.1796; found: 480.1775. 
Methyl (1-adamantyl 4,7,8,9-tetra-O-acetyl-5-azido-3,5-dideoxy-2-thio-D-glycero-α-
D-galacto-non-2-ulopyranosid)onate (296): Method 1: To a solution of 295 (420 mg; 
1.30 mmol) in 8 mL of dry pyridine was added acetic anhydride (0.99 mL; 10.44 mmol). 
The resulting mixture was stirred under argon at room temperature for 4 h, then was 
diluted with ethyl acetate and washed successively with saturated aq NaHCO3 solution, 1 
N HCl and again with saturated aq NaHCO3 solution. The organic layer was then dried 
(Na2SO4) and concentrated under reduced pressure. The residue was purified by column 
chromatography on silica gel eluting with 30% EtOAc in hexane to afford 296 (480 mg; 
84%). Method 2: A solution of sialoside 220 (300 mg; 0.47 mmol) in dry 
dichloromethane (4.6 mL) was treated with dry pyridine (0.38 mL; 4.68 mmol) under 
argon and cooled to -10 °C. After stirring for 15 min, crushed nitrosyl tetrafluoroborate 
(218 mg; 1.87 mmol) was added in one portion. The reaction was stirred for -10 °C until 
TLC/MS showed complete conversion, then was diluted with cold dichloromethane (25 
mL) and washed with cold 1 N HCl, saturated NaHCO3 and brine. The organic layer was 
dried over anhydrous Na2SO4 and concentrated under 10 °C to give the nitrosated 
sialoside 221 which was carried forward without any further purification. A solution of 
the crude nitrosated sialoside 221 (320 mg; 0.48 mmol) in dry dichloromethane (4.8 mL) 
and 2,2,2-trifluoroethanol (55 µL; 0.72 mmol) under argon at -10 °C was stirred for 30 
min and treated with freshly prepared sodium isopropoxide in isopropanol (0.2 N; 9.49 
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mL; 1.91 mmol). After stirring for 3 mins, the reaction mixture was treated with 1.7 N 
hydrazoic acid in chloroform231 (5.61 mL; 9.54 mmol). The reaction mixture was further 
stirred at -10 °C for 10 min, warmed to 0 °C and quenched with saturated aq NaHCO3. It 
was then diluted with dichloromethane, washed with cold brine, dried (Na2SO4) and 
concentrated under reduced pressure. The residue was purified by column 
chromatography on silica gel eluting with 30% EtOAc in hexane to afford 296 (135 mg; 
46%). [α]21D +63.2 (c 1.0, CHCl3); 1H NMR (400 MHz, CDCl3) δ 5.48 (d, J = 9.8 Hz, 
1H), 5.28 (d, J = 9.8 Hz, 1H), 4.69 (t, J = 9.5 Hz, 1H), 4.25 (dd, J = 11.4, 4.6 Hz, 2H), 
3.79 (s, 3H), 3.16 (t, J = 10.1 Hz, 1H), 2.75 (dd, J = 12.7, 4.6 Hz, 1H), 2.17 (s, 3H), 2.16 
(s, 3H), 2.08 (s, 3H), 2.04 (s, 3H), 1.86 (m, 9H), 1.65 (m, 6H); 13C NMR (101 MHz, 
CDCl3) δ 170.7, 170.0, 169.9, 169.6. 169.6, 84.1, 72.8, 71.2, 68.4, 67.6, 61.5, 60.1, 52.8, 
51.2, 43.5, 39.3, 35.9, 29.9, 21.0, 20.9, 20.8; ESI-HRMS (C28H39N3NaO11S): [M+Na]+ 
m/z: 648.2203; found: 648.2180. 
Methyl [methyl (4,7,8,9-tetra-O-acetyl-3,5-dideoxy-5-acetamido-D-glycero-α-D-
gulo-non-2-ulopyranosid)onate]-(2→6)-2,3,4-tri-O-acetyl-β-D-galactopyranoside 
(297): To a solution of 232 (50 mg, 0.06 mmol) in 10 mL of 1,4-dioxane/water (1:1) was 
added 50 mg of 5% Pd/C (100 wt%) followed by 0.18 mL of glacial acetic acid. The 
resulting mixture was stirred at room temperature under hydrogen gas (1 atm) for 16 h. 
Then the solution was filtered off and the solvents were evaporated. To the residue, 5 
mL of Ac2O and 5 mL of pyridine were added and the resulting mixture was stirred at 
room temperature for 10 h. Then the solvents were evaporated and the residue was 
subjected to column chromatography on silica gel (5% MeOH in CH2Cl2) to afford the 
colorless oil 297 (35 mg; 82%). [α]21D -13.8 (c 0.5, CHCl3); 1H NMR (600 MHz, CDCl3) 
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δ 6.16 (d, J = 9.6 Hz, 1H), 5.61 (d, J = 3.3 Hz, 1H), 5.46 (dd, J = 7.0, 3.8 Hz, 1H), 5.17 
(dd, J = 10.5, 7.9 Hz, 1H), 5.11 -  5.03 (m, 2H), 4.81 - 4.73 (m, 1H), 4.69 - 4.62 (m, 1H), 
4.41 (t, J = 9.4 Hz, 1H), 4.21 (dt, J = 12.7, 6.4 Hz, 1H), 4.16 (dd, J = 11.8, 6.1 Hz, 1H), 
3.97 (dd, J = 7.0, 1.2 Hz, 1H), 3.91 - 3.86 (m, 1H), 3.79 (s, 3H), 3.78 - 3.74 (m, 1H), 
3.57 - 3.50 (m, 1H), 3.48 (s, 3H), 2.35 (dd, J = 13.4, 4.7 Hz, 1H), 2.14 (s, 3H), 2.13 (s, 
3H), 2.12 (s, 3H), 2.09 (s, 3H), 2.06 (s, 3H), 2.02 (s, 3H), 1.97 (s, 3H), 1.95 (s, 3H); 13C 
NMR (151 MHz, CDCl3) δ 171.1, 170.8, 170.4, 170.2, 170.1, 170.0, 169.6, 169.5, 167.5, 
102.0, 99.3, 73.4, 71.5, 71.3, 71.1, 68.8, 68.6, 67.3, 67.1, 62.9, 61.0, 57.0, 53.0, 45.5, 
32.8, 23.0, 23.0, 20.9, 20.8, 20.8, 20.7, 20.6, 20.6; ESI-HRMS (C33H47NNaO21): 
[M+Na]+ m/z: 816.2538; found: 816.2487. 
Methyl [methyl (4,7,8,9-tetro-O-acetyl-3,5-dideoxy-5-acetamido-D-glycero-α-D-
gulo-non-2-ulopyranosid)onate]-(2→3)-2,4,6-tri-O-acetyl-β-D-galactopyranoside 
(298): To a solution of 233 (30 mg, 0.03 mmol) in 6 mL of 1,4-dioxane/water (1:1) was 
added 30 mg of 5% Pd/C (100 wt%) followed by 0.1 mL of glacial acetic acid. The 
resulting mixture was stirred at room temperature under hydrogen gas (1 atm) for 16 h. 
Then the solution was filtered off and the solvents were evaporated. To the residue, 3 
mL of Ac2O and 3 mL of pyridine were added and the resulting mixture was stirred at 
room temperature for 10 h. Then the solvents were evaporated and the residue was 
subjected to column chromatography on silica gel (5% MeOH in CH2Cl2) to afford the 
colorless oil 298 (19 mg; 77%). [α]21D -16.2 (c 0.5, CHCl3); 1H NMR (600 MHz, CDCl3) 
δ 5.88 (d, J = 9.9 Hz, 1H), 5.41 (d, J = 7.1 Hz, 1H), 5.04 (d, J = 3.7 Hz, 1H), 5.02 (td, J 
= 5.9, 3.4 Hz, 1H), 4.89 - 4.81 (m, 2H), 4.63 (dd, J = 9.9, 3.5 Hz, 1H), 4.40 (dd, J = 9.4, 
3.9 Hz, 1H), 4.33 (d, J = 7.9 Hz, 1H), 4.22 (dd, J = 11.8, 5.5 Hz, 1H), 4.17-4.13 (m, 1H), 
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4.12-4.07 (m, 2H), 3.85 (s, 3H), 3.79 - 3.72 (m, 1H), 3.50 (s, 3H), 3.49 (d, J = 7.0 Hz, 
1H), 2.40 (dd, J = 13.3, 4.9 Hz, 1H), 2.22 (s, 3H), 2.13 (s, 3H), 2.11 (s, 3H), 2.09 (s, 
3H), 2.07 (s, 3H), 2.04 (s, 3H), 2.00 (s, 3H), 1.97 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 
170.5, 170.4, 170.3, 170.3, 170.2, 169.9, 169.8, 169.7, 167.9, 101.9, 96.8, 73.1, 72.0, 
71.7, 71.2, 70.5, 69.3, 67.5, 67.5, 61.9, 60.9, 57.0, 53.1, 45.4, 32.4, 23.1, 21.3, 20.7, 
20.7, 20.6, 20.6, 20.5, 20.5; ESI-HRMS (C33H47NNaO21): [M+Na]+ m/z: 816.2538; 
found: 816.2483. 
Methyl [methyl (4,7,8,9-tetra-O-acetyl-3,5-dideoxy-5-acetamido-D-glycero-α-D-
galacto-non-2-ulopyranosid)onate]-(2→6)-2,3,4-tri-O-acetyl-β-D-galactopyranoside 
(301): To a solution of 204 (100 mg, 0.12 mmol) in 14 mL of 1,4-dioxane/water (1:1) 
was added 100 mg of 5% Pd/C (100 wt%) followed by 0.36 mL of glacial acetic acid. 
The resulting mixture was stirred at room temperature under hydrogen gas (1 atm) for 16 
h. Then the palladium catalyst was filtered off and the solvents were evaporated. To the 
residue, 7 mL of Ac2O and 7 mL of pyridine were added and the resulting mixture was 
stirred at room temperature for 10 h. Then the solvents were evaporated and the residue 
was subjected to column chromatography on silica gel (5% MeOH in CH2Cl2) to afford 
301 (72 mg; 84%). [α]21D -11.6 (c 0.5, CHCl3); 1H NMR (600 MHz, CDCl3) δ 5.42 (d, J 
= 3.3 Hz, 1H), 5.36-5.31 (m, 1H), 5.26 (dd, J = 8.9, 1.8 Hz, 1H), 5.15 (dd, J = 10.2, 8.0 
Hz, 1H), 5.05 - 5.00 (m, 1H), 4.86 - 4.79 (m, 1H), 4.43 (dd, J = 7.9, 1.1 Hz, 1H), 4.34 - 
4.25 (m, 1H), 4.10-3.97 (m, 4H), 3.90 (t, J = 6.8 Hz, 1H), 3.77 (m, 1H), 3.76 (s, 3H), 
3.51 (s, 3H), 3.42 - 3.35 (m, 1H), 2.50 (dd, J = 12.9, 4.6 Hz, 1H), 2.16 (s, 3H), 2.12 (s, 
3H) 2.11 (s, 3H), 2.05 (s, 3H), 2.01 (s, 3H), 2.00 (s, 3H), 1.95 (s, 3H), 1.86 (s, 3H) ; 13C 
NMR (151 MHz, CDCl3) δ 170.9, 170.6, 170.3, 170.2, 170.1, 170.00, 169.7, 169.6, 
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167.9, 101.9, 98.9, 72.6, 71.4, 71.1, 69.1, 68.7, 68.1, 67.2, 67.1, 62.7, 62.6, 57.0, 52.9, 
49.3, 37.9, 23.2, 21.0, 20.8, 20.8, 20.7, 20.7, 20.6, 20.5; ESI-HRMS (C33H47NNaO21): 
[M+Na]+ m/z: 816.2538; found: 816.2474. 
Methyl [methyl(4,7,8,9-tetro-O-acetyl-3,5-dideoxy-5-acetamido-D-glycero-α-D-
galacto-non-2-ulopyranosid)onate]-(2→3)-2,4,6-tri-O-acetyl-β-D-galactopyranoside 
(302): To a solution of 290 (90 mg, 0.11 mmol) in 12 mL of 1,4-dioxane:water (1:1) was 
added 90 mg of 5% Pd/C (100 wt%) followed by 0.29 mL of glacial acetic acid. The 
resulting mixture was stirred at room temperature under hydrogen gas (1 atm) for 16 h. 
Then the palladium catalyst was filtered off and the solvents were evaporated. To the 
residue, 6 mL of Ac2O and 6 mL of pyridine were added and the resulting mixture was 
stirred at room temperature for 10 h. Then the solvents were evaporated and the residue 
was subjected to column chromatography on silica gel (5% MeOH in CH2Cl2) to afford 
302 (64 mg; 84%). [α]21D -12.2 (c 0.5, CHCl3); 1H NMR (600 MHz, CDCl3) δ 5.56 - 
5.52 (m, 1H), 5.37 (dd, J = 9.2, 2.7 Hz, 1H), 5.08 (d, J = 10.3 Hz, 1H), 5.01 (dd, J = 
10.1, 8.0 Hz, 1H), 4.91 (d, J = 3.3 Hz, 1H), 4.89 - 4.84 (m, 1H), 4.54 (dd, J = 10.2, 3.4 
Hz, 1H), 4.50 (d, J = 8.0 Hz, 1H), 4.34 (dd, J = 12.5, 2.7 Hz, 1H), 4.09 - 3.97 (m, 4H), 
3.85 (d, J = 6.6 Hz, 1H), 3.83 (s, 3H), 3.63 (dd, J = 10.7, 2.7 Hz, 1H), 3.51 (s, 3H), 2.57 
(dd, J = 12.7, 4.6 Hz, 1H), 2.21 (s, 3H), 2.17 (s, 3H), 2.07 (s, 3H), 2.06 (s, 3H), 2.05 (s, 
3H), 2.03 (s, 3H), 1.99 (s, 3H), 1.84 (s, 3H) ; 13C NMR (151 MHz, CDCl3) δ 170.9, 
170.6, 170.5, 170.4, 170.3, 170.3, 169.7, 169.6, 167.9, 101.7, 96.0, 72.0, 71.4, 70.5, 
69.6, 69.3, 67.8, 67.7, 67.0, 62.3, 62.0, 56.9, 53.2, 49.1, 37.5, 23.2, 21.5, 21.0, 20.8, 
20.8, 20.7, 20.7, 20.6; ESI-HRMS (C33H47NNaO21): [M+Na]+ m/z: 816.2538; found: 
816.2502. 
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Methyl [(3,5-dideoxy-5-acetamido-D-glycero-α-D-gulo-non-2-ulopyranosid)onic 
acid]-(2→6)-β-D-galactopyranoside (299): To a solution of 297 (30 mg; 0.06 mmol) in 
3 mL of H2O was added 0.5 mL of saturated aq. Ba(OH)2. The resulting solution was 
stirred at 60 °C for 2 h. Then the reaction mixture was brought to room temperature and 
bubbled with CO2, followed by filtering off the precipitate formed. The filtrate was then 
frozen using a dry ice-acetone bath and lyophilized to obtain the white foam 299 (16.8 
mg, 92%). [α]21D -2.3 (c 0.5, H2O); 1H NMR (600 MHz, D2O) δ 4.15 (dd, J = 9.7, 5.6 
Hz, 1H), 3.87 (dd, J = 10.1, 8.3 Hz, 1H), 3.79 (d, J = 2.2 Hz, 1H), 3.76 (d, J = 3.0 Hz, 
1H), 3.72 (t, J = 4.2 Hz, 1H), 3.68 (t, J = 3.5 Hz, 1H), 3.67 (m, 2H), 3.63 (d, J = 3.8 Hz, 
1H), 3.53 (dd, J = 7.6, 2.5 Hz, 1H), 3.50 (d, J = 3.3 Hz, 1H), 3.48 - 3.45 (m, 1H), 3.43 (s, 
3H), 3.37 - 3.30 (m, 1H), 2.36 (dd, J = 12.8, 4.6 Hz, 1H), 1.88 (s, 3H), 1.54 (t, J = 12.8 
Hz, 1H); 13C NMR (151 MHz, D2O) δ 174.7, 173.6, 103.9, 100.8, 73.5, 72.5, 72.2, 72.1, 
70.5, 70.4, 68.8, 66.7, 63.9, 62.1, 57.4, 50.4, 35.5, 22.1; ESI-HRMS (C18H30NO14): [M-
H]- m/z: 484.1666; found: 484.1736. 
Methyl [(3,5-dideoxy-5-acetamido-D-glycero-α-D-gulo-non-2-ulopyranosid)onic 
acid]-(2→3)-β-D-galactopyranoside (300): To a solution of 298 (10 mg; 0.02 mmol) in 
2 mL of H2O was added 0.2 mL of saturated aq. Ba(OH)2. The resulting solution was 
stirred at 60 °C for 2 h. Then the reaction mixture was brought to room temperature and 
bubbled with CO2, followed by filtering off the precipitate formed. The filtrate was then 
frozen using a dry ice-acetone bath and lyophilized to obtain the white foam 300 (5.7 
mg, 93%). [α]21D -1.6 (c 0.5, H2O); 1H NMR (600 MHz, D2O) δ 4.21 (d, J = 8.0 Hz, 1H),  
4.13 (d, J = 3.6 Hz, 1H), 4.00 (dd, J = 10.0, 2.9 Hz, 1H), 3.78 (d, J = 9.6 Hz, 1H), 3.68 
(m, 4H), 3.57 (m, 3H), 3.53 - 3.46 (m, 2H), 3.41 (s, 3H), 2.42 (dd, J = 12.5, 4.4 Hz, 1H), 
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1.89 (s, 3H), 1.56 (t, J = 12.5 Hz, 1H); 13C NMR (151 MHz, D2O) δ 174.7, 173.8, 103.6, 
99.6, 75.3, 74.8, 72.2, 71.8, 70.9, 69.3, 66.8, 66.6, 61.9, 60.9, 60.0, 57.1, 50.2, 35.6, 
22.0; ESI-HRMS (C18H30NO14): [M-H]- m/z: 484.1666; found: 484.1697. 
Methyl [(3,5-dideoxy-5-acetamido-D-glycero-α-D-gulo-non-2-ulopyranosid)onic 
acid]-(2→3)-β-D-galactopyranoside (303): To a solution of 301 (40 mg; 0.08 mmol) in 
4 mL of H2O was added 0.7 mL of saturated aq. Ba(OH)2. The resulting solution was 
stirred at 60 °C for 2 h. Then the reaction mixture was brought to room temperature and 
bubbled with CO2, followed by filtering off the precipitate formed. The filtrate was then 
frozen using a dry ice-acetone bath and lyophilized to obtain the white foam 303 (22.1 
mg, 93%). [α]21D -1.4 (c 0.5, H2O); 1H NMR (600 MHz, D2O) δ 4.14 (d, J = 6.8 Hz, 1H), 
3.77 (dd, J = 6.7, 2.1 Hz, 1H), 3.71 (d, J = 10.5 Hz, 1H), 3.65 (t, J = 9.9 Hz, 1H), 3.61 (t, 
J = 4.3 Hz, 1H), 3.53 (m, 2H), 3.49 - 3.47 (m, 3H), 3.47 - 3.43 (m, 1H), 3.40 (s, 3H), 
3.32 (t, J = 8.4 Hz, 1H), 2.56 (dd, J = 12.4, 3.5 Hz, 1H), 1.86 (s, 3H), 1.52 (t, J = 12.0 
Hz, 1H); 13C NMR (151 MHz, D2O) δ 175.0, 173.4, 103.8, 100.4, 73.3, 72.6, 72.5, 71.7, 
70.6, 68.6, 68.2, 68.1, 63.3, 62.6, 57.3, 51.8, 40.1, 22.0%); ESI-HRMS (C18H30NO14): 
[M-H]- m/z: 484.1666; found: 484.1692. 
Methyl [(3,5-dideoxy-5-acetamido-D-glycero-α-D-galacto-non-2-ulopyranosid)onic 
acid]-(2→3)-β-D-galactopyranoside (304): To a solution of 302 (50.0 mg; 0.1 mmol) 
in 5 mL of H2O was added 0.8 mL of saturated aq. Ba(OH)2. The resulting solution was 
stirred at 60 °C for 2 h. Then the reaction mixture was brought to room temperature and 
bubbled with CO2, followed by filtering off the precipitate formed. The filtrate was then 
frozen using a dry ice-acetone bath and lyophilized to obtain the white foam 304 (29.0 
mg, 95%). [α]21D +0.3 (c 0.5, H2O); 1H NMR (600 MHz, D2O) δ 4.21 (d, J = 7.4 Hz, 
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1H), 3.91 (dd, J = 7.3 Hz, 2.4 Hz, 1H), 3.77 (d, J = 6.5 Hz, 1H), 3.67 (m, 3H), 3.59 - 
3.54 (m, 2H), 3.53 - 3.42 (m, 4H), 3.41 (s, 3H), 2.57 (d, J = 12.1 Hz, 1H), 1.85 (s, 3H), 
1.62 (t, J = 12.1 Hz, 1H); 13C NMR (151 MHz, D2O) δ 174.9, 173.8, 103.4, 99.8, 75.8, 
74.8, 72.8, 71.7, 69.1, 68.2, 68.0, 67.5, 62.5, 60.9, 57.00, 51.6, 39.5, 22.0; ESI-HRMS 
(C18H30NO14): [M-H]- m/z: 484.1666; found: 484.1717. 
Methyl (1-Adamantanyl 5-acetamido-3,5-dideoxy-8,9-O-isopropylidene-2-thio-D-
glycero-β-D-galacto-non-2-ulopyranosid)onate (318): A stirred solution of 160 (20 g, 
31 mmol) in anhydrous methanol (500 mL) was treated with NaOMe (335 mg; 1.67 
mmol) and stirred under argon at room temperature for 2 h, then quenched by addition of 
Amberlyst 15- H+ ion exchange resin, filtered and concentrated to dryness. The residue 
was taken up in dry acetone (200 mL) under argon and treated with 2,2-
dimethoxypropane (6.25 mL; 51 mmol) followed by camphor-10-sulfonic acid (250 mg; 
1.08 mmol). The reaction mixture was stirred for 5 h and then quenched with 
triethylamine (0.5 mL). The solvents were evaporated and the residue was dissolved in 
ethyl acetate and washed with water and brine. The organic layer was dried over Na2SO4 
and concentrated to dryness to give a residue that was purified by silica gel column 
chromatography eluting with 10% MeOH in CH2Cl2 to give 318 as a white solid (14.9 g; 
93%), with 1H and 13C NMR consistent with the reported data.143 1H NMR (600 MHz, 
CDCl3) δ 6.68 (d, J = 8.6 Hz, 1H), 4.19 – 4.13 (m, 1H), 4.13 – 4.07 (m, 1H), 4.04 (d, J = 
10.5 Hz, 1H), 4.01 – 3.94 (m, 2H), 3.76 (s, 3H), 3.44 (s, 1H), 2.49 (dd, J = 13.4, 4.3 Hz, 
1H), 2.03 – 1.96 (m, 4H), 1.95 – 1.88 (m, 6H), 1.87 – 1.79 (m, 4H), 1.57 (s, 6H), 1.35 (s, 
3H), 1.23 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 172.9, 171.1, 108.7, 74.1 72.2, 70.8, 
67.3, 66.5, 53.1, 52.7, 52.3, 50.5, 50.0, 43.5, 43.0, 35.9, 29.7, 26.9, 26.7, 25.1, 23.1. 
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Methyl (1-Adamantanyl 5-acetamido-4-O-acetyl-3,5-dideoxy-8,9-O-isopropylidene-
2-thio-D-glycero-β-D-galacto-non-2-ulopyranosid)onate (319): To a stirred solution of 
318 (14 g; 27.2 mmol) in a 1:7 mixture of pyridine and CH2Cl2 (140 mL) was added 
acetyl chloride (1.94 mL; 13.6 mmol) dropwise at -20 °C. After stirring for 1 h, the 
reaction mixture was quenched by addition of saturated aqueous NaHCO3. The aqueous 
layer was extracted twice with CH2Cl2 and the combined organic layers were washed 
with water, brine, dried over Na2SO4, filtered and concentrated. The residue was purified 
by silica gel column chromatography eluting with 5% MeOH in CH2Cl2 to give 319 as an 
off-white solid (13.6 g; 90%). The 1H and 13C NMR were consistent with the reported 
data.7 1H NMR (600 MHz, CDCl3) δ 5.98 (t, J = 12.2 Hz, 1H), 5.42 – 5.31 (m, 1H), 4.26 
– 4.20 (m, 1H), 4.18 – 4.10 (m, 4H), 4.07 – 4.02 (m, 1H), 3.98 – 3.90 (m, 1H), 3.78 (s, 
3H), 3.46 (t, J = 6.8 Hz, 1H), 2.52 (dd, J = 13.5, 4.7 Hz, 1H), 2.04 – 2.00 (m, 4H), 1.96 
(s, 8H), 1.92 – 1.87 (m, 3H), 1.67 – 1.56 (m, 6H), 1.37 (s, 3H), 1.26 (s, 3H); 13C NMR 
(151 MHz, CDCl3) δ 172.2, 171.8, 170.1, 108.8, 85.9, 74.0, 72.6, 70.6, 68.5, 67.4, 52.7, 
52.0, 50.5, 43.1, 40.3, 36.0, 29.8, 26.8, 25.2, 23.1, 21.0. 
Methyl (1-adamantanyl 5-acetamido-4-O-acetyl-3,5-dideoxy-8,9-O-isopropylidene-7-
O-(tert-butyldimethylsilyl)-2-thio-D-glycero-β-D-galacto-non-2-ulopyranosid)onate 
(320): To a stirred solution of 319 (6.2 g; 11.2 mmol) in dry CH2Cl2 (80 mL) at 0 °C 
were added DMAP (136 mg; 1.17 mmol) and Et3N (7.78 mL; 55.8 mmol), followed after 
stirring  at 0 °C for 10 min by TBSOTf (5.13 mL; 22.3 mmol). The resulting solution was 
brought to room temperature and stirred for 2 h, then washed with water and extracted 
with CH2Cl2. The organic layer was collected, dried over Na2SO4 and evaporated to 
dryness. The residue was subjected to column chromatography over silica gel eluting 
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with 45% EtOAc in hexanes to give 320 as off-white solid (6.65 g; 89%). [α]21D −74.3 (c 
1.0, CHCl3); 1H NMR (600 MHz, CDCl3) δ 5.35 (d, J = 9.1 Hz, 1H), 4.25 (d, J = 10.7 
Hz, 1H), 4.21 (dd, J = 12.6, 6.3 Hz, 1H), 4.06 – 3.93 (m, 3H), 3.83 – 3.80 (m, 1H), 3.76 
(s, 3H), 2.44 (dd, J = 13.6, 4.7 Hz, 1H), 2.00 (s, 6H), 1.90 (s, 3H), 1.64 (s, 6H), 1.39 (s, 
3H), 1.28 (s, 3H), 0.89 (s, 8H), 0.84 (s, 9H), 0.17 (s, 3H), 0.09 (s, 3H); 13C NMR (151 
MHz, CDCl3) δ 170.9, 170.2, 169.7, 108.4, 85.8, 75.0, 73.5, 72.4, 70.2, 66.3, 52.5, 51.2, 
50.2, 43.2, 39.6, 36.0, 29.8, 26.5, 26.2, 26.0, 25.7, 24.9, 23.4, 21.0, 18.4, 18.1, -3.0, -3.8, -
3.9; ESI-HRMS (C33H55NO9NaSiS) [M +  Na]+ m/z 692.3265, found 692.3261. 
Methyl (1-adamantanyl 5-acetamido-4-O-acetyl-7-O-(tert-butyldimethylsilyl)-3,5-
dideoxy-9-O-(2,4,6-triisopropylbenzenesulfonyl)-2-thio-D-glycero-β-D-galacto-non-
2-ulopyranosid)onate (322): To a stirred solution of 24 (2.5 g; 3.73 mmol) in dry 
CH2Cl2 (100 mL) at 0 °C was added 1:1 TFA:H2O (5.5 mL) dropwise. The resulting 
mixture was stirred at 0 °C for 0.5 h, followed by 1 h at room temperature, then was 
quenched by addition of saturated aqueous NaHCO3 (50 mL) and stirred for 15 min, and 
finally extracted with CH2Cl2.  The combined organic phase was dried over Na2SO4 and 
evaporated to dryness to give the intermediate diol 321 as a white solid (2.4 g, 3.8 mmol), 
which was dissolved in dry pyridine (20 mL) and treated with 2,4,6-
triisopropylbenzenesulfonyl chloride (8.1 g; 26.6 mmol). The resulting solution was 
stirred at room temperature for 16 h, then concentrated to dryness and the residue 
subjected to column chromatography over silica gel eluting with 45% EtOAc in hexanes 
to give 322 as a white solid (2.54 g; 76%). [α]21D −61.5 (c 1.0, CHCl3); 1H NMR (600 
MHz, CDCl3) δ 7.16 (s, 2H), 5.34 (dd, J = 9.9, 5.5 Hz, 1H), 5.24 (ddd, J = 11.1, 9.5, 4.7 
Hz, 1H), 4.30 (t, J = 6.3 Hz, 5H), 4.20 – 4.06 (m, 3H), 3.96 (d, J = 5.1 Hz, 1H), 3.78 (s, 
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3H), 3.52 (br s, 1H), 2.93 – 2.84 (m, 1H), 2.43 (dd, J = 12.7, 4.6 Hz, 1H), 1.99 (s, 6H), 
1.97 – 1.89 (m, 5H), 1.88 (s, 3H), 1.83 (d, J = 10.8 Hz, 3H), 1.64 (s, 6H), 1.30 – 1.19 (m, 
18H), 0.84 (s, 9H), 0.12 (s, 3H), 0.03 (s, 3H):  13C NMR (151 MHz, CDCl3) δ 171.0, 
170.3, 169.9, 153.7, 150.9, 129.0, 123.7, 85.8, 73.5, 71.8, 71.5, 70.7, 69.6, 52.8, 50.7, 
50.3, 43.5, 39.6, 35.9, 34.2, 29.8, 29.6, 25.9, 24.8, 24.7, 23.5, 23.5, 23.5, 20.9, 18.2, -4.1, 
-4.9; ESI-HRMS (C45H73NO11NaS2Si) [M + Na]+ m/z 918.4292, found 918.4292. 
Methyl (1-adamantanyl 5-acetamido-4-O-acetyl-7-O-(tert-butyldimethylsilyl)-3,5-
dideoxy-9-O-(2,4,6-triisopropylbenzenesulfonyl)-8-oxo-2-thio-β-D-galacto-non-2-
ulopyranosid)onate (323): To a stirred solution of 322 (2.4 g; 2.68 mmol) in dry CH2Cl2 
(50 mL) at 0 °C was added Dess-Martin periodinane (1.7 g; 4.02 mmol). The resulting 
mixture was brought to room temperature and stirred for 1 h then quenched with 20% 
aqueous Na2S2O3 and extracted with CH2Cl2. The organic layer was dried over Na2SO4 
and evaporated to dryness, and the residue subjected to column chromatography over 
silica gel eluting with 40% EtOAc in hexanes to give 323 as a white solid (2.06 g; 86%). 
[α]21D −61.5 (c 1.0, CHCl3); 1H NMR (600 MHz, CDCl3) δ 7.16 (s, 2H), 5.45 (d, J = 13.3 
Hz, 1H), 5.38 (d, J = 10.0 Hz, 1H), 5.28 (ddd, J = 12.0, 10.0, 4.6 Hz, 3H), 4.66 (d, J = 
13.3 Hz, 3H), 4.29 – 4.20 (m, 2H), 4.18 – 4.09 (m, 2H), 4.08 – 4.00 (m, 1H), 3.86 (s, 3H), 
2.93 – 2.85 (m, 1H), 2.46 (dd, J = 13.5, 4.6 Hz, 1H), 2.04 – 1.98 (m, 2H), 1.97 (s, 3H), 
1.88 (s, 3H), 1.86 – 1.80 (m, 5H), 1.70 – 1.56 (m, 7H), 1.28 – 1.14 (m, 18H), 0.77 (s, 
9H), -0.05 (s, 3H), -0.32 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 203.6, 170.9, 170.3, 
170.2, 153.8, 151.0, 128.6, 123.8, 86.0, 76.4, 74.5, 72.3, 69.9, 52.8, 50.8, 49.3, 43.2, 39.7, 
36.0, 35.9, 34.3, 29.7, 29.7, 25.8, 25.7, 25.1, 24.4, 23.6, 23.5, 23.4, 20.9, 17.8, -4.5, -6.00; 
ESI-HRMS (C45H71NO11NaS2Si) [M + Na]+ m/z 916.4136, found 916.4130. 
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Methyl (1-adamantanyl 5-acetamido-4-O-acetyl-7-O-(tert-butyldimethylsilyl)-3,5-
dideoxy-9-O-(2,4,6-triisopropylbenzenesulfonyl)-2-thio-L-glycero-α-D-galacto-non-
2-ulopyranosid)onate (324): A solution of 323 (2.06 g; 2.31 mmol) in CH2Cl2 (60 mL) 
was cooled to -78 °C, and a solution of cerium (III) chloride heptahydrate (2.56 g; 6.91 
mmol) in methanol (15 mL) was added. After 1 h, NaBH4 (135 mg; 3.46 mmol) was 
added to the reaction mixture, which was then stirred at -78 °C for 2 h before it was 
quenched with saturated aqueous NH4Cl, brought to room temperature and solvents were 
evaporated. The residue was taken up in EtOAc, washed with brine, and evaporated to 
dryness. The residue was subjected to column chromatography over silica gel eluting 
with 50% EtOAc in hexanes to give 324 as a white solid (1.82 g; 88%). [α]21D −83.4 (c 
1.0, CHCl3); 1H NMR (600 MHz, CDCl3) δ 7.15 (s, 2H), 5.51 – 5.46 (m, 1H), 5.27 (ddd, 
J = 11.2, 9.3, 4.7 Hz, 1H), 4.27 – 4.20 (m, 2H), 4.20 – 4.05 (m, 5H), 4.04 – 3.98 (m, 1H), 
3.97 (s, 1H), 3.76 (s, 3H), 2.94 – 2.84 (m, 1H), 2.41 (dd, J = 13.7, 4.7 Hz, 1H), 2.02 (s, 
1H), 1.99 (s, 8H), 1.93 (d, J = 11.9 Hz, 1H), 1.89 (s, 3H), 1.84 (d, J = 11.5 Hz, 3H), 1.64 
(s, 6H), 1.27 – 1.20 (m, 18H), 0.85 (s, 9H), 0.14 (s, 3H), 0.06 (s, 3H); 13C NMR (151 
MHz, CDCl3) δ 171.2, 170.5, 170.3, 153.6, 150.8, 129.2, 123.7, 85.6, 72.5, 71.4, 70.1, 
69.7, 69.3, 60.4, 52.7, 51.7, 50.3, 43.5, 39.5, 36.0, 34.2, 29.8, 29.5, 25.9, 24.8, 24.7, 23.6, 
23.5, 21.0, 20.9, 18.3, 14.2, -3.7, -5.1; ESI-HRMS (C45H73NO11NaS2Si) [M + Na]+ m/z 
918.4292, found 918.4306. 
Methyl (1-adamantanyl 5-acetamido-4-O-acetyl-7-O-(tert-butyldimethylsilyl)-3,5,9-
tri-deoxy-9-iodo-2-thio-L-glycero-α-D-galacto-non-2-ulopyranosid)onate (325): A 
stirred solution of 324 (1.8 g; 2.02 mmol) in dry acetone (25 mL) was treated with NaI (3 
g; 20.2 mmol) and heated to 50 °C for 24 h. The solvent was evaporated and the residue 
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was subjected to column chromatography over silica gel eluting with 50% EtOAc in 
hexanes to give 325 as a white solid (1.29 g; 87%). [α]21D −52.7 (c 1.0, CHCl3); 1H NMR 
(600 MHz, CDCl3) δ 7.20 (s, 2H), 5.48 (d, J = 9.0 Hz, 1H), 5.29 – 5.18 (m, 1H), 4.24 (dd, 
J = 10.5, 3.4 Hz, 1H), 4.17 – 4.06 (m, 2H), 4.02 (t, J = 3.7 Hz, 1H), 3.91 (dd, J = 10.5, 
5.8 Hz, 1H), 3.78 (s, 3H), 3.39 (dd, J = 10.2, 6.2 Hz, 1H), 3.34 (dd, J = 10.2, 5.9 Hz, 1H), 
2.40 (dd, J = 13.7, 4.8 Hz, 1H), 1.99 (s, 6H), 1.96 – 1.90 (m, 1H), 1.90 (s, 3H), 1.85 (d, J 
= 10.6 Hz, 3H), 1.64 (s, 6H), 1.23 (t, J = 7.1 Hz, 1H), 0.90 (s, 9H), 0.18 (s, 3H), 0.13 (s, 
3H); 13C NMR (151 MHz, CDCl3) δ 171.0, 170.4, 170.1, 85.5, 73.6, 72.4, 70.6, 69.7, 
60.4, 52.7, 51.6, 50.3, 43.6, 43.5, 39.5, 36.0, 29.9, 29.8, 26.1, 26.0, 23.6, 20.9, 18.3, 14.2, 
11.1, -3.7, -4.7; ESI-HRMS (C30H50INO8NaSSi) [M + Na]+ m/z 762.1969, found 
762.1953. 
Methyl (1-adamantanyl 5-acetamido-4-O-acetyl-7-O-(tert-butyldimethylsilyl)-3,5,9-
tri-deoxy-2-thio-L-glycero-α-D-galacto-non-2-ulopyranosid)onate (326): A solution 
of 325 (1.29 g; 1.74 mmol) in EtOAc:Et3N (10:1; 21 mL) was treated with 10% Pd/C 
(1.29 g; 100 wt%) and  stirred under 1 atm of H2 pressure for 1 h. The catalyst was 
filtered off and the filtrate was evaporated to dryness. The residue was subjected to 
column chromatography over silica gel eluting with 65% EtOAc in hexanes to give 326 
as a colorless oil (1.07 g; 92%). [α]21D –88.3 (c 1.0, CHCl3); 1H NMR (600 MHz, CDCl3) 
δ 5.45 (d, J = 8.9 Hz, 1H), 5.28 – 5.20 (m, 1H), 4.27 (dd, J = 10.6, 2.9 Hz, 1H), 4.12 (dd, 
J = 19.4, 9.7 Hz, 1H), 3.96 – 3.89 (m, 1H), 3.77 (s, 3H), 3.69 – 3.60 (m, 1H), 2.41 (dd, J 
= 13.7, 4.8 Hz, 1H), 2.00 (s, 9H), 1.96 – 1.91 (m, 1H), 1.89 (s, 3H), 1.84 (d, J = 10.8 Hz, 
3H), 1.64 (s, 6H), 1.29 – 1.17 (m, 4H), 0.92 (s, 9H), 0.18 (s, 3H), 0.09 (s, 3H); 13C NMR 
(151 MHz, CDCl3) δ 170.9, 170.4, 169.9, 85.5, 77.2, 72.9, 70.0, 67.3, 52.6, 51.5, 50.2, 
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43.4, 39.6, 36.0, 29.8, 29.3, 26.0, 23.6, 20.9, 20.6, 18.3, -3.8, -4.8; ESI-HRMS 
(C30H51NO8NaSSi) [M + Na]+ m/z 636.3002, found 636.3011. 
Methyl (1-adamantanyl 5-acetamido-4,8-di-O-acetyl-7-O-(tert-butyldimethylsilyl)-
3,5,9-tri-deoxy-2-thio-L-glycero-α-D-galacto-non-2-ulopyranosid)onate (327): To a 
stirred solution of 326 (1.07 g; 1.73 mmol) in dry CH2Cl2 (30 mL) was added DMAP (22 
mg; 0.18 mmol) followed by Et3N (0.72 mL; 5.18 mmol). The resulting mixture was 
cooled to 0 °C and Ac2O (0.24 mL; 2.60 mmol) was added dropwise. The resulting 
mixture was then brought to room temperature and stirred for 2 h before the solvent was 
evaporated to dryness and the residue purified by  column chromatography over silica gel 
eluting with 50% EtOAc in hexanes to give 327 as a white solid (1.04 g; 91%). [α]21D – 
113.0 (c 1.0, CHCl3); 1H NMR (600 MHz, CDCl3) δ 5.56 (d, J = 8.2 Hz, 1H), 5.24 – 5.15 
(m, 1H), 5.05 – 4.95 (m, 1H), 4.31 (dd, J = 10.7, 2.1 Hz, 1H), 4.02 – 3.96 (m, 1H), 3.84 
(dd, J = 7.8, 2.3 Hz, 1H), 3.77 (s, 3H), 2.41 (dd, J = 13.8, 4.6 Hz, 1H), 2.01 (s, 6H), 1.98 
(s, 6H), 1.97 – 1.91 (m, 1H), 1.90 (s, 3H), 1.84 (d, J = 10.8 Hz, 3H), 1.64 (s, 6H), 1.27 (d, 
J = 6.4 Hz, 3H), 0.90 (s, 9H), 0.18 (s, 3H), 0.06 (s, 3H): 13C NMR (151 MHz, CDCl3) δ 
170.7, 170.2, 169.9, 169.8, 85.7, 75.1, 72.7, 71.4, 70.5, 52.6, 51.4, 50.1, 43.4, 39.6, 36.0, 
29.8, 25.9, 23.4, 21.6, 21.0, 18.2, 17.3, -4.3, -4.6; ESI-HRMS (C32H53NO9NaSSi) [M + 
Na]+ m/z 678.3108, found 678.3122. 
Methyl (1-adamantanyl 4,8-di-O-acetyl-7-O-(tert-butyldimethylsilyl)-3,9-dideoxy-2-
thio-L-glycero-α-D-galacto-non-2-ulopyranosid)onate; Methyl (1-adamantanyl 4,8-
di-O-acetyl-7-O-(tert-butyldimethylsilyl)-3,9-dideoxy-2-thio-L-glycero-α-D-gulo-non-
2-ulopyranosid)onate (329): A solution of sialoside 327 (300 mg; 0.46 mmol) in dry 
dichloromethane (6 mL) was treated with dry pyridine (0.32 mL; 3.96 mmol) under argon 
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and cooled to -10 °C. After the solution was stirred for 15 min, crushed nitrosyl 
tetrafluoroborate (206 mg; 1.74 mmol) was added in one portion, after which the reaction 
mixture was stirred at -10 °C until TLC/MS showed complete conversion. The reaction 
mixture was diluted with cold dichloromethane (12 mL) and washed with cold 1 N HCl, 
saturated aqueous NaHCO3 and brine. The organic layer was dried over anhydrous 
Na2SO4 and concentrated to dryness below 10 °C to give the crude N-nitroso-sialoside, 
which was carried forward without any further purification. The crude N-nitroso-sialoside 
(315 mg; 0.46 mmol) was taken in levulinic acid (3 mL) and the resulting solution was 
heated to 50 °C for 6 h. After cooling to room temperature the reaction mixture was 
diluted with CH2Cl2 and quenched dropwise with saturated aqueous NaHCO3. The 
aqueous layer was extracted with CH2Cl2 and the combined organic layer was dried over 
Na2SO4 and evaporated to dryness to give the crude 5-O-levulinyl derivative 328 as a 
yellowish oil (330 mg). To a solution of this crude levulinate 328 (330 mg; 0.46 mmol) in 
dry CH2Cl2 (10 mL) was added pyridine (1.03 mL) followed by hydrazine monohydrate 
(92 µL; 1.83 mmol) and acetic acid (0.79 mL). The resulting solution was stirred at room 
temperature for 1 h, then was quenched with saturated aqueous NH4Cl and extracted with 
CH2Cl2. The organic layer was collected, dried over Na2SO4 and concentrated to dryness. 
The residue was subjected to column chromatography over silica gel eluting with 35% 
EtOAc in hexane to give 329 as a white solid (107 mg; 38% for 3 steps) in 1:1 mixture. 
[α]21D – 51.3 (c 1.0, CHCl3); 1H NMR (400 MHz, CDCl3) δ 5.39 (d, J = 5.6 Hz, 1H), 5.24 
– 5.15 (m, 2H), 5.14 – 5.08 (m, 1H), 4.49 (d, J = 6.8 Hz, 1H), 4.36 (dd, J = 10.0, 3.5 Hz, 
1H), 3.95 (t, J = 4.6 Hz, 1H), 3.91 (dd, J = 5.2, 3.6 Hz, 1H), 3.78 (s, 3H), 3.77 (s, 3H), 
3.75 – 3.68 (m, 2H), 3.61 (s, 1H), 2.86 (d, J = 3.0 Hz, 1H), 2.75 (s, 1H), 2.70 (s, 1H), 
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2.54 (dd, J = 13.2, 5.0 Hz, 9H), 2.44 (dd, J = 13.6, 5.6 Hz, 9H), 2.08 (s, 3H), 2.07 (s, 3H), 
2.06 – 2.04 (m, 3H), 1.97 (s, 3H), 1.91 – 1.83(m, 6H), 1.71 (d, J = 2.1 Hz, 1H), 1.67 (s, 
9H), 1.34 (d, J = 6.4 Hz, 3H), 1.29 (d, J = 6.6 Hz, 3H), 1.25 (s, 3H), 0.92 (s, 9H), 0.90 (s, 
9H), 0.21 (s, 3H), 0.13 (s, 3H), 0.12 (s, 3H), 0.11 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 
172.6, 170.4, 170.3, 170.2, 170.0, 89.8, 86.9, 85.8, 75.3, 74.4, 73.3, 72.9, 72.1, 71.8, 71.0, 
70.7, 70.5, 52.6, 50.0, 45.9, 43.6, 43.4, 38.8, 36.0, 29.8, 25.8, 25.7, 21.5, 21.4, 21.1, 20.9, 
18.1, 18.0, 17.8, 16.4, -4.3, -4.4, -4.6, -4.9; ESI-HRMS (C30H50O9NaSSi)[M + Na]+ m/z 
637.2843, found 637.2833. 
Methyl (1-Adamantanyl 5-acetamido-4-O-acetyl-3,5-dideoxy-8,9-O-isopropylidene-
7-O-(2-naphthyl)methyl-2-thio-D-glycero-β-D-galacto-non-2-ulopyranosid)onate 
(330): To a stirred solution of 319 (5.76 g; 10.37 mmol) in dry DMF (55 mL) under 
argon was added 2-(bromomethyl)naphthalene (5.04 g; 17.66 mmol). The resulting 
mixture was stirred at -10 °C for 15 min. Then NaH (60% mineral oil; 767 mg; 11.77 
mmol) was added to it at -10 °C. The resulting mixture was brought to 0 °C and stirred 
for 3 h, then quenched with H2O, diluted with EtOAc and washed with water and brine. 
The organic layer was collected, dried over Na2SO4 and concentrated under reduced 
pressure. The residue was subjected to column chromatography over silica gel with 50% 
EtOAc in hexanes to obtain 330 an off-white solid (5.91 g; 82%). [α]21D −66.7 (c 1.0, 
CHCl3); 1H NMR (600 MHz, CDCl3) δ 7.85 (s, 1H), 7.80 – 7.75 (m, 3H), 7.59 (d, J = 8.4 
Hz, 1H), 7.48 – 7.40 (m, 2H), 5.45 – 5.32 (m, 1H), 5.25 (d, J = 9.5 Hz, 1H), 5.02 – 4.83 
(m, 2H), 4.38 – 4.26 (m, 2H), 4.26 – 4.07 (m, 3H), 3.94 – 3.91 (m, 1H), 3.78 (s, 3H), 2.47 
(dd, J = 13.4, 4.7 Hz, 1H), 2.03 – 1.94 (m, 8H), 1.92 – 1.83 (m, 4H), 1.80 (s, 3H), 1.63 (s, 
6H), 1.47 (s, 3H), 1.30 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 170.8, 170.1, 170.0, 
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136.0, 133.2, 132.9, 128.0, 127.9, 127.6, 127.1, 126.6, 125.9, 125.8, 108.0, 86.0, 76.9, 
76.4, 74.6, 73.0, 69.3, 65.8, 52.6, 50.6, 50.1, 43.3, 39.6, 36.0, 29.8, 26.5, 24.4, 23.3, 21.0; 
ESI-HRMS (C38H49NO9NaS) [M + Na]+ m/z 718.3026, found 718.3011. 
Methyl (1-Adamantanyl 4-O-acetyl-3,5-dideoxy-5-en-8,9-O-isopropylidene-7-O-(2-
naphthyl)methyl-2-thio-β-D-ribo-non-2-ulopyranosid)onate (332), and, Methyl (1-
Adamantanyl 4-O-acetyl-3-deoxy-8,9-O-isopropylidene-5-O-levulinoyl-7-O-(2-
naphthyl)methyl-2-thio-D-glycero-β-D-galacto-non-2-ulopyranosid)onate (333): A 
solution of 330 (5.7 g; 8.17 mmol) in dry dichloromethane (60 mL) was treated with dry 
pyridine (6.65 mL; 81.7 mmol) under argon and cooled to -10 °C. After stirring for 15 
min, crushed nitrosyl tetrafluoroborate (3.8 g; 32.8 mmol) was added in one portion to 
the solution after which stirring was continued at -10 °C until completion of the reaction 
(TLC/MS). The reaction mixture was diluted with cold dichloromethane (120 mL) and 
washed with cold 1 N HCl, saturated aq NaHCO3 and brine. The organic layer was dried 
over anhydrous Na2SO4 and concentrated below 10 °C to obtain the N-nitrosyl derivative 
331, which was carried forward without further purification. To a solution of the crude 
nitrosated sialoside intermediate 331 (5.94 g; 6.7 mmol) in dry dichloromethane (70 mL) 
at -10 °C was added a mixture of cold solution of 18-crown-6 (3.9 g; 14.8 mmol) and 
freshly prepared sodium 2,2,2-trifluoroethoxide (1.64 g; 13.4 mmol) in dry 
dichloromethane (35 mL). After stirring for 5 min, the reaction mixture was treated with 
a cold solution of levulinic acid (15.6 g; 134.3 mmol) in dry dichloromethane (70 mL) 
and stirred at -10 °C for 10 min, then warmed to 0 °C, quenched with saturated aqueous 
NaHCO3, diluted with dichloromethane, washed with cold brine, dried over Na2SO4, and 
concentrated under reduced pressure. The residue was purified by column 
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chromatography over silica gel eluting with 4% acetone in toluene to afford 332 (1.1 g; 
21%) and 6% acetone in toluene to afford 333 (3.4 g; 55%) as off-white solids. 332: 
[α]21D −12.3 (c 1.0, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.86 – 7.78 (m, 4H), 7.53 – 
7.43 (m, 3H), 5.29 – 5.24 (m, 1H), 5.21 (d, J = 5.3 Hz, 1H), 5.01 (t, J = 11.7 Hz, 1H), 
4.68 (d, J = 11.7 Hz, 1H), 4.53 (dd, J = 11.0, 6.2 Hz, 1H), 4.10 (d, J = 6.5 Hz, 1H), 4.10 
(d, J = 6.5 Hz, 1H), 4.04 (d, J = 4.5 Hz, 1H), 3.80 (d, J = 6.5 Hz, 1H), 3.76 (s, 3H), 2.65 – 
2.59 (m, 1H), 2.25 (dd, J = 12.7, 4.7 Hz, 1H), 2.04 – 1.94 (m, 10H), 1.62 (br s, 7H), 1.45 
(s, 3H), 1.39 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 170.1, 170.0, 154.2, 135.7, 132.2, 
132.9, 127.9, 127.8, 127.6, 126.4, 126.0, 126.0, 125.7, 109.4, 96.8, 83.9, 78.4, 76.3, 72.0, 
65.3, 62.5, 52.4, 50.9, 43.8, 43.3,36.7, 36.0, 29.9, 29.8, 26.5, 25.5, 21.2; ESI-HRMS 
(C36H44O8NaS) [M + Na]+ m/z 659.2655, found 659.2641. 333: [α]21D −66.9 (c 1.0, 
CHCl3); 1H NMR (600 MHz, CDCl3) δ 7.86 – 7.74 (m, 4H), 7.54 (d, J = 8.5 Hz, 1H), 
7.47 – 7.39 (m, 2H), 5.45 – 5.38 (m, 1H), 5.24 (t, J = 9.6 Hz, 1H), 4.97 (d, J = 10.8 Hz, 
1H), 4.67 (d, J = 10.9 Hz, 1H), 4.46 (dd, J = 9.8, 1.7 Hz, 1H), 4.40 – 4.35 (m, 1H), 4.26 – 
4.22 (m, 1H), 4.17 (dd, J = 8.5, 7.2 Hz, 1H), 3.99 (d, J = 2.0 Hz, 1H), 3.76 (s, 3H), 2.68 – 
2.62 (m, 2H), 2.53 (t, J = 2.0 Hz, 1H), 2.51 (d, J = 4.9 Hz, 1H), 2.49 – 2.45 (m, 2H), 2.34 
(s, 1H), 2.14 (s, 3H), 2.07 – 1.96 (m, 7H), 1.93 – 1.86 (m, 4H), 1.65 (s, 6H), 1.48 (s, 3H), 
1.30 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 206.0, 171.5, 170.3, 169.8, 135.8, 133.2, 
132.9, 129.0, 128.2, 128.0, 127.8, 127.6, 127.0, 126.6, 125.8, 125.7, 108.0, 85.9, 76.8, 
75.9, 74.7, 72.3, 69.5, 69.3, 65.5, 52.5, 50.2, 43.3, 39.3, 37.6, 36.1, 36.0, 29.9, 29.7, 27.9, 
26.5, 24.3, 20.9; ESI-HRMS (C41H52O11NaS) [M + Na]+ m/z 775.3128, found 775.3109. 
 
 
 
 
 
168 
Methyl (1-Adamantanyl 4-O-acetyl-3-deoxy-5-O-levulinoyl-7-O-(2-naphthyl)methyl-
9-O-(2,4,6-triisopropylbenzenesulfonyl)-2-thio-D-glycero-α-D-galacto-non-2-
ulopyranosid)onate (335): To a stirred solution of 333 (3.2 g; 4.2 mmol) in 
dichloromethane (170 mL) at 0 °C was added 1:1 v/v TFA:H2O mixture (8.2 mL) 
dropwise. The resulting mixture was stirred at 0 °C for 0.5 h and then brought to room 
temperature. The reaction mixture was further stirred for 1 h at room temperature and 
then quenched with saturated aqueous NaHCO3. The reaction mixture was diluted with 
dichloromethane and washed with brine, dried (Na2SO4) and evaporated to dryness to 
give the crude 8,9-diol derivative 334 as a white solid (3.03 g, 4.3 mmol) that was taken 
up in dry dichloromethane:triethylamine (88 mL; 10:1) under argon and treated with 
Bu2SnO (0.38 g; 1.3 mmol) and 2,4,6-triisopropylbenzenesulfonyl chloride (TPSCl) (2.57 
g; 8.5 mmol). The resulting mixture was stirred at room temperature for 10 h, then was 
filtered and evaporated to dryness. The residue was subjected to column chromatography 
over silica gel eluting with 40% EtOAc in hexanes to give 335 as a white solid (3.45 g; 
83%). [α]21D −48.2 (c 1.0, CHCl3); 1H NMR (600 MHz, CDCl3) δ 7.98 – 7.67 (m, 4H), 
7.53 – 7.35 (m, 3H), 7.18 (s, 2H), 5.44 – 5.34 (m, 1H), 5.24 (t, J = 9.4 Hz, 1H), 4.81 (d, J 
= 11.0 Hz, 1H), 4.70 (d, J = 11.0 Hz, 1H), 4.65 (dd, J = 9.8, 2.9 Hz, 1H), 4.52 (dd, J = 
10.5, 2.3 Hz, 1H), 4.40 – 4.32 (m, 1H), 4.31 – 4.25 (m, 1H), 4.24 – 4.11 (m, 2H), 3.90 – 
3.79 (m, 1H), 3.76 (s, 3H), 2.96 – 2.84 (m, 1H), 2.59 – 2.44 (m, 2H), 2.45 – 2.29 (m, 2H), 
2.28 – 2.16 (m, 1H), 2.00 (s, 6H), 1.91 (s, 6H), 1.77 (d, J = 10.1 Hz, 3H), 1.69 – 1.46 (m, 
6H), 1.35 – 1.16 (m, 18H); 13C NMR (151 MHz, CDCl3) δ 206.1, 171.6, 170.3, 170.1, 
153.7, 150.9, 134.9, 133.1, 133.0, 129.2, 128.1, 128.0, 127.6, 127.3, 126.4, 126.0, 126.0, 
123.7, 85.6, 76.9, 73.9, 71.0, 70.8, 69.1, 68.8, 52.8, 50.4, 43.3, 39.2, 37.5, 35.9, 34.2, 
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29.7, 29.7, 29.5, 27.9, 24.8, 24.7, 23.5, 20.8; ESI-HRMS (C53H70O13NaS2) [M + Na]+ m/z 
1001.4156, found 1001.4144. 
Methyl (1-Adamantanyl 4-O-acetyl-3-deoxy-5-O-levulinoyl-7-O-(2-naphthyl)methyl-
9-O-(2,4,6-triisopropylbenzenesulfonyl)-2-thio-L-glycero-α-D-galacto-non-2-
ulopyranosid)onate (338): To a stirred solution of 335 (3.35 g; 3.42 mmol) in dry 
dichloromethane (60 mL) under argon at 0 °C was added dry pyridine (2.2 mL; 27.4 
mmol) followed by Tf2O (2.3 mL; 13.7 mmol) dropwise. The resulting mixture was 
stirred at 0 °C for 1 h then was diluted with dichloromethane and washed sequentially 
with 1 N HCl, saturated aqueous NaHCO3 and brine. The organic layer was collected, 
dried over Na2SO4 and evaporated to dryness to get the triflated derivative 337. To the 
intermediate 337 in dry acetonitrile (60 mL) under argon was added tetrabutylammonium 
nitrite (5.94 g; 20.5 mmol). The reaction mixture was stirred at room temperature for 10 
h, then was diluted with EtOAc and washed with water. The organic layer was collected, 
dried (Na2SO4) and concentrated under vacuum and the residue purified by column 
chromatography over silica gel eluting with 40% EtOAc in hexanes to afford 338 as a 
white solid (2.4 g; 72%). [α]21D −74.6 (c 1.0, CHCl3); 1H NMR (600 MHz, CDCl3) δ 7.87 
– 7.73 (m, 4H), 7.52 – 7.39 (m, 3H), 7.18 (s, 2H), 5.48 – 5.36 (m, 1H), 5.34 (t, J = 9.4 
Hz, 1H), 4.85 (d, J = 11.1 Hz, 1H), 4.75 (d, J = 11.1 Hz, 1H), 4.66 (dd, J = 9.7, 3.8 Hz, 
1H), 4.33 – 4.21 (m, 2H), 4.19 – 4.06 (m, 3H), 3.89 – 3.81 (m, 1H), 3.74 (s, 3H), 3.35 (br 
s, 1H), 2.89 (dt, J = 13.7, 6.8 Hz, 1H), 2.69 – 2.58 (m, 1H), 2.57 – 2.42 (m, 3H), 2.42 – 
2.34 (m, 1H), 2.06 (s, 3H), 2.01 (s, 3H), 1.98 – 1.85 (m, 6H), 1.77 (d, J = 11.6 Hz, 3H), 
1.64 – 1.47 (m, 6H), 1.34 – 1.17 (m, 18H); 13C NMR (151 MHz, CDCl3) δ 206.1, 172.2, 
170.2, 153.7, 150.8, 134.9, 133.2, 133.1, 129.1, 128.2, 128.0, 127.6, 127.1, 126.1, 126.1, 
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126.0, 123.8, 85.5, 75.7, 74.6, 70.7, 70.2, 69.5, 69.4, 69.2, 52.7, 50.4, 43.2, 39.1, 37.6, 
35.9, 34.2, 29.7, 29.7, 29.6, 28.0, 24.7, 24.7, 23.5, 20.9; ESI-HRMS (C53H70O13NaS2) [M 
+ Na]+ m/z 1001.4156, found 1001.4153. 
Methyl (1-Adamantanyl 4-O-acetyl-3-deoxy-9-iodo-5-O-levulinoyl-7-O-(2-
naphthyl)methyl-2-thio-L-glycero-α-D-galacto-non-2-ulopyranosid)onate (339): To a 
solution of 338 (2.2 g; 2.24 mmol) in dry acetone (35 mL) was added NaI (3.35 g; 22.43 
mmol). The resulting mixture was heated to reflux for 22 h then evaporated to dryness 
and the residue purified by column chromatography over silica gel eluting with 40% 
EtOAc in hexanes to give 339 as a colorless oil (1.5 g; 81%). [α]21D −82.1 (c 1.0, CHCl3): 
1H NMR (600 MHz, CDCl3) δ 7.91 – 7.75 (m, 4H), 7.47 (dt, J = 10.3, 7.5 Hz, 3H), 5.47 – 
5.33 (m, 1H), 5.28 (t, J = 9.4 Hz, 1H), 4.93 (t, J = 11.5 Hz, 1H), 4.79 (d, J = 11.5 Hz, 
1H), 4.65 (dd, J = 9.8, 4.1 Hz, 1H), 4.00 (dd, J = 10.2, 5.3 Hz, 1H), 3.90 (t, J = 3.9 Hz, 
1H), 3.78 (s, 3H), 3.47 (dd, J = 10.1, 6.3 Hz, 1H), 3.41 (dd, J = 10.1, 6.1 Hz, 1H), 3.27 (s, 
1H), 2.74 (d, J = 6.7 Hz, 1H), 2.66 – 2.56 (m, 1H), 2.55 – 2.47 (m, 2H), 2.47 – 2.40 (m, 
1H), 2.40 – 2.32 (m, 1H), 2.06 (s, 3H), 2.01 (s, 3H), 1.94 – 1.87 (m, 6H), 1.78 (d, J = 11.6 
Hz, 3H), 1.69 – 1.50 (m, 6H); 13C NMR (151 MHz, CDCl3) δ 206.1, 172.0, 170.4, 170.1, 
85.5, 77.8, 74.5, 71.0, 70.3, 69.9, 69.1, 52.8, 50.4, 43.3, 39.2, 37.6, 35.9, 29.8, 29.7, 29.6, 
28.0, 20.9, 10.3; ESI-HRMS (C38H47O10NaSI) [M + Na]+ m/z 845.1832, found 845.1839. 
Methyl (1-Adamantanyl 4-O-acetyl-3,9-dideoxy-5-O-levulinoyl-7-O-(2-
naphthyl)methyl-2-thio-L-glycero-α-D-galacto-non-2-ulopyranosid)onate (340): To a 
stirred solution of 339 (1.5 g; 1.82 mmol) in EtOAc:Et3N ( 33 mL; 10:1) was added 10% 
Pd/C (1.5 g; 100 wt%). The resulting mixture was stirred under 1 atm of hydrogen for 1 h 
then filtered and concentrated under vacuum. The residue was subjected to column 
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chromatography over silica gel eluting with 45% EtOAc in hexanes to obtain 340 as a 
white solid (1.16 g; 91%). [α] 21D −61.1 (c 1.0, CHCl3); 1H NMR (600 MHz, CDCl3) δ 
7.92 – 7.72 (m, 4H), 7.51 (d, J = 8.4 Hz, 1H), 7.49 – 7.40 (m, 2H), 5.41 (ddd, J = 11.5, 
9.0, 4.9 Hz, 1H), 5.29 (t, J = 9.4 Hz, 1H), 4.91 (d, J = 11.4 Hz, 1H), 4.77 (d, J = 11.4 Hz, 
1H), 4.63 (dd, J = 9.9, 3.4 Hz, 1H), 4.08 (dt, J = 10.5, 5.8 Hz, 1H), 3.78 (s, 3H), 3.48 (t, J 
= 3.7 Hz, 1H), 2.92 (d, J = 4.4 Hz, 1H), 2.67 – 2.36 (m, 5H), 2.07 (s, 3H), 2.00 (s, 3H), 
1.99 – 1.89 (m, 7H), 1.83 (d, J = 11.8 Hz, 3H), 1.59 (s, 6H), 1.32 (d, J = 6.4 Hz, 3H); 13C 
NMR (151 MHz, CDCl3) δ 206.1, 171.9, 170.3, 170.1, 135.6, 133.2, 133.0, 128.1, 127.9, 
127.6, 126.7, 126.1, 126.0, 125.9, 85.5, 81.2, 74.6, 70.9, 70.3, 69.3, 67.5, 52.7, 50.3, 43.3, 
39.2, 37.6, 35.9, 29.8, 29.6, 28.0, 20.9, 20.7; ESI-HRMS (C38H48O10NaS) [M + Na]+ m/z 
719.2866, found 719.2849. 
Methyl (1-Adamantanyl 4,8-di-O-acetyl-3,9-dideoxy-5-O-levulinoyl-7-O-(2-
naphthyl)methyl-2-thio-L-glycero-α-D-galacto-non-2-ulopyranosid)onate (341): To a 
stirred solution of 340 (1.1 g; 1.57 mmol) in dry dichloromethane (25 mL) was added 
DMAP (19 mg; 0.16 mmol) followed by Et3N (0.66 mL; 4.72 mmol). The resulting 
mixture was cooled to 0 °C and Ac2O (0.23 mL; 2.37 mmol) was added. The resulting 
mixture was brought to room temperature and stirred for 3 h then concentrated to dryness 
and the residue subjected to column chromatography over silica gel eluting with 40% 
EtOAc in hexanes to give 341 as a colorless oil (1.11 g; 95%). [α]21D −66.3 (c 1.0, 
CHCl3); 1H NMR (600 MHz, CDCl3) δ 7.90 – 7.73 (m, 4H), 7.55 – 7.46 (m, 1H), 7.49 – 
7.40 (m, 2H), 5.37 (ddd, J = 11.3, 8.6, 4.8 Hz, 9H), 5.24 – 5.11 (m, 1H), 4.91 (d, J = 11.5 
Hz, 1H), 4.78 (d, J = 11.5 Hz, 1H), 4.57 (dd, J = 9.8 Hz, 3.9 Hz, 1H), 3.78 (s, 3H), 3.60 
(dd, J = 6.0, 3.9 Hz, 7H), 2.73 – 2.66 (m, 1H), 2.62 – 241 (m, 5H), 2.10 (s, 3H), 2.00 (s, 
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3H), 2.00 (s, 3H), 1.99 – 1.83 (m, 9H), 1.69 – 1.51 (m, 7H), 1.35 (d, J = 6.4 Hz, 1H); 13C 
NMR (151 MHz, CDCl3) δ 206.1, 171.7, 170.3, 170.2, 170.1, 135.7, 133.2, 132.9, 127.9, 
127.9, 127.6, 126.7, 126.1, 126.0, 125.8, 85.4, 79.3, 74.4, 70.3, 70.1, 69.5, 52.7, 50.3, 
43.5, 39.1, 37.6, 36.0, 29.8, 29.7, 28.0, 21.3, 20.9, 16.8; ESI-HRMS (C40H50O11NaS) [M 
+ Na]+ m/z 761.2977, found 761.2972. 
Methyl (1-Adamantanyl 4,8-di-O-acetyl-3,9-dideoxy-5-O-levulinoyl-2-thio-L-
glycero-α-D-galacto-non-2-ulopyranosid)onate (342): A stirred solution of 341 (1.06 
g; 1.4 mmol) in dichloromethane:H2O (105 mL; 20:1) was treated with DDQ (0.64 g; 
5.62 mmol) and stirred at room temperature for 4 h before it was diluted with 
dichloromethane (100 mL) and washed with saturated aqueous NaHCO3 (90 mL X 3). 
The organic layer was collected, dried over Na2SO4 and concentrated under vacuum. The 
residue was subjected to column chromatography over silica gel eluting with 75% EtOAc 
in hexanes to give 342 as a white solid (0.67 g; 78%). [α]21D −76.5 (c 1.0, CHCl3); 1H 
NMR (600 MHz, CDCl3) δ 5.38 (ddd, J = 11.3, 9.0, 4.8 Hz, 1H), 5.12 (t, J = 9.3 Hz, 1H), 
5.05 – 4.95 (m, 1H), 4.27 (dd, J = 9.7, 1.9 Hz, 1H), 3.80 (s, 3H), 3.51 (t, J = 6.4 Hz, 1H), 
2.81 – 2.66 (m, 3H), 2.61 – 2.50 (m, 3H), 2.16 (s, 3H), 2.09 (s, 3H), 2.01 (s, 3H), 2.00 – 
1.94 (m, 5H), 1.84 (d, J = 11.8 Hz, 3H), 1.75 (s, 2H), 1.64 (s, 6H), 1.32 (d, J = 6.3 Hz, 
3H); 13C NMR (151 MHz, CDCl3) δ 206.1, 171.9, 170.7, 170.1, 170.1, 85.5, 71.9, 71.5, 
70.6, 69.9, 68.9, 52.8, 50.4, 43.5, 39.2, 37.7, 36.0, 29.8, 29.7, 27.9, 21.3, 20.9, 17.2; ESI-
HRMS (C29H42O11NaS) [M + Na]+ m/z 621.2346, found 621.2343. 
Methyl (1-Adamantanyl 4,8-di-O-acetyl-3,9-dideoxy-2-thio-L-glycero-α-D-galacto-
non-2-ulopyranosid)onate (312): To a stirred solution of 342 (600 mg; 0.99 mmol) in 
dry dichloromethane (30 mL) was added pyridine (2.8 mL) and hydrazine monohydrate 
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(1.4 mL; 3.96 mmol) followed by glacial acetic acid (2.0 mL). The resulting solution was 
stirred at room temperature for 1 h then diluted with saturated aqueous NH4Cl and 
extracted with dichloromethane. The organic layer was collected, dried (Na2SO4) and 
evaporated to dryness. The residue was subjected to column chromatography over silica 
gel eluting with 80% EtOAc in hexanes to obtain 312 as a colorless oil (437 mg; 87%). 
[α]21D −61.1 (c 1.0, CHCl3); 1H NMR (400 MHz, CDCL3) δ 5.24 – 5.16 (m, 1H), 5.12 
(dt, J = 10.5, 5.2 Hz, 1H), 4.17 (d, J = 9.4 Hz, 6H), 3.83 (s, 1H), 3.79 (s, 3H), 3.70 (t, J = 
8.2 Hz, 1H), 2.91 (s, 1H), 2.81 (s, 1H), 2.55 (dd, J = 13.6, 4.8 Hz, 1H), 2.10 (s, 3H), 2.06 
(s, 3H), 2.03 – 1.93 (m, 5H), 1.90 – 1.80 (m, 4H), 1.72 (s, 2H), 1.64 (s, 5H), 1.32 (d, J = 
6.3 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 171.4, 170.9, 170.6, 85.6, 73.4, 72.7, 72.4, 
70.9, 70.1, 52.7, 50.3, 43.5, 39.1, 36.0, 29.8, 21.4, 21.1, 17.3; ESI-HRMS (C24H36O9NaS) 
[M + Na]+ m/z 523.1978, found 523.1982. 
Methyl (1-Adamantanyl 4,8-di-O-acetyl-5,7-di-azido-3,5,7,9-tetra-deoxy-2-thio-L-
glycero-α-L-manno-non-2-ulopyranosid)onate (311): A stirred solution of 312 (400 
mg; 0.8 mmol) in dry dichloromethane (25 mL) at 0 °C was treated with pyridine (0.76 
mL; 9.6 mmol) followed bydropwise addition of Tf2O (0.8 mL; 4.8 mmol). The resulting 
mixture was stirred at 0 °C for 1 h then was diluted with dichloromethane and washed 
with 1 N HCl, saturated aqueous NaHCO3 and brine solution. The organic layer was 
collected, dried (Na2SO4) and evaporated to dryness and the residue taken up in dry DMF 
(25 mL) at 0 °C and treated with NaN3 (2.05 g; 31.99 mmol). The resulting mixture was 
stirred at 0 °C for 24 h then was diluted with EtOAc, and washed with water. The organic 
layer was collected, dried (Na2SO4) and evaporated to dryness. The residue was subjected 
to column chromatography over silica gel eluting with 20% EtOAc in hexanes to give 
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311 as a white solid (307 mg; 70%). [α]21D −33.1 (c 1.0, CHCl3); 1H NMR (400 MHz, 
CDCl3) δ 5.33 (tdd, J = 12.7, 5.7, 2.7 Hz, 1H), 4.16 – 4.07 (m, 2H), 4.02 (dd, J = 9.8, 2.2 
Hz, 1H), 3.82 (s, 3H), 2.33 – 2.26 (m, 2H), 2.11 (s, 3H), 2.09 (s, 3H), 2.05 – 1.92 (m, 
5H), 1.81 (d, J = 11.7 Hz, 3H), 1.65 (s, 4H), 1.56 (s, 3H), 1.32 (d, J = 6.3 Hz, 3H); 13C 
NMR (101 MHz, CDCl3) δ 169.8 (X 3), 86.1, 77.6, 77.2, 70.4, 69.2, 69.1, 65.1, 59.1, 
52.8, 50.6, 43.6, 35.9, 34.7, 29.8, 29.7, 21.1, 20.7, 14.2; ESI-HRMS (C24H34N6O7NaS) 
[M + Na]+ m/z 573.2107, found 573.2104. 
General Coupling Protocol with Donor 311: A mixture of donor 311 (50 mg; 0.09 
mmol), acceptor (0.11 mmol), and activated 4Å  acid-washed powdered molecular sieves 
(200 mg; 2 g/mmol of donor) in CH2Cl2/CH3CN (2:1, 2.0 mL) was stirred for 2 h at room 
temperature under argon then  cooled to -78 °C, and treated with N-iodosuccinimide (24 
mg; 0.11 mmol) and TfOH (2 µL; 0.013 mmol). The reaction mixture was stirred at -78 
°C for 7 h and then quenched with triethylamine (10 µL). The mixture was diluted with 
CH2Cl2, filtered through Celite, washed with 20% aqueous Na2S2O3, dried over Na2SO4, 
and concentrated under reduced pressure. The residue was purified by column 
chromatography over silica gel eluting with mixtures of EtOAc and hexanes to afford the 
coupled products. 
Methyl [Benzyl (4,8-di-O-acetyl-5,7-di-azido-3,5,7,9-tetra-deoxy-L-glycero-β-L-
manno-non-2-ulopyranosid)onate] (43): Glycoside 343 was prepared according to the 
general glycosylation procedure from donor 311 (50 mg; 0.09 mmol) and benzyl alcohol 
(12 µL; 0.11 mmol) in CH2Cl2/CH3CN (2.1 mL, 2:1) at -78 °C. After chromatographic 
purification over silica gel eluting with 25% EtOAc in hexanes, 343 was obtained as a 
colorless oil (37.9 mg; 89%). [α]21D −36.3 (c 1.0, CHCl3); 1H NMR (600 MHz, CDCl3) δ 
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7.43 – 7.26 (m, 5H), 5.44 (qd, J = 6.4, 2.6 Hz, 1H), 4.97 – 4.88 (m, 1H), 4.76 (d, J = 11.5 
Hz, 1H), 4.43 (d, J = 11.5 Hz, 1H), 4.09 – 4.04 (m, 2H), 3.71 (s, 3H), 3.64 – 3.61 (m, 
1H), 2.47 (dd, J = 12.7, 4.5 Hz, 1H), 2.26 (t, J = 12.8 Hz, 1H), 2.13 (s, 3H), 2.10 (s, 3H), 
1.38 (d, J = 6.4 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 169.9, 168.5, 136.6, 128.3, 
127.9, 127.8, 71.6, 70.7, 69.3, 66.7, 63.9, 58.2, 52.8, 32.3, 29.7, 21.0, 20.6, 12.9; ESI-
HRMS (C21H26N6O8Na) [M + Na]+ m/z 513.1710, found 513.1718. 
Methyl [Methyl (4,8-di-O-acetyl-5,7-di-azido-3,5,7,9-tetra-deoxy-L-glycero-β-L-
manno-non-2-ulopyranosid)onate]-(2→6)-2,3,4-tri-O-benzyl-β-D-galactopyranoside 
(344): Glycoside 344 was prepared according to the general glycosylation procedure 
from donor 311 (50 mg; 0.09 mmol) and methyl 2,3,4-tribenzyl-β-D-galactopyranoside 
187 as acceptor (50.3 mg; 0.11 mmol) in CH2Cl2/CH3CN (2.1 mL, 2:1) at -78 °C. After 
chromatographic purification over silica gel eluting with 25% EtOAc in hexanes, 344 
was obtained as a white foam (63.8 mg; 83%). [α]21D −23.1 (c 1.0, CHCl3); 1H NMR (600 
MHz, CDCl3) δ 7.63 – 6.98 (m, 15H), 5.34 (qd, J = 6.4, 2.5 Hz, 1H), 4.97 (t, J = 9.6 Hz, 
1H), 4.92 – 4.84 (m, 2H), 4.78 – 4.70 (m, 3H), 4.61 (d, J = 11.5 Hz, 1H), 4.29 (d, J = 7.6 
Hz, 1H), 4.04 (s, 1H), 3.97 (dd, J = 9.9, 2.1 Hz, 1H), 3.88 (d, J = 2.6 Hz, 1H), 3.85 – 3.75 
(m, 2H), 3.59 (s, 3H), 3.57 – 3.49 (m, 6H), 2.40 (dd, J = 12.7, 4.5 Hz, 1H), 2.21 – 2.14 
(m, 2H), 2.13 (s, 3H), 2.07 (s, 3H), 1.33 (d, J = 6.5 Hz, 3H); 13C NMR (151 MHz, 
CDCl3) δ 169.7, 169.5, 167.9, 138.9, 138.6, 128.3, 128.2, 128.0, 128.0, 127.6, 127.4, 
127.4, 127.2, 104.9, 99.3, 81.9, 79.5, 75.0, 74.3, 73.3, 72.9, 72.5, 71.6, 70.6, 69.3, 63.8, 
62.5, 58.1, 57.1, 52.8, 32.1, 29.7, 21.00, 20.6, 12.9; ESI-HRMS (C42H50N6O13Na) [M + 
Na]+ m/z 869.3334, found 869.3327. 
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Methyl [Methyl (4,8-di-O-acetyl-5,7-di-azido-3,5,7,9-tetra-deoxy-L-glycero-β-L-
manno-non-2-ulopyranosid)onate]-(2→3)-2,4,6-tri-O-benzyl-β-D-galactopyranoside 
(345): Glycoside 345 was prepared according to the general glycosylation procedure 
from donor 311 (60 mg; 0.11 mmol) and methyl 2,4,6-tribenzyl-β-D-galactopyranoside 
188 as acceptor (60.4 mg; 0.13 mmol) in CH2Cl2/CH3CN (2.4 mL, 2:1) at -78 °C. After 
chromatographic purification over silica gel eluting with 25% EtOAc in hexanes, 345 
was obtained as a white foam (71 mg; 77%). [α]21D −32.3 (c 1.0, CHCl3); 1H NMR (400 
MHz, CDCl3) δ 7.80 – 6.92 (m, 15H), 5.50 – 5.32 (m, 1H), 4.94 (ddd, J = 11.4, 5.9, 4.3 
Hz, 2H), 4.84 (d, J = 10.9 Hz, 1H), 4.64 (d, J = 10.9 Hz, 1H), 4.59 – 4.49 (m, 3H), 4.33 
(d, J = 7.7 Hz, 1H), 4.01 – 3.92 (m, 3H), 3.86 (d, J = 3.0 Hz, 1H), 3.73 (s, 3H), 3.72 – 
3.60 (m, 4H), 3.57 (s, 3H), 3.38 (dd, J = 9.9, 1.4 Hz, 1H), 2.41 (t, J = 12.9 Hz, 1H), 2.30 
(dd, J = 13.5, 5.1 Hz, 1H), 2.05 (s, 3H), 2.00 (s, 3H), 1.29 (d, J = 6.5 Hz, 3H); 13C NMR 
(101 MHz, CDCl3) δ 169.7, 169.4, 167.9, 139.1, 138.5, 128.4, 128.3, 128.1, 128.0, 127.8, 
127.5, 127.5, 127.2, 104.8, 100.4, 77.6, 77.5, 76.3, 75.2, 74.8, 74.0, 73.6, 71.5, 70.2, 69.7, 
69.5, 63.5, 57.9, 57.1, 53.0, 29.7, 21.0, 20.6, 12.7; ESI-HRMS (C42H50N6O13Na) [M + 
Na]+ m/z 869.3334, found 869.3348. 
Methyl [Methyl (4,8-di-O-acetyl-5,7-di-azido-3,5,7,9-tetra-deoxy-L-glycero-β-L-
manno-non-2-ulopyranosid)onate]-(2→4)-2,3,6-tri-O-benzyl-β-D-galactopyranoside 
(346): Glycoside 346 was prepared according to the general glycosylation procedure 
using donor 311 (50 mg; 0.09 mmol) and methyl 2,3,6-tribenzyl-β-D-galactopyranoside 
230 as acceptor (50.3 mg; 0.11 mmol) in CH2Cl2/CH3CN (2.1 mL, 2:1) at -78 °C. After 
chromatographic purification over silica gel eluting with 25% EtOAc in hexanes, 346 
was obtained as a white foam (40.6 mg; 53%). [α]21D −16.7 (c 1.0, CHCl3); 1H NMR (400 
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MHz, CDCl3) δ 7.39 – 7.31 (m, 10H), 7.23 – 7.14 (m, 5H), 5.52 (dd, J = 6.4, 1.8 Hz, 1H), 
5.40 – 5.32 (m, 1H), 4.84 (d, J = 10.8 Hz, 1H), 4.78 (d, J =12.5 Hz, 1H), 4.67 (d, J = 7.1 
Hz, 1H), 4.64 (d, J = 7.9 Hz, 1H), 4.47 (d, J = 11.6 Hz, 1H), 4.41 (d, J = 10.8 Hz, 1H), 
4.22 (d, J = 7.6 Hz, 1H), 4.13 – 3.88 (m, 5H), 3.81 (t, J = 10.8 Hz, 1H), 3.63 – 3.54 (m, 
2H), 3.52 (s, 3H), 3.46 (s, 3H), 3.41 (dd, J = 10.0, 2.5 Hz, 1H), 2.37 (dd, J = 12.9, 3.5 Hz, 
1H), 2.14 (s, 3H), 2.08 (s, 3H), 1.21 (d, J = 6.4 Hz, 3H); 13C NMR (101 MHz, d2o) δ 
169.8, 169.3, 167.7, 138.4, 137.6, 136.8, 128.5, 128.4, 128.1, 128.0, 128.0, 127.9, 127.4, 
127.3, 105.2, 98.8, 81.4, 78.2, 76.6, 75.2, 73.4, 72.2, 70.4, 68.4, 67.1, 66.1, 64.7, 58.8, 
57.1, 52.0, 33.3, 29.6, 20.9, 20.5, 13.5; ESI-HRMS (C42H50N6O13Na) [M + Na]+ m/z 
869.3334, found 573.3338. 
Methyl [Methyl (7-acetamido-4,8-di-O-acetyl-5-azido-3,5,7,9-tetra-deoxy-L-glycero-
β-L-manno-non-2-ulopyranosid)onate]-(2→3)-2,4,6-tri-O-benzyl-β-D-
galactopyranoside (349): To a stirred solution of 345 (20 mg; 0.024 mmol) in dry 
CHCl3 (1.0 mL) were added 2,6-lutidine (0.3 mL) and thioacetic acid (0.3 mL, 166.7 
mmol). The resulting mixture was heated at 60 °C for 10 h then concentrated under 
vacuum and the residue subjected to column chromatography over silica gel eluting with 
65% EtOAc in hexanes to give 349 as a colorless oil (13.9 mg; 68%). [α] 21D −38.2 (c 0.8, 
CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.48 – 7.26 (m, 15H), 5.60 (d, J = 9.8 Hz, 1H), 
5.34 – 5.21 (m, 1H), 5.01 – 4.89 (m, 2H), 4.84 (d, J = 11.0 Hz, 1H), 4.72 – 4.61 (m, 2H), 
4.60 – 4.46 (m, 3H), 4.32 (d, J = 7.7 Hz, 1H), 4.01 (dd, J = 10.0, 3.1 Hz, 1H), 3.87 (d, J = 
3.0 Hz, 1H), 3.82 – 3.74 (m, 2H), 3.72 (s, 3H), 3.66 – 3.60 (m, 2H), 3.56 (s, 3H), 2.47 (t, 
J = 13.0 Hz, 1H), 2.26 (dd, J = 13.4, 4.6 Hz, 1H), 2.16 – 2.04 (m, 2H), 2.03 (s, 3H), 2.01 
(s, 3H), 1.97 (s, 3H), 1.25 (d, J = 6.3 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 170.0, 
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169.9, 169.8, 168.2, 139.1, 138.5, 138.3, 128.4, 128.3, 128.1, 127.9, 127.8, 127.7, 127.4, 
127.4, 127.1, 104.8, 100.4, 77.6, 77.6, 76.0, 75.1, 74.8, 73.7, 73.4, 71.9, 69.9, 69.4, 68.9, 
58.3, 57.0, 52.8, 51.4, 47.9, 29.7, 23.5, 21.1, 20.6, 14.1; ESI-HRMS (C44H54N4O14Na) [M 
+ Na]+ m/z 885.3534, found 885.3546. 
Methyl [Methyl (7-acetamido-4,8-di-O-acetyl-3,5,7,9-tetra-deoxy-5-(1,1-
dimethylethoxy)carbonylamino-L-glycero-β-L-manno-non-2-ulopyranosid)onate]-
(2→3)-2,4,6-tri-O-benzyl-β-D-galactopyranoside (350): To a stirred solution of 349 
(10 mg; 0.012 mmol) in pyridine (1 mL) were added H2O (104 µL; 5.78 mmol), Et3N (25 
µL; 0.18 mmol) and 1,3-propanedithiol (24 µL; 0.24 mmol). The resulting mixture was 
stirred at room temperature for 2 h then concentrated under vacuum and the residue 
subjected to column chromatography over silica gel eluting with 10% MeOH in CH2Cl2 
as solvent to afford the crude 5-amino derivative as a white solid (7.6 mg). This solid (7.6 
mg; 0.008 mmol) was dissolved in 1,4-dioxane (0.5 mL) and treated with Et3N (5 µL; 
0.03 mmol) and Boc2O (3.5 µL; 0.015 mmol). The resulting mixture was heated at 60 °C 
for 10 h then concentrated under vacuum and the residue subjected to column 
chromatography over silica gel eluting with 75% EtOAc in hexanes to give 350 as a 
colorless oil (7.8 mg; 72%): [α]21D −26.3 (c 0.4, CHCl3); 1H NMR (600 MHz, CDCl3) δ 
7.52 – 7.20 (m, 15H), 5.31 – 5.23 (m, 2H), 4.90 (d, J = 11.4 Hz, 1H), 4.87 – 4.81 (m, 
2H), 4.80 – 4.74 (m, 1H), 4.66 (d, J = 11.0 Hz, 1H), 4.56 (dd, J = 11.1, 6.2 Hz, 2H), 4.53 
– 4.46 (m, 2H), 4.31 (d, J = 7.7 Hz, 1H), 4.16 (d, J = 9.3 Hz, 1H), 3.96 (dd, J = 9.9, 2.9 
Hz, 1H), 3.91 – 3.87 (m, 1H), 3.70 (s, 3H), 3.68 – 3.61 (m, 3H), 3.55 (s, 3H), 2.34 (dd, J 
= 13.4, 4.5 Hz, 1H), 2.10 – 1.98 (m, 3H), 1.94 (s, 3H), 1.92 (s, 3H), 1.92 (s, 3H), 1.43 (s, 
9H), 1.26 (d, J = 6.6 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 170.3, 170.1, 169.4, 167.9, 
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155.7, 139.1, 138.3, 128.4, 128.3, 128.3, 128.00, 127.8, 127.6, 127.5, 127.1, 104.7, 100.6, 
80.0, 77.6, 76.0, 75.2, 74.9, 73.5, 72.5, 69.6, 69.3, 68.1, 57.0, 52.9, 50.2, 47.9, 45.9, 30.3, 
28.5, 28.2, 23.3, 21.1, 20.7, 14.0; ESI-HRMS (C49H64N2O16Na) [M + Na]+ m/z 959.415 , 
found 959.4161. 
Methyl [(7-acetamido-3,5,7,9-tetra-deoxy-5-(1,1-dimethylethoxy)carbonylamino-L-
glycero-β-L-manno-non-2-ulopyranosid)onate]-(2→3)-β-D-galactopyranoside (351): 
A solution of 350 (6.0 mg; 0.0064 mmol) in 1:1 aqueous Ba(OH)2:1,4-dioxane (0.6 mL) 
was heated at 60 °C for 1 h then cooled to room temperature saturated with CO2 and 
filtered. The filtrate was evaporated under vacuum and the residue taken up in 1:1 
H2O:1,4-dioxane (0.6 mL) then treated with 10% Pd/C (6.0 mg; 100 wt%) and stirred 
under 1 atm of hydrogen for 16 h. The reaction mixture was filtered and the filtrate was 
lyophilization to give 351 as a white foam (2.9 mg; 80%). [α]21D −8.3 (c 0.2, D2O); 1H 
NMR (600 MHz, D2O) δ 4.37 (d, J = 8.0 Hz, 1H), 4.10 (dt, J = 12.7, 6.2 Hz, 1H), 4.05 
(dd, J = 9.9, 3.2 Hz, 1H), 4.01 – 3.96 (m, 1H), 3.91 (d, J = 2.9 Hz, 1H), 3.86 (d, J = 2.9 
Hz, 1H), 3.81 – 3.75 (m, 2H), 3.74 – 3.67 (m, 3H), 3.66 – 3.61 (m, 2H), 3.57 (s, 3H), 3.55 
– 3.48 (m, 2H), 2.53 – 2.42 (m, 1H), 2.20 – 2.11 (m, 1H), 2.01 (s, 1H), 1.97 (s, 3H), 1.80 
(s, 1H), 1.63 (t, J = 12.6 Hz, 1H), 1.56 – 1.49 (m, 1H), 1.41 (s, 9H), 1.36 – 1.29 (m, 1H), 
1.19 (d, J = 6.9 Hz, 3H); 13C NMR (151 MHz, D2O) δ 173.6, 172.9, 157.4, 103.6, 100.3, 
80.3, 75.5, 74.9, 73.6, 71.6, 69.3, 69.1, 67.1, 66.6, 61.0, 60.4, 57.1, 53.6, 49.3, 35.3, 27.7, 
22.1, 16.7; ESI-HRMS (C38H48O10NaS) [M - H]- m/z 567.2401, found 567.2411. 
Methyl [Benzyl (5,7-di-acetamido-4,8-di-O-acetyl-3,5,7,9-tetra-deoxy-L-glycero-β-L-
manno-non-2-ulopyranosid)onate] (347): To a stirred solution of glycoside 343 (20 
mg; 0.04 mmol) in dry pyridine (1.0 mL) was added AcSH (1.0 mL). The resulting 
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mixture was stirred at room temperature for 40 h then concentrated to dryness and the 
residue subjected to column chromatography over silica gel eluting with 8% MeOH in 
CH2Cl2 to give 347 as a colorless oil (15.6 mg; 73%). [α]21D −42.1 (c 1.0, CHCl3); 1H 
NMR (600 MHz, CDCl3) δ 7.48 – 7.24 (m, 5H), 5.81 (d, J = 9.4 Hz, 1H), 5.71 (d, J = 
10.7 Hz, 1H), 5.37 – 5.25 (m, 1H), 4.84 (d, J = 11.3 Hz, 1H), 4.82 – 4.76 (m, 1H), 4.58 – 
4.47 (m, 2H), 4.41 (d, J = 11.3 Hz, 1H), 4.01 (dd, J = 10.0, 1.8 Hz, 1H), 3.72 (s, 3H), 
2.49 (dd, J = 13.2, 4.5 Hz, 1H), 2.03 (s, 3H), 1.98 (s, 3H), 1.98 (s, 3H), 1.90 – 1.87 (m, 
1H), 1.35 (d, J = 6.7 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 170.9, 170.6, 170.5, 169.9, 
168.4, 136.5, 128.4, 128.1, 128.0, 99.2, 72.4, 70.0, 67.7, 66.9, 52.7, 50.5, 45.3, 33.2, 29.7, 
23.3, 23.3, 21.2, 20.9, 14.1; ESI-HRMS (C25H34N2O10Na) [M + Na]+ m/z 545.2111, 
found 545.2127. 
5,7-Di-acetamido-3,5,7,9-tetradeoxy-L-glycero-α-L-manno-2-nonulosonic Acid - 
Pse5Ac7Ac (2): A stirred solution of 347 (10.0 mg; 0.02 mmol) in 1:1 aqueous 
Ba(OH)2:1,4-dioxane (1.0 mL) was heated at 60 °C for 1 h then cooled to room 
temperature , saturated with CO2 and filtered. The filtrate was evaporated to dryness and 
then taken up in 1:1 H2O:1,4-dioxane (1.0 mL), treated with 10% Pd/C (10.0 mg; 100 
wt%) and  stirred under 1 atm of hydrogen for 14 h. The solution was filtered and the 
filtrate was subjected to lyophilization to give 2 as a white foam (5.2 mg; 81%) whose 1H 
and 13C NMR data were consistent with the literature.43,97,140,141 1H NMR (600 MHz, 
D2O) δ 4.25 (br s, 1H), 4.21 – 4.11 (m, 3H), 4.04 (d, J = 10.4 Hz, 1H), 2.02 (s, 3H), 1.99 
(s, 3H), 1.95 (dd, J = 13.3, 4.8 Hz, 1H), 1.80 (t, J = 12.7 Hz, 1H), 1.12 (d, J = 6.4 Hz, 
3H); 13C NMR (151 MHz, D2O) δ 176.3, 174.7, 173.9, 96.3, 70.0, 66.8, 65.3, 52.9, 48.8, 
34.8, 22.0, 21.9, 15.1. 
 
 
 
 
181 
Methyl [Methyl (4,8-di-O-acetyl-5-azido-3,5,7,9-tetra-deoxy-7-(1,1-
dimethylethoxy)carbonylamino-L-glycero-β-L-manno-non-2-ulopyranosid)onate]-
(2→3)-2,4,6-tri-O-benzyl-β-D-galactopyranoside (352): To a stirred solution of 345 
(15 mg; 0.018 mmol) in pyridine (1.0 mL) at 0 °C were added H2O (0.16 mL; 8.88 
mmol), Et3N (37 µL; 0.266 mmol) and 1,3-propanedithiol (9 µL; 0.09 mmol).  The 
resulting solution was stirred at 0 °C for 5 h, then concentrated under vacuum and the 
residue subjected to column chromatography over silica gel eluting with 75% EtOAc in 
hexanes to give a white fluffy solid (8 mg) which was taken to the next step without any 
further characterization. To a solution of the above solid (8 mg; 0.01 mmol) in 1,4-
dioxane (1.0 mL) were added Et3N (27 µL; 0.19 mmol) and Boc2O (21.2 mg; 0.1 mmol). 
The resulting mixture was heated at 60 °C for 10 h then concentrated under vacuum and 
the residue was subjected to column chromatography over silica gel eluting with 35% 
EtOAc in hexanes to give 351 as a colorless oil (8.3 mg; 51% ). [α] 21D −24.3 (c 0.5, 
CHCl3); 1H NMR (600 MHz, CDCl3) δ 7.59 – 7.04 (m, 15H), 5.33 (d, J = 6.4 Hz, 1H), 
4.87 (d, J = 11.4 Hz, 1H), 4.81 – 4.76 (m, 2H), 4.64 (dd, J = 6.5, 4.4 Hz, 1H), 4.57 (d, J = 
10.4 Hz, 1H), 4.49 (d, J = 11.2 Hz, 2H), 4.45 (d, J = 11.9 Hz, 1H), 4.36 – 4.27 (m, 3H), 
3.92 (d, J = 7.1 Hz, 1H), 3.79 – 3.72 (m, 2H), 3.69 (s, 3H), 3.68 – 3.58 (m, 4H), 3.55 (s, 
3H), 3.43 – 3.32 (m, 2H), 2.42 (d, J = 9.1 Hz, 1H), 2.03 (s, 3H), 1.94 (s, 3H), 1.47 (s, 
9H), 1.26 (d, J = 6.4 Hz, 1H); 13C NMR (151 MHz, CDCl3) δ 169.9, 169.7, 167.8, 155.3, 
138.8, 138.5, 138.0, 128.3, 128.2, 128.0, 127.8, 127.7, 127.6, 127.5, 127.3, 104.7, 99.9, 
80.4, 77.4, 76.4, 76.3, 75.0, 74.8, 73.5, 73.3, 72.1, 70.3, 68.8, 67.6, 63.9, 57.1, 53.0, 46.3, 
30.9, 29.7, 28.3, 21.1, 20.7, 12.8; ESI-HRMS (C47H60N4O15Na) [M + Na]+ m/z 943.3953, 
found 943.3975. 
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Methyl [Methyl (5-acetamido-4,8-di-O-acetyl-3,5,7,9-tetra-deoxy-7-N-(1,1-
dimethylethoxy)carbonylamino-L-glycero-β-L-manno-non-2-ulopyranosid)onate]-
(2→3)-2,4,6-tri-O-benzyl-β-D-galactopyranoside (353): A stirred solution of 352 (8.0 
mg; 0.009 mmol) in dry pyridine (0.5 mL) was treated with  AcSH (0.5 mL), after 15 h at 
room temperature with further pyridine (0.5 mL) and AcSH (0.5 mL), and after another 
15 at room temperature with pyridine (0.5 mL) and AcSH (0.5 mL).  Finally, stirring was 
continued for 15 h (total 45 h) at room temperature before the solvents were evaporated 
and the residue was subjected to column chromatography over silica gel eluting with 75% 
EtOAc in hexanes to give 353 as a colorless oil (5.8 mg; 71%). [α]21D −22.1 (c 0.4, 
CHCl3); 1H NMR (600 MHz, CDCl3) δ 7.46 – 7.17 (m, 15H), 5.31 – 5.24 (m, 1H), 5.22 
(d, J = 10.4 Hz, 1H), 4.90 (d, J = 11.4 Hz, 1H), 4.87 – 4.72 (m, 2H), 4.66 (d, J = 11.0 Hz, 
1H), 4.59 – 4.53 (m, 2H), 4.52 – 4.45 (m, 2H), 4.30 (d, J = 7.7 Hz, 1H), 4.16 (d, J = 10.0 
Hz, 1H), 3.95 (d, J = 9.6 Hz, 1H), 3.87 (s, 1H), 3.70 (s, 3H), 3.68 – 3.61 (m, 2H), 3.55 (s, 
3H), 2.41 – 2.28 (m, 2H), 1.95 (s, 3H), 1.92 (s, 3H), 1.92 (s, 3H), 1.43 (s, 9H), 1.26 (d, J 
= 6.7 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 170.3, 170.1, 169.4, 167.9, 155.8, 139.1, 
138.3, 130.8, 128.8, 128.4, 128.3, 128.0, 127.8, 127.7, 127.5, 127.2, 104.7, 100.6, 80.0, 
77.6, 76.0, 75.2, 74.9, 73.5, 72.5, 69.6, 69.3, 68.1, 68.1, 57.1, 52.9, 50.2, 45.9, 31.9, 28.2, 
22.7, 21.2, 20.6, 19.8, 14.1; ESI-HRMS (C49H64N2O16Na) [M + Na]+ m/z 959.4154, 
found 959.4142. 
Methyl [(5-acetamido-3,5,7,9-tetra-deoxy-7-N-(1,1-dimethylethoxy)carbonylamino-
L-glycero-β-L-manno-non-2-ulopyranosid)onate]-(2→3)-β-D-galactopyranoside 
(354): A stirred solution of 353 (4.0 mg; 0.0043 mmol) in 1:1 aq. Ba(OH)2 and 1,4-
dioxane (0.4 mL) was heated to 60 °C for 1 h, then cooled to room temperature, saturated 
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with CO2, and filtered.  The filtrate was evaporated in vacuum and then taken up in 1:1 
H2O:1,4-dioxane (0.4 mL) and treated with 10% Pd/C (4.0 mg; 100 wt%). The resulting 
solution was stirred under 1 atm of hydrogen for 16 h, then filtered and lyophilized to 
give 354 as a white foam (2.0 mg; 83%). [α]21D −4.8 (c 0.13, D2O); 1H NMR (600 MHz, 
D2O) δ 4.37 (d, J = 8.0 Hz, 1H), 4.13 – 4.07 (m, 1H), 4.04 (d, J = 9.9 Hz, 1H), 3.97 (dd, J 
= 13.3, 8.1 Hz, 1H), 3.91 (s, 1H), 3.85 (s, 1H), 3.81 – 3.75 (m, 2H), 3.74 – 3.68 (m, 3H), 
3.67 – 3.62 (m, 2H), 3.56 (s, 3H), 3.53 – 3.47 (m, 2H), 3.43 (dd, J = 11.9, 5.6 Hz, 1H), 
2.53 – 2.45 (m, 1H), 2.15 (s, 1H), 2.05 (s, 1H), 1.96 (s, 3H), 1.62 (t, J = 12.4 Hz, 1H), 
1.53 (br s, 1H), 1.40 (s, 9H), 1.31 (d, J = 6.9 Hz, 1H), 1.19 (d, J =  6.3 Hz, 3H); 13C NMR 
(151 MHz, D2O) δ 173.6, 173.0, 157.2, 103.5, 100.2, 80.2, 75.4, 74.8, 73.5, 69.2, 68.9, 
67.0, 66.5, 65.5, 60.9, 57.1, 53.6, 49.2, 45.4, 45.3, 35.3, 23.2, 22.0, 16.5; ESI-HRMS 
(C38H48O10NaS) [M - H]- m/z 567.2401, found 567.2415. 
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 Legionaminic acid (Leg) and pseudaminic acid (Pse) are deoxy acetamido 
analogues of the most common sialic acid, N-acetylneuraminic acid (NeuAc) that are 
found in microorganisms. Leg and Pse are rare but important class of sialic acids, as their 
glycosides are found in lipopolysaccharides and glycoproteins of several pathogenic 
Gram-negative bacteria including Pseudomonas aeruginosa, Legionella pneumophila 
serogroup 1, Campylobacter jejuni, and Campylobacter coli. As such, the stereoselective 
glycosylation of the equatorial Leg and Pse donors, and the role played by their side 
chain conformations in anomeric reactivity and selectivity are the focus of this thesis. 
 Chapter two describes the synthesis of a Leg donor in 15 straightforward steps 
and 17% overall yield from the commercially available N-acetylneuraminic acid. The 
synthesized legionaminic acid donor showed excellent equatorial selectivity when 
glycosylated with various primary, secondary and tertiary acceptors when using 
NIS/TfOH as activator at -78 ºC in 1:2 acetonitrile/dichloromethane. The selectivity was, 
nevertheless, less than the 5-azido NeuAc donro synthesized in Chpater three. The 9-
deoxy nature of the side chain made the donor less disarming and afforded greater 
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oxocarbenium-like character in the transition state, a major factor attributing to some loss 
in the glycosylation selectivity.  
 Chapter three describes the synthesis of an intermediate 5-epi-NeuAc donor 
having the same C-5 configuration as pseudaminic acid. The glycosylation reactions of 
various primary and secondary alcohols including a sialic acid based acceptor with this 
donor under the standard glycosylation reaction conditions gave exquisite equatorial 
selectivity. Conformational analysis reveals the side chain of the donor to have 
undergone a conformational change from the predominant gg- to the less active gt-
conformation in order to avoid the steric and dipolar repulsion between the C5-N5 bond 
and the side chain. This change in conformation offsets the negative effect of the axial 
azide at the 5-position. Additionally, the stereoselective synthesis of the NeuAc 
glycosides obtained from the 5-azido NeuAc donor was in apparent contradiction to the 
selectivity observed for the various literature 5-azido NeuAc donors, and showcased the 
importance of low temperature (-78 ºC) in the control of glycosylation selectivity.  
Chapter four describes the synthesis of a pseudaminic acid donor in 20 steps and 
5% overall yield from the commercially available N-acetylneuraminic acid. 
Glycosylation reactions of various primary and hindered secondary alcohols under the 
standard glycosylation reaction conditions gave exquisite equatorial selectivity and good 
to excellent yields. The excellent selectivity observed is attributed to the inversion of 
configuration at the 5- and 7-positions, which creates a strong dipolar and steric repulsion 
between the C5-N5 bond and the side chain. To avoid this, the donor undergoes a 
conformational change from the predominant gg- to the least active tg-conformation and 
and is rendered more selective in the glycosylation reaction. For selected glycosides, 
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regioselective reductions of the azides were performed to afford deprotected glycosides 
with differentially blocked amines, suitable for accessing the bacterial 
lipopolysaccharides. 
 Chapter five includes the overall conclusion of the dissertation, which is 
followed by the detailed experimental procedures employed in synthesizing all the sialic 
acid derivatives in chapter six. 
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